[go: up one dir, main page]

WO2022228387A1 - Compounds as parp inhibitors - Google Patents

Compounds as parp inhibitors Download PDF

Info

Publication number
WO2022228387A1
WO2022228387A1 PCT/CN2022/088989 CN2022088989W WO2022228387A1 WO 2022228387 A1 WO2022228387 A1 WO 2022228387A1 CN 2022088989 W CN2022088989 W CN 2022088989W WO 2022228387 A1 WO2022228387 A1 WO 2022228387A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cycloalkyl
heterocyclyl
heteroaryl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/088989
Other languages
French (fr)
Inventor
Hua Xu
Xianlong WANG
Zuwen ZHOU
Zhifu Li
Qihong Liu
Haohan TAN
Yue RONG
Hongbin Liu
Lihua Jiang
Shu Lin
Xingdong ZHAO
Weibo Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fochon Biosciences Ltd
Original Assignee
Fochon Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fochon Biosciences Ltd filed Critical Fochon Biosciences Ltd
Priority to CN202280031108.XA priority Critical patent/CN117321051A/en
Publication of WO2022228387A1 publication Critical patent/WO2022228387A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • PARP poly (ADP-ribose) polymerase
  • Hyper-proliferative diseases like cancer and inflammation are attracting the scientific community to provide therapeutic benefits. In this regard efforts have been made to identify and target specific mechanisms which play a role in proliferating the diseases.
  • PARPs belong to a protein family that contains PARP catalytic domains, and approximately 18 members have been discovered so far. PARP can be activated by damaged DNA fragments and catalyzes the attachment of poly (ADP-ribose) to various target proteins, which results in the modulation of catalytic activity and protein-protein interactions of the target proteins. PARP has been implicated in several biological processes, including DNA repair, gene transcription, cell cycle progression (including proliferation and differentiation) , cell death, chromatin functions, genomic (e.g. chromosomal) stability and telomere length.
  • Activation of PARP and the resultant formation of poly can be induced by DNA strand breaks after exposure to chemotherapy, ionizing radiation, oxygen free radicals, or nitric oxide (NO) . Because this cellular ADP-ribose transfer process is associated with the repair of DNA strand breakage in response to DNA damage caused by radiotherapy or chemotherapy, it can contribute to the resistance that often develops to various types of cancer therapies. Consequently, inhibition of PARP is expected to retard intracellular DNA repair and enhance the antitumor effects of cancer therapies.
  • PARP inhibitors have been shown to potentiate radiation and chemotherapy by increasing apoptosis of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals.
  • PARP inhibitors were disclosed in the arts, e.g. WO 2004080976 and WO 2009050469, many suffer from having short half-life or toxicity. Therefore, there is a need for new PARP inhibitors that have at least one advantageous property selected from solubility, drug-drug interactions, potency, stability, selectivity, toxicity, drug resistance, pharmacokinetics and pharmacodynamics properties as an alternative for the treatment of hyper-proliferative diseases.
  • a novel class of PARP inhibitors is provided herein.
  • X 1 is selected from N and CR 6 ;
  • X 2 is selected from N and CR 7 ;
  • X 3 is selected from N and CR 8 ;
  • X 4 is selected from N and CR 9 ;
  • Ring Q 1 is selected from C 3-10 cycloalkyl, heterocyclyl, and heteroaryl;
  • Ring Q 2 is selected from heterocyclyl, aryl, and heteroaryl;
  • L is selected from a bond, - (CR C0 R D0 ) u -, - (CR C0 R D0 ) u O (CR C0 R D0 ) t -, - (CR C0 R D0 ) u NR A0 (CR C0 R D0 ) t -, and - (CR C0 R D0 ) u S (CR C0 R D0 ) t -;
  • R 3 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, CN, NO 2 , -NR A3 R B3 , -OR A3 and -C (O) R A3 , wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R X3 ;
  • R 4 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, CN, NO 2 , -NR A4 R B4 , -OR A4 , -C (O) R A4 , wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R X4 ;
  • R 3 and R 4 together with the atoms to which they are attached form a C 3-10 cycloalkyl or heterocyclic ring of 4 to 12 members containing 1, 2 or 3 heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups;
  • each R A0 is independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1- 4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X0 ;
  • each R A1 and R B1 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X1 ;
  • each R A2 and R B2 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X2 ;
  • each R A3 and R B3 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X3 ;
  • each R A4 and R B4 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X4 ;
  • each R A5 and R B5 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X5 ;
  • each R A6 and R B6 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X6 ;
  • each R A7 and R B7 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X7 ;
  • each R A8 and R B8 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X8 ;
  • each R A9 and R B9 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X9 ;
  • each R C0 and R D0 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X0 ;
  • R C0 and R D0 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen and optionally substituted with 1, 2 or 3 R X0 groups;
  • each R E1 , R E2 , R E5 , R E6 , R E7 , R E8 and R E9 are independently selected from hydrogen, C 1- 10 alkyl, CN, NO 2 , -OR a1 , -SR a1 , -S (O) r R a1 , -C (O) R a1 , -C (O) OR a1 , -C (O) NR a1 R b1 and -S (O) r NR a1 R b1 ;
  • each R X0 , R X1 , R X2 , R X3 , R X4 , R X5 , R X6 , R X7 , R X8 and R X9 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, halogen, CN, NO 2 , - (CR c1 R d1 ) t NR a1 R b1 , - (CR c1 R d1 ) t OR b1 , - (CR c1 R d1 ) t C (O) R a1 , - (CR c1 R
  • each R a1 and each R b1 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y ;
  • R a1 and R b1 together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R Y groups;
  • each R c1 and each R d1 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y ;
  • R c1 and R d1 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1, 2 or 3 R Y groups;
  • each R e1 is independently selected from hydrogen, C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, CN, NO 2 , -OR a2 , -SR a2 , -S (O) r R a2 , -C (O) R a2 , -C (O) OR a2 , -S (O) r NR a2 R b2 and -C (O) NR a2 R b2 ;
  • each R Y is independently selected from C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, halogen, CN, -NO 2 , -NR a2 R b2 , -OR a2 , -SR a2 , -S (O) r R a2 , -S (O) 2 OR a2 , -OS (O) 2 R b2 , -S (O) r NR a2 R b2 , -P (O) R a2 R b2 , -P (O) (OR a2 ) (OR b2 ) , - (CR c2 R d
  • each R a2 and each R b2 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1- 10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino, di (C 1-10 alkyl) amino, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl
  • R a2 and R b2 together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
  • each R c2 and each R d2 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino, di (C 1-10 alkyl) amino, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino,
  • R c2 and R d2 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
  • each R e2 is independently selected from hydrogen, CN, NO 2 , C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, -C (O) C 1-4 alkyl, -C (O) C 3-10 cycloalkyl, -C (O) OC 1-4 alkyl, -C (O) OC 3-10 cycloalkyl, -C (O) N (C 1-4 alkyl) 2 , -C (O) N (C 3-10 cycloalkyl) 2 , -S (O) 2 C 1-4 alkyl, -S (O) 2 C 3-10 cycloalkyl, -S (O) 2 C 1-4 alkyl, -S (O) 2 C 3-10 cycloalkyl, -S (O) 2 N (C 1-4 alkyl) 2 and -S (O)
  • n is selected from 0, 1, 2, 3 and 4;
  • n is selected from 0, 1, 2, 3 and 4;
  • each r is independently selected from 0, 1 and 2;
  • each t is independently selected from 0, 1, 2, 3 and 4;
  • each u is independently selected from 0, 1, 2, 3 and 4.
  • compositions comprising a compound of formula (I) or at least one pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
  • the disclosure provides methods for modulating PARP1, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, thereby modulating said PARP1.
  • a method to treat, ameliorate or prevent a condition which responds to inhibition of PARP1 comprising administering to a system or subject in need of such treatment an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said condition.
  • the present disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a condition mediated by PARP1.
  • the compounds of the disclosure may be used alone or in combination with a second therapeutic agent to treat a condition mediated by PARP1.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating a condition mediated by PARP1.
  • the condition herein includes but not limited to, an autoimmune disease, a transplantation disease, an infectious disease or a cell proliferative disorder.
  • the disclosure provides methods for treating a cell proliferative disorder, comprising administering to a system or subject in need of such treatment an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said condition.
  • the present disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a cell-proliferative disorder.
  • the compounds of the disclosure may be used alone or in combination with a chemotherapeutic agent to treat a cell proliferative disorder.
  • the cell proliferative disorder disclosed herein includes but not limited to, lymphoma, osteosarcoma, melanoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered to a system comprising cells or tissues, or to a subject including a mammalian subject such as a human or animal subject.
  • substituent groups are specified by their conventional chemical formulas, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left.
  • CH 2 O is equivalent to OCH 2 .
  • substituted means that a hydrogen atom is replaced by a substituent. It is to be understood that substitution at a given atom is limited by valency.
  • C i-j or “i-j membered” used herein means that the moiety has i-j carbon atoms or i-j atoms.
  • C 1-6 alkyl means said alkyl has 1-6 carbon atoms.
  • C 3-10 cycloalkyl means said cycloalkyl has 3-10 carbon atoms.
  • any variable e.g. R
  • R any variable
  • the group may be optionally substituted by at most two R and R has independent option at each case.
  • a combination of substituents and/or the variants thereof are allowed only if such a combination will result in a stable compound.
  • hetero means heteroatom or heteroatom radical (i.e. a radical containing heteroatom) , i.e. the atoms beyond carbon and hydrogen atoms or the radical containing such atoms.
  • the heteroatom (s) is independently selected from the group consisting of O, N, S, P and the like.
  • the two or more heteroatoms may be the same, or part or all of the two or more heteroatoms may be different.
  • alkyl refers to branched or straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Unless otherwise specified, “alkyl” refers to C l-10 alkyl. For example, C 1-6 , as in “C l-6 alkyl” is defined to include groups having 1, 2, 3, 4, 5, or 6 carbons in a linear or branched arrangement.
  • C l-8 alkyl includes but is not limited to methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl, pentyl, hexyl, heptyl, and octyl.
  • cycloalkyl employed alone or in combination with other terms, refers to a saturated monocyclic or multicyclic (e.g. bicyclic or tricyclic) hydrocarbon ring system, usually with 3 to 16 ring atoms.
  • the ring atoms of cycloalkyl are all carbon and the cycloalkyl contains zero heteroatoms and zero double bonds.
  • two or more rings can be fused or bridged or spiro together.
  • monocyclic ring systems include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • the bridged cycloalkyl is a polycyclic ring system containing 3-10 carbon atoms, which contains one or two alkylene bridges, each alkylene bridge consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system.
  • Cycloalkyl can be fused with aryl or heteroaryl group. In some embodiments, cycloalkyl is benzocondensed.
  • bridged cycloalkyl ring systems include, but are not limited to, bicyclo [1.1.1] pentane, bicyclo [3.1.1] heptane, bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, bicyclo [3.2.2] nonane, bicyclo [3.3.1] nonane, bicyclo [4.2.1] nonane, tricyclo [3.3.1.03, 7] nonane and tricyclo [3.3.1.13, 7] decane (adamantane) .
  • the cycloalkyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring system.
  • alkenyl refers to a non-aromatic hydrocarbon radical, straight, branched or cyclic, containing 2-10 carbon atoms and at least one carbon to carbon double bond.
  • the cyclic refers to monocyclic or multicyclic. In a multicyclic alkenyl, two or more rings can be fused or bridged or spiro together. In some embodiments, one carbon to carbon double bond is present, and up to four non-aromatic carbon-carbon double bonds may be present.
  • C 2-6 alkenyl means an alkenyl radical having 2-6 carbon atoms.
  • Alkenyl groups include but are not limited to ethenyl, propenyl, butenyl, 2-methylbutenyl, cyclopentenyl and cyclohexenyl.
  • the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated.
  • alkynyl refers to a hydrocarbon radical, straight, branched or cyclic, containing 2-10 carbon atoms and at least one carbon to carbon triple bond. In some embodiments, up to three carbon-carbon triple bonds may be present.
  • C 2-6 alkynyl means an alkynyl radical having 2-6 carbon atoms.
  • Alkynyl groups include but are not limited to ethynyl, propynyl, butynyl, and 3-methylbutynyl.
  • the straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated.
  • halogen refers to fluorine, chlorine, bromine and iodine.
  • alkoxy refers to an alkyl as defined above, which is single bonded to an oxygen atom. The attachment point of an alkoxy radical to a molecule is through the oxygen atom. An alkoxy radical may be depicted as -O-alkyl.
  • C 1-10 alkoxy refers to an alkoxy radical containing 1-10 carbon atoms, having straight or branched moieties. Alkoxy group includes but is not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy, hexyloxy, and the like.
  • cycloalkoxy refers to cycloalkyl as defined above, which is single bonded to an oxygen atom. The attachment point of a cycloalkoxy radical to a molecule is through the oxygen atom. A cycloalkoxy radical may be depicted as -O-cycloalkyl. “C 3-10 cycloalkoxy” refers to a cycloalkoxy radical containing 3-10 carbon atoms. Cycloalkoxy can be fused with aryl or heteroaryl group. In some embodiments, cycloalkoxy is benzocondensed. Cycloalkoxy group includes but is not limited to, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • alkylthio refers to an alkyl radical as defined above, which is single bonded to a sulfur atom. The attachment point of an alkylthio radical to a molecule is through the sulfur atom. An alkylthio radical may be depicted as -S-alkyl.
  • C 1-10 alkylthio refers to an alkylthio radical containing 1-10 carbon atoms, having straight or branched moieties.
  • Alkylthio group includes but is not limited to, methylthio, ethylthio, propylthio, isopropylthio, butylthio, hexylthio, and the like.
  • cycloalkylthio employed alone or in combination with other terms, refers to cycloalkyl as defined above, which is single bonded to a sulfur atom. The attachment point of a cycloalkylthio radical to a molecule is through the sulfur atom. A cycloalkylthio radical may be depicted as -S-cycloalkyl. “C 3-10 cycloalkylthio” refers to a cycloalkylthio radical containing 3-10 carbon atoms. Cycloalkylthio can be fused with aryl or heteroaryl group. In some embodiments, cycloalkylthio is benzocondensed. Cycloalkylthio group includes but is not limited to, cyclopropylthio, cyclobutylthio, cyclohexylthio, and the like.
  • alkylamino refers to an alkyl as defined above, which is single bonded to a nitrogen atom. The attachment point of an alkylamino radical to a molecule is through the nitrogen atom. An alkylamino radical may be depicted as -NH (alkyl) .
  • C 1-10 alkylamino refers to an alkylamino radical containing 1-10 carbon atoms, having straight or branched moieties.
  • Alkylamino group includes but is not limited to, methylamino, ethylamino, propylamino, isopropylamino, butylamino, hexylamoino, and the like.
  • cycloalkylamino employed alone or in combination with other terms, refers to cycloalkyl as defined above, which is single bonded to a nitrogen atom. The attachment point of a cycloalkylamino radical to a molecule is through the nitrogen atom.
  • a cycloalkylamino radical may be depicted as -NH (cycloalkyl) .
  • C 3-10 cycloalkylamino refers to a cycloalkylamino radical containing 3-10 carbon atoms.
  • Cycloalkylamino can be fused with aryl or heteroaryl group. In some embodiments, cycloalkylamino is benzocondensed. Cycloalkylamino group includes but is not limited to, cyclopropylamino, cyclobutylamino, cyclohexylamino, and the like.
  • di (alkyl) amino refers to two alkyl as defined above, which are single bonded to a nitrogen atom.
  • the attachment point of an di (alkyl) amino radical to a molecule is through the nitrogen atom.
  • a di (alkyl) amino radical may be depicted as -N (alkyl) 2 .
  • di (C 1-10 alkyl) amino refers to a di (C 1-10 alkyl) amino radical wherein the alkyl radicals each independently contains 1-10 carbon atoms, having straight or branched moieties.
  • aryl refers to a monovalent, monocyclic-, bicyclic-or tricyclic aromatic hydrocarbon ring system having 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms (a “C 6-14 aryl” group) , particularly a ring having 6 carbon atoms (a “C 6 aryl” group) , e.g. a phenyl group; or a ring having 10 carbon atoms (a “C 10 aryl” group) , e.g. a naphthyl group; or a ring having 14 carbon atoms, (a “C 14 aryl” group) , e.g. an anthranyl group.
  • Aryl can be fused with cycloalkyl or heterocycle group.
  • Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals.
  • Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in “-yl” by removal of one hydrogen atom from the carbon atom with the free valence are named by removing “-yl” and adding “-idene” to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene.
  • heteroaryl refers to a monovalent, monocyclic-, bicyclic-or tricyclic aromatic ring system having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms (a “5-to 14-membered heteroaryl” group) , particularly 5 or 6 or 9 or 10 atoms, and which contains at least one heteroatom which may be identical or different, said heteroatom selected from N, O and S.
  • Heteroaryl can be fused with cycloalkyl or heterocycle group.
  • “heteroaryl” refers to
  • a 5-to 8-membered monocyclic aromatic ring containing one or more, for example, from 1 to 4, or, in some embodiments, from 1 to 3, heteroatoms selected from N, O and S, with the remaining ring atoms being carbon; or
  • a 8-to 12-membered bicyclic aromatic ring system containing one or more, for example, from 1 to 6, or, in some embodiments, from 1 to 4, or, in some embodiments, from 1 to 3, heteroatoms selected from N, O and S, with the remaining ring atoms being carbon; or
  • a 11-to 14-membered tricyclic aromatic ring system containing one or more, for example, from 1 to 8, or, in some embodiments, from 1 to 6, or, in some embodiments, from 1 to 4, or in some embodiments, from 1 to 3, heteroatoms selected from N, O and S, with the remaining ring atoms being carbon.
  • the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • heteroaryl groups include, but are not limited to, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, pyrazin-2-yl, pyrazin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, pyridazinyl, triazinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, triazolyl, tetrazolyl, thienyl, furyl.
  • heteroaryl groups include but are not limited to indolyl, benzothienyl, benzofuryl, benzoimidazolyl, benzotriazolyl, quinoxalinyl, quinolinyl, and isoquinolinyl.
  • Heteroaryl is also understood to include the N-oxide derivative of any nitrogen-containing heteroaryl.
  • Bivalent radicals derived from univalent heteroaryl radicals whose names end in “-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylidene.
  • heterocycle employed alone or in combination with other terms, (and variations thereof such as “heterocyclic” , or “heterocyclyl” ) broadly refers to a saturated or unsaturated mono-or multicyclic (e.g. bicyclic or tricyclic) aliphatic ring system, usually with 3 to 16 ring atoms, wherein at least one (e.g. 2, 3 or 4) ring atom is heteroatom independently selected from O, S, N and P (preferably O, S, N) .
  • two or more rings can be fused or bridged or spiro together.
  • Heterocycle can be fused with aryl or heteroaryl group.
  • heterocycle is benzocondensed.
  • Heterocycle also includes ring systems substituted with one or more oxo or imino moieties.
  • the C, N, S and P atoms in the heterocycle ring are optionally substituted by oxo.
  • the C, S and P atoms in the heterocycle ring are optionally substituted by imino, and imino can be unsubstituted or substituted.
  • the point of the attachment may be carbon atom or heteroatom in the heterocyclic ring, provided that attachment results in the creation of a stable structure.
  • the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure result.
  • Suitable heterocycles include, for example, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-3-yl, imidazolidin-4-yl, imidazolidin-5-yl, pyrazolidin-1-yl, pyrazolidin-2-yl, pyrazolidin-3-yl, pyrazolidin-4-yl, pyrazolidin-5-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, hexahydropyridazin-1-yl, hexahydropyridazin-3-yl, hexahydropyridazin-4-yl and tetrahydropyridy
  • Morpholinyl groups are also contemplated, such as morpholin-1-yl, morpholin-2-yl, morpholin-3-yl and morpholin-4-yl.
  • heterocycle with one or more oxo moieties include but are not limited to, piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-thiomorpholinyl and 1, 1-dioxo-thiomorpholinyl.
  • Bicyclic heterocycles include, for example:
  • aryl-alkyl refers to an alkyl moiety as defined above substituted by an aryl group as defined above.
  • exemplary aryl-alkyl groups include but are not limited to benzyl, phenethyl and naphthylmethyl groups. In some embodiments, aryl-alkyl groups have 7-20 or 7-11 carbon atoms.
  • C 1-4 refers to the alkyl portion of the moiety and does not describe the number of atoms in the aryl portion of the moiety.
  • heterocyclyl-alkyl refers to alkyl as defined above substituted by heterocyclyl as defined above.
  • C 1-4 alkyl refers to the alkyl portion of the moiety and does not describe the number of atoms in the heterocyclyl portion of the moiety.
  • cycloalkyl-alkyl refers to alkyl as defined above substituted by cycloalkyl as defined above.
  • C 3-10 cycloalkyl-C l-4 alkyl refers to the cycloalkyl portion of the moiety and does not describe the number of atoms in the alkyl portion of the moiety
  • C 1-4 refers to the alkyl portion of the moiety and does not describe the number of atoms in the cycloalkyl portion of the moiety.
  • heteroaryl-alkyl refers to alkyl as defined above substituted by heteroaryl as defined above.
  • C 1- 4 refers to the alkyl portion of the moiety and does not describe the number of atoms in the heteroaryl portion of the moiety.
  • substitution of alkyl, cycloalkyl, heterocyclyl, aryl and/or heteroaryl refers to substitution of each of those groups individually as well as to substitutions of combinations of those groups. That is, if R is aryl-C l- 4 alkyl and may be unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R X , it should be understood that the aryl portion may be unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R X and the alkyl portion may also be unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituens, independently selected from R X .
  • salts derived from inorganic bases may be selected, for example, from aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium and zinc salts. Further, for example, the pharmaceutically acceptable salts derived from inorganic bases may be selected from ammonium, calcium, magnesium, potassium and sodium salts. Salts in the solid form may exist in one or more crystalline forms, or polymorphs, and may also be in the form of solvates, such as hydrates.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases may be selected, for example, from salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N, N'-dibenzylethylene-diamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine and tripropylamine, tromethamine.
  • basic ion exchange resins
  • salts may be prepared using at least one pharmaceutically acceptable non-toxic acid, selected from inorganic and organic acids.
  • acid may be selected, for example, from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric and p-toluenesulfonic acids.
  • such acid may be selected, for example, from citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric and tartaric acids.
  • administering should be understood to mean providing a compound or a pharmaceutically acceptable salt thereof to the individual in recognized need of treatment.
  • the term “effective amount” means the amount of the a compound or a pharmaceutically acceptable salt that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • composition in relation to a pharmaceutical composition is intended to encompass a product comprising the active ingredient (s) and the inert ingredient (s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • pharmaceutically acceptable it is meant compatible with the other ingredients of the formulation and not unacceptably deleterious to the recipient thereof.
  • subject in reference to individuals suffering from a disorder, a condition, and the like, encompasses mammals and non-mammals.
  • mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
  • non-mammals include, but are not limited to, birds, fish and the like.
  • the mammal is a human.
  • treat, ” “treating” or “treatment, ” and other grammatical equivalents as used herein, include alleviating, abating or ameliorating a disease or condition, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition, and are intended to include prophylaxis.
  • the terms further include achieving a therapeutic benefit and/or a prophylactic benefit.
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
  • compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
  • protecting group refers to a substituent that can be commonly employed to block or protect a certain functionality while reacting other functional groups on the compound.
  • an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include but are not limited to acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC) , benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc) .
  • a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality.
  • Suitable protecting groups include but are not limited to acetyl and silyl.
  • a “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Common carboxy-protecting groups include -CH 2 CH 2 SO 2 Ph, cyanoethyl, 2- (trimethylsilyl) ethyl, 2- (trimethylsilyl) ethoxymethyl, 2- (p-toluenesulfonyl) ethyl, 2- (p-nitrophenylsulfenyl) ethyl, 2- (diphenylphosphino) -ethyl, nitroethyl and the like.
  • protecting groups and their use see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley &Sons, New York, 1991.
  • NH protecting group includes, but not limited to, trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycarbonyl, para-nitrobenzylcarbonyl, ortho-bromobenzyloxycarbonyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, para-methoxybenzyloxycarbonyl, 3, 4-dimethoxybenzyl-oxycarbonyl, 4- (phenylazo) -benzyloxycarbonyl, 2-furfuryloxycarbonyl, diphenylmethoxycarbonyl, 1, 1-dimethylpropoxy-carbonyl, isopropoxycarbonyl, phthaloyl, succinyl, alanyl, leu
  • C (O) OH protecting group includes, but not limited to, methyl, ethyl, n-propyl, isopropyl, 1, 1-dimethylpropyl, n-butyl, tert-butyl, phenyl, naphthyl, benzyl, diphenylmethyl, triphenylmethyl, para-nitrobenzyl, para-methoxybenzyl, bis (para-methoxyphenyl) methyl, acetylmethyl, benzoylmethyl, para-nitrobenzoylmethyl, para-bromobenzoylmethyl, para-methanesulfonylbenzoylmethyl, 2-tetrahydropyranyl, 2-tetrahydrofuranyl, 2, 2, 2-trichloro-ethyl, 2- (trimethylsilyl) ethyl, acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, phthalimidomethyl, succinimid
  • OH or SH protecting group includes, but not limited to, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3, 4-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 1, 1-dimethylpropoxycarbonyl, isopropoxycarbonyl, isobutyloxycarbonyl, diphenylmethoxycarbonyl, 2, 2, 2-trichloroethoxycarbonyl, 2, 2, 2-tribromoethoxycarbonyl, 2- (trimethylsilyl) ethoxycarbonyl, 2- (phenylsulfonyl) ethoxycarbonyl, 2- (triphenylphosphonio) ethoxycarbonyl, 2-furfuryloxycarbonyl, 1-adamantyloxycarbonyl, vinyloxycarbonyl, allyl
  • Geometric isomers may exist in the present compounds.
  • Compounds of this invention may contain carbon-carbon double bonds or carbon-nitrogen double bonds in the E or Z configuration, wherein the term “E” represents higher order substituents on opposite sides of the carbon-carbon or carbon-nitrogen double bond and the term “Z” represents higher order substituents on the same side of the carbon-carbon or carbon-nitrogen double bond as determined by the Cahn-Ingold-Prelog Priority Rules.
  • the compounds of this invention may also exist as a mixture of "E” and "Z” isomers. Substituents around a cycloalkyl or heterocycloalkyl are designated as being of cis or trans configuration.
  • the invention contemplates the various isomers and mixtures thereof resulting from the disposal of substituents around an adamantane ring system.
  • Two substituents around a single ring within an adamantane ring system are designated as being of Z or E relative configuration.
  • C. D. Jones, M. Kaselj, R. N. Salvatore, W. J. le Noble J. Org. Chem. 1998, 63, 2758-2760 See C. D. Jones, M. Kaselj, R. N. Salvatore, W. J. le Noble J. Org. Chem. 1998, 63, 2758-2760.
  • Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, in which the terms "R” and “S” are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10.
  • Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those carbon atoms. Atoms with an excess of one configuration over the other are assigned the configuration present in the higher amount, preferably an excess of about 85-90%, more preferably an excess of about 95-99%, and still more preferably an excess greater than about 99%.
  • this invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers.
  • Compounds of the invention can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature.
  • Isotopes can be radioactive or non-radioactive isotopes.
  • Isotopes of atoms such as hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine include, but are not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 32 P, 35 S, 18 F, 36 Cl and 125 I.
  • Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.
  • the isotope-labeled compounds contain deuterium ( 2 H) , tritium ( 3 H) or 14 C isotopes.
  • Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope-labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope-labeled reagent for a non-labeled reagent.
  • compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuterated acid such as D 2 SO 4 /D 2 O.
  • a deuterated acid such as D 2 SO 4 /D 2 O.
  • the isotope-labeled compounds of the invention may be used as standards to determine the effectiveness of PARP1 inhibitors in binding assays.
  • Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975) ) .
  • Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp.
  • non-radioactive isotope containing drugs such as deuterated drugs called “heavy drugs” can be used for the treatment of diseases and conditions related to PARP1 activity.
  • Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment.
  • Examples of the amount of enrichment include but are not limited to from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %.
  • Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmacokinetic profile or efficacy relative to the non-isotopic compound.
  • this invention provides to a compound of formula (I) :
  • X 1 is selected from N and CR 6 ;
  • X 2 is selected from N and CR 7 ;
  • X 3 is selected from N and CR 8 ;
  • X 4 is selected from N and CR 9 ;
  • Ring Q 1 is selected from C 3-10 cycloalkyl, heterocyclyl, and heteroaryl;
  • Ring Q 2 is selected from heterocyclyl, aryl, and heteroaryl;
  • L is selected from a bond, - (CR C0 R D0 ) u -, - (CR C0 R D0 ) u O (CR C0 R D0 ) t -, - (CR C0 R D0 ) u NR A0 (CR C0 R D0 ) t -, and - (CR C0 R D0 ) u S (CR C0 R D0 ) t -;
  • R 3 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, CN, NO 2 , - NR A3 R B3 , -OR A3 and -C (O) R A3 , wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R X3 ;
  • R 4 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, CN, NO 2 , -NR A4 R B4 , -OR A4 , -C (O) R A4 , wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R X4 ;
  • R 3 and R 4 together with the atoms to which they are attached form a C 3-10 cycloalkyl or heterocyclic ring of 4 to 12 members containing 1, 2 or 3 heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups;
  • each R A0 is independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1- 4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X0 ;
  • each R A1 and R B1 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X1 ;
  • each R A2 and R B2 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X2 ;
  • each R A3 and R B3 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X3 ;
  • each R A4 and R B4 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X4 ;
  • each R A5 and R B5 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X5 ;
  • each R A6 and R B6 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X6 ;
  • each R A7 and R B7 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X7 ;
  • each R A8 and R B8 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X8 ;
  • each R A9 and R B9 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X9 ;
  • each R C0 and R D0 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X0 ;
  • R C0 and R D0 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen and optionally substituted with 1, 2 or 3 R X0 groups;
  • each R E1 , R E2 , R E5 , R E6 , R E7 , R E8 and R E9 are independently selected from hydrogen, C 1- 10 alkyl, CN, NO 2 , -OR a1 , -SR a1 , -S (O) r R a1 , -C (O) R a1 , -C (O) OR a1 , -C (O) NR a1 R b1 and -S (O) r NR a1 R b1 ;
  • each R X0 , R X1 , R X2 , R X3 , R X4 , R X5 , R X6 , R X7 , R X8 and R X9 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, halogen, CN, NO 2 , - (CR c1 R d1 ) t NR a1 R b1 , - (CR c1 R d1 ) t OR b1 , - (CR c1 R d1 ) t C (O) R a1 , - (CR c1 R
  • each R a1 and each R b1 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y ;
  • R a1 and R b1 together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R Y groups;
  • each R c1 and each R d1 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y ;
  • R c1 and R d1 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1, 2 or 3 R Y groups;
  • each R e1 is independently selected from hydrogen, C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, CN, NO 2 , -OR a2 , -SR a2 , -S (O) r R a2 , -C (O) R a2 , -C (O) OR a2 , -S (O) r NR a2 R b2 and -C (O) NR a2 R b2 ;
  • each R Y is independently selected from C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, halogen, CN, -NO 2 , -NR a2 R b2 , -OR a2 , -SR a2 , -S (O) r R a2 , -S (O) 2 OR a2 , -OS (O) 2 R b2 , -S (O) r NR a2 R b2 , -P (O) R a2 R b2 , -P (O) (OR a2 ) (OR b2 ) , - (CR c2 R d
  • each R a2 and each R b2 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1- 10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino, di (C 1-10 alkyl) amino, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl
  • R a2 and R b2 together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
  • each R c2 and each R d2 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino, di (C 1-10 alkyl) amino, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino,
  • R c2 and R d2 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
  • each R e2 is independently selected from hydrogen, CN, NO 2 , C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, -C (O) C 1-4 alkyl, -C (O) C 3-10 cycloalkyl, -C (O) OC 1-4 alkyl, -C (O) OC 3-10 cycloalkyl, -C (O) N (C 1-4 alkyl) 2 , -C (O) N (C 3-10 cycloalkyl) 2 , -S (O) 2 C 1-4 alkyl, -S (O) 2 C 3-10 cycloalkyl, -S (O) 2 C 1-4 alkyl, -S (O) 2 C 3-10 cycloalkyl, -S (O) 2 N (C 1-4 alkyl) 2 and -S (O)
  • n is selected from 0, 1, 2, 3 and 4;
  • n is selected from 0, 1, 2, 3 and 4;
  • each r is independently selected from 0, 1 and 2;
  • each t is independently selected from 0, 1, 2, 3 and 4;
  • each u is independently selected from 0, 1, 2, 3 and 4.
  • the invention provides a compound of Embodiment (1) or a pharmaceutically acceptable salt thereof, wherein X 1 is N.
  • the invention provides a compound of Embodiment (1) or a pharmaceutically acceptable salt thereof, wherein X 1 is CR 6 .
  • the invention provides a compound of any one of Embodiments (1) - (3) or a pharmaceutically acceptable salt thereof, wherein X 2 is N.
  • the invention provides a compound of any one of Embodiments (1) - (3) or a pharmaceutically acceptable salt thereof, wherein X 2 is CR 7 .
  • the invention provides a compound of any one of Embodiments (1) - (5) or a pharmaceutically acceptable salt thereof, wherein X 3 is N.
  • the invention provides a compound of any one of Embodiments (1) - (5) or a pharmaceutically acceptable salt thereof, wherein X 3 is CR 8 .
  • the invention provides a compound of any one of Embodiments (1) - (7) or a pharmaceutically acceptable salt thereof, wherein X 4 is N.
  • the invention provides a compound of any one of Embodiments (1) - (7) or a pharmaceutically acceptable salt thereof, wherein X 4 is CR 9 .
  • the invention provides a compound of any one of Embodiment (1) and (3) - (9) or a pharmaceutically acceptable salt thereof, wherein R 6 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2 , -NR A6 R B6 , -OR A6 , -C (O) R A6 , -C (O) OR A6 , -OC (O) R A6 , -C (O) NR A6 R B6 , -NR A6 C (O) R B6 , -OC (O) NR A6 R B6 , -NR A6 C (O) OR B6 , -NR A6 C (O) NR A6 R B6 , -NR A6 C (S) NR A6 R B6 , -S (O) 2 OR A6 , -OS (O) 2 R A6 , -OS (O) 2 R A6
  • R 6 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2 , -OH and -NH 2 .
  • R 6 is selected from hydrogen F, Cl, CN, and methyl.
  • the invention provides a compound of any one of Embodiment (1) - (3) and (5) - (10) or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2 , -NR A7 R B7 , -OR A7 , -C (O) R A7 , -C (O) OR A7 , -OC (O) R A7 , -C (O) NR A7 R B7 , -NR A7 C (O) R B7 , -OC (O) NR A7 R B7 , -NR A7 C (O) OR B7 , -NR A7 C (O) NR A7 R B7 , -NR A7 C (S) NR A7 R B7 , -S (O) 2 OR A7 , -OS (O) 2 R A7
  • the invention provides a compound of Embodiment (11) or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2 , -NR A7 R B7 and -OR A7 , wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X7 .
  • R 7 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2 , -OH and -NH 2 .
  • R 7 is selected from hydrogen and F.
  • the invention provides a compound of any one of Embodiment (1) - (5) and (7) - (12) or a pharmaceutically acceptable salt thereof, wherein R 8 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2 , -NR A8 R B8 , -OR A8 , -C (O) R A8 , -C (O) OR A8 , -OC (O) R A8 , -C (O) NR A8 R B8 , -NR A8 C (O) R B8 , -OC (O) NR A8 R B8 , -NR A8 C (O) OR B8 , -NR A8 C (O) NR A8 R B8 , -NR A8 C (S) NR A8 R B8 , -S (O) 2 OR A8 , -OS (O) 2 R A
  • the invention provides a compound of Embodiment (13) or a pharmaceutically acceptable salt thereof, wherein R 8 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2 , -NR A8 R B8 and -OR A8 , wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X8 .
  • R 8 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2 , -OH and -NH 2 .
  • R 8 is hydrogen.
  • the invention provides a compound of any one of Embodiment (1) - (7) and (9) - (14) or a pharmaceutically acceptable salt thereof, wherein R 9 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2 , -NR A9 R B9 , -OR A9 , -C (O) R A9 , -C (O) OR A9 , -OC (O) R A9 , -C (O) NR A9 R B9 , -NR A9 C (O) R B9 , -OC (O) NR A9 R B9 , -NR A9 C (O) OR B9 , -NR A9 C (O) NR A9 R B9 , -NR A9 C (S) NR A9 R B9 , -S (O) 2 OR A9 , -OS (O) 2 R A9 , -OS (O)
  • the invention provides a compound of Embodiment (15) or a pharmaceutically acceptable salt thereof, wherein R 9 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2 , -NR A9 R B9 and -OR A9 , wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X9 .
  • R 9 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2 , -OH and -NH 2 .
  • R 9 is hydrogen.
  • the invention provides a compound of any one of Embodiments (1) - (16) or a pharmaceutically acceptable salt thereof, wherein the moiety in Formula (I) is selected from In another Embodiment, in Formula (I) is
  • the invention provides a compound of any one of Embodiments (1) - (17) or a pharmaceutically acceptable salt thereof, wherein R 5 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2 , -NR A5 R B5 , -OR A5 , -C (O) R A5 , -C (O) OR A5 , -OC (O) R A5 , -C (O) NR A5 R B5 , -NR A5 C (O) R B5 , -OC (O) NR A5 R B5 , -NR A5 C (O) OR B5 ,
  • the invention provides a compound of Embodiment (18) or a pharmaceutically acceptable salt thereof, wherein R 5 is selected from hydrogen, halogen, methyl, ethyl, methoxy, ethoxy, isopropyl, cyclopropyl, phenyl, CN, NO 2 , -NH 2 and -OH, wherein methyl, ethyl, isopropyl, cyclopropyl and phenyl are each unsubstituted or substituted with at least one substituent, independently selected from R X5 .
  • R 5 is selected from hydrogen, halogen, methyl, ethyl, methoxy, ethoxy, isopropyl, cyclopropyl, phenyl, CN, NO 2 , -NH 2 and -OH, wherein methyl, ethyl, isopropyl, cyclopropyl and phenyl are each unsubstituted or substituted with at least one substituent, independently
  • R 5 is selected from hydrogen, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, methoxy, ethoxy, isopropyl, methoxymethyl, cyclopropyl and phenyl.
  • the invention provides a compound of any one of Embodiments (1) - (19) or a pharmaceutically acceptable salt thereof, wherein Q 1 is heterocyclyl.
  • the invention provides a compound of Embodiment (20) or a pharmaceutically acceptable salt thereof, wherein Q 1 is selected from In another Embodiment, Q 1 is selected from
  • the invention provides a compound of any one of Embodiments (1) - (21) or a pharmaceutically acceptable salt thereof, wherein each R 2 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, C 3- 10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2 , -NR A2 R B2 , -OR A2 , -C (O) R A2 , -C (O) OR A2 , -OC (O) R A2 , -C (O) NR A2 R B2 , -NR A2 C (O) R B2 , -OC (O) NR A2 R B2 , -NR A2 C (O) OR B2
  • the invention provides a compound of Embodiment (22) or a pharmaceutically acceptable salt thereof, wherein each R 2 is independently selected from hydrogen, F, Cl, Br, methyl, ethyl, isopropyl, cyclopropyl, methoxy, ethoxy, -OC (O) CH 3 , -CN, -NO 2 , -NH 2 and -OH, wherein methyl, ethyl, isopropyl and cyclopropyl are each unsubstituted or substituted with at least one substituent, independently selected from R X2 .
  • each R 2 is independently selected from hydrogen, F, Cl, Br, methyl, ethyl, isopropyl, cyclopropyl, methoxy, ethoxy, -OC (O) CH 3 , -CN, -NO 2 , -NH 2 and -OH, wherein methyl, ethyl, isopropyl and cyclopropyl are each unsubstituted or substituted with at least one substituent, independently selected from methoxy, ethoxy, F, Cl, Br, -CN, -NO 2 , -NH 2 and -OH.
  • each R 2 is independently selected from hydrogen, F, Cl, Br, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, ethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, methoxy, ethoxy, methoxymethyl, -OC (O) CH 3 , -CN, -NO 2 , -NH 2 and -OH.
  • Embodiment (24) the invention provides a compound of any one of Embodiments (1) - (23) or a pharmaceutically acceptable salt thereof, wherein the moiety in Formula (I) is selected from
  • the invention provides a compound of any one of Embodiments (1) - (24) or a pharmaceutically acceptable salt thereof, wherein L is selected from a bond, -CR C0 R D0 -, - (CR C0 R D0 ) u O (CR C0 R D0 ) t -, - (CR C0 R D0 ) u NR A0 (CR C0 R D0 ) t -and - (CR C0 R D0 ) u S (CR C0 R D0 ) t -.
  • the invention provides a compound of Embodiment (25) or a pharmaceutically acceptable salt thereof, wherein L is selected from a bond, -CH 2 -, -O-, -NH-, and -S-. In another Embodiment, L is selected from a bond, -O-and -NH-.
  • the invention provides a compound of any one of Embodiments (1) - (26) or a pharmaceutically acceptable salt thereof, wherein Q 2 is selected from 5-12 membered heterocyclyl, aryl, and heteroaryl.
  • the invention provides a compound of Embodiment (27) or a pharmaceutically acceptable salt thereof, wherein Q 2 is selected from In another Embodiment, wherein Q 2 is selected from
  • each R 1 is independently selected from methyl, ethyl, isopropyl, cyclopropyl, F, Cl, CN, NO 2 , -NR A1 R B1 , -NR A1 C (O) R B1 , -NR A1 C (O) OR B1 , -NR A1 C (O) NR A1 R B1 , -NR A1 S (O) r R B1 , -OR A1 , -C (O) R A1 , -C (O) OR A1 , -OC (O) R A1 , -C (O) NR A1 R B1 , -C (O) NR A1 S (O) r R A1 , -C (O) NR A1 S (O) r NR A1 R B1 , -C (O) NR A1 NR A1 R B1 , -C (O) NR A1 NR A1 R B1 , -C
  • the invention provides a compound of Embodiment (30) or a pharmaceutically acceptable salt thereof, wherein each R A1 and R B1 are independently selected from hydrogen, deuterium, C 1-10 alkyl, C 3-10 cycloalkyl, heterocyclyl and C 1-10 alkoxy, wherein alkyl, cycloalkyl, heterocyclyl and alkoxy are each unsubstituted or substituted with at least one substituent, independently selected from R X1 .
  • each R A1 and R B1 are independently selected from hydrogen, deuterium, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, methoxy and ethoxy, wherein methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, methoxy and ethoxy are each unsubstituted or substituted with at least one substituent, independently selected from R X1 .
  • the invention provides a compound of Embodiment (30) or a pharmaceutically acceptable salt thereof, wherein each “R A1 and R B1 ” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 8 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X1 groups.
  • the invention provides a compound of any one of Embodiments (1) - (32) or a pharmaceutically acceptable salt thereof, wherein each R X1 is independently selected from C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, halogen, CN, NO 2 , - (CR c1 R d1 ) t NR a1 R b1 , - (CR c1 R d1 ) t OR b1 , - (CR c1 R d1 ) t NR a1 C (O) R b1 , - (CR c1 R d1 ) t NR a1 C (O) OR b1 and - (CR c1 R d1 ) t NR a1 S (O) r R b1 , wherein alkyl and cycloalkyl are each unsubstituted or substituted
  • the invention provides a compound of Embodiment (33) or a pharmaceutically acceptable salt thereof, wherein each R X1 is independently selected from methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -OH, -NO 2 , -NH 2 , -NHCH 3 , -NHCH 2 CH 3 , -NHC (O) CH 3 , -NHC (O) OCH 3 , wherein methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, methoxy and ethoxy are each unsubstituted or substituted with at least one substituent, independently selected from R Y .
  • each R X1 is independently selected from methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, isopropyl, tert-butyl, cyclopropyl, methoxy, ethoxy, F, -CN, -NH 2 , -NHCH 3 , -NHCH 2 CH 3 , -NHC (O) CH 3 , -NHC (O) OCH 3 ,
  • the invention provides a compound of any one of Embodiments (1) - (34) or a pharmaceutically acceptable salt thereof, wherein the moiety in Formula (I) is selected from
  • the invention provides a compound of any one of Embodiments (1) - (35) or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, -NH 2 and -OH, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X3 .
  • R 3 is selected from hydrogen and methyl, wherein methyl is unsubstituted or substituted with at least one substituent, independently selected from R X3 .
  • the invention provides a compound of Embodiment (36) or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from hydrogen and methyl.
  • the invention provides a compound of any one of Embodiments (1) - (37) or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, -NH 2 and -OH, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X4 . In another Embodiment, wherein R 4 is selected from hydrogen and methyl, which is unsubstituted or substituted with at least one substituent, independently selected from R X4 .
  • the invention provides a compound of Embodiment (38) or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from hydrogen and methyl.
  • the invention provides a compound of any one of Embodiments (1) - (35) or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 together with the atoms to which they are attached form a C 3-10 cycloalkyl or heterocyclic ring of 4 to 8 members containing 1, 2 or 3 heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups.
  • the invention provides a compound of Embodiment (40) or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 together with the atoms to which they are attached form a cyclopropyl, and optionally substituted with 1, 2 or 3 R X3 groups. In another Embodiment, wherein R 3 and R 4 together with the atoms to which they are attached form a cyclopropyl.
  • the invention provides a compound selected from
  • the invention provides a compound selected from
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of any one of Embodiments (1) - (43) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.
  • the invention provides a method of treating, ameliorating or preventing a condition, which responds to inhibition of PARP1, comprising administering to a subject in need of such treatment an effective amount of a compound of any one of Embodiments (1) - (43) , or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent.
  • the invention provides a use of a compound of any one of Embodiments (1) - (43) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a cell-proliferative disorder.
  • the invention provides a use of a compound of Embodiment (46) or a pharmaceutically acceptable salt thereof, wherein the cell- proliferative disorder is includes but not limited to, breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, testicular cancer, lung cancer (including NSCLC, SCLC, squamous cell carcinoma or adenocarcinoma) , esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer (including RCC) , liver cancer (including HCC) , pancreatic cancer, stomach (i.e., gastric) cancer, thyroid cancer, chronic lymphocytic leukemia (CLL) , lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia and myeloma.
  • the cell- proliferative disorder is includes but not limited to, breast cancer, ovarian cancer, bladder cancer,
  • composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
  • kits comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof; and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the composition is to be administered, storage information for the composition, dosing information and instructions regarding how to administer the composition.
  • the kit comprises the compound in a multiple dose form.
  • an article of manufacture comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof; and packaging materials.
  • the packaging material comprises a container for housing the compound.
  • the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the compound.
  • the article of manufacture comprises the compound in a multiple dose form.
  • a therapeutic method comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
  • a method of inhibiting a PARP1 comprising contacting the PARP1 with a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
  • a method of inhibiting a PARP1 comprising causing a compound disclosed herein, or a pharmaceutically acceptable salt thereof to be present in a subject in order to inhibit the PARP1 in vivo.
  • a method of inhibiting PARP1 comprising administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits the PARP1 in vivo, the second compound being a compound according to any one of the above embodiments and variations.
  • a method of treating a disease state for which a PARP1 possesses activity that contributes to the pathology and/or symptomology of the disease state comprising causing a compound disclosed herein, or a pharmaceutically acceptable salt thereof to be present in a subject in a therapeutically effective amount for the disease state.
  • a method of treating a disease state for which a PARP1 possesses activity that contributes to the pathology and/or symptomology of the disease state comprising administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits the PARP1 in vivo.
  • the compounds of the present invention may be the first or second compounds.
  • the disease state is selected from the group consisting of cancerous hyperproliferative disorders (e.g., brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, epidermoid, esophageal, testicular, gynecological or thyroid cancer) ; non-cancerous hyperproliferative disorders (e.g., benign hyperplasia of the skin (e.g., psoriasis) , restenosis, and benign prostatic hypertrophy (BPH) ) ; pancreatitis; kidney disease; pain; preventing blastocyte implantation; treating diseases related to vasculogenesis or angiogenesis (e.g., tumor angiogenesis, acute and chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and
  • a method of treating a disease state for which a mutation in the PARP1 gene contributes to the pathology and/or symptomology of the disease state including, for example, melanomas, lung cancer, colon cancer and other tumor types.
  • the present invention relates to the use of a compound of any of the above embodiments and variations as a medicament. In yet another of its aspects, the present invention relates to the use of a compound according to any one of the above embodiments and variations in the manufacture of a medicament for inhibiting a PARP1.
  • the present invention relates to the use of a compound according to any one of the above embodiments and variations in the manufacture of a medicament for treating a disease state for which a PARP1 possesses activity that contributes to the pathology and/or symptomology of the disease state.
  • compounds of the disclosure will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents.
  • a therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors known to those of ordinary skill in the art.
  • the required dosage will also vary depending on the mode of administration, the particular condition to be treated and the effect desired.
  • an indicated daily dosage in the larger mammal may be in the range from about 0.5 mg to about 2000 mg, or more particularly, from about 0.5 mg to about 1000 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form.
  • Suitable unit dosage forms for oral administration comprise from ca. 1 to 50 mg active ingredient.
  • Compounds of the disclosure may be administered as pharmaceutical compositions by any conventional route; for example, enterally, e.g., orally, e.g., in the form of tablets or capsules; parenterally, e.g., in the form of injectable solutions or suspensions; or topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form.
  • enterally e.g., orally, e.g., in the form of tablets or capsules
  • parenterally e.g., in the form of injectable solutions or suspensions
  • topically e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form.
  • compositions comprising a compound of the present disclosure in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent may be manufactured in a conventional manner by mixing, granulating, coating, dissolving or lyophilizing processes.
  • pharmaceutical compositions comprising a compound of the disclosure in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent.
  • Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance.
  • the pharmaceutical compositions are solutions of the active ingredient, including suspensions or dispersions, such as isotonic aqueous solutions.
  • suspensions or dispersions such as isotonic aqueous solutions.
  • dispersions or suspensions can be made up before use.
  • the pharmaceutical compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.
  • Suitable preservatives include but are not limited to antioxidants such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid.
  • solutions or suspensions may further comprise viscosity-increasing agents, including but not limited to, sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, gelatins, or solubilizers, e.g. Tween 80 (polyoxyethylene (20) sorbitan mono-oleate) .
  • viscosity-increasing agents including but not limited to, sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, gelatins, or solubilizers, e.g. Tween 80 (polyoxyethylene (20) sorbitan mono-oleate) .
  • Suspensions in oil may comprise as the oil component the vegetable, synthetic, or semi-synthetic oils customary for injection purposes.
  • oils customary for injection purposes.
  • examples include but are not limited to liquid fatty acid esters that contain as the acid component a long-chained fatty acid having 8-22 carbon atoms, or in some embodiments, 12-22 carbon atoms.
  • Suitable liquid fatty acid esters include but are not limited to lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brassidic acid and linoleic acid, and if desired, may contain antioxidants, for example vitamin E, 3-carotene or 3, 5-di-tert-butyl-hydroxytoluene.
  • the alcohol component of these fatty acid esters may have six carbon atoms and may be monovalent or polyvalent, for example a mono-, di-or trivalent, alcohol. Suitable alcohol components include but are not limited to methanol, ethanol, propanol, butanol or pentanol or isomers thereof; glycol and glycerol.
  • Suitable fatty acid esters include but are not limited ethyl-oleate, isopropyl myristate, isopropyl palmitate, M 2375, (polyoxyethylene glycerol) , M 1944 CS (unsaturated polyglycolized glycerides prepared by alcoholysis of apricot kernel oil and comprising glycerides and polyethylene glycol ester) , LABRASOL TM (saturated polyglycolized glycerides prepared by alcoholysis of TCM and comprising glycerides and polyethylene glycol ester; all available from GaKefosse, France) , and/or 812 (triglyceride of saturated fatty acids of chain length C8 to C12 from Hüls AG, Germany) , and vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil, or groundnut oil.
  • vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, ses
  • compositions for oral administration may be obtained, for example, by combining the active ingredient with one or more solid carriers, and if desired, granulating a resulting mixture, and processing the mixture or granules by the inclusion of additional excipients, to form tablets or tablet cores.
  • Suitable carriers include but are not limited to fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starches, for example corn, wheat, rice or potato starch, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, carboxymethyl starch, crosslinked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate.
  • fillers such as sugars, for example lactose, saccharose, mannitol or sorbitol
  • cellulose preparations and/or calcium phosphates for example tricalcium phosphate or calcium hydrogen phosphate
  • binders such as starches, for example
  • Additional excipients include but are not limited to flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.
  • flow conditioners and lubricants for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.
  • Tablet cores may be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arable, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient.
  • concentrated sugar solutions which may comprise gum arable, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate.
  • Dyes or pigments may be added to the tablets or tablet coatings,
  • compositions for oral administration may also include hard capsules comprising gelatin or soft-sealed capsules comprising gelatin and a plasticizer, such as glycerol or sorbitol.
  • the hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, such as corn starch, binders, and/or glidants, such as talc or magnesium stearate, and optionally stabilizers.
  • the active ingredient may be dissolved or suspended in suitable liquid excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type, may also be added.
  • suitable liquid excipients such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type, may also be added.
  • compositions suitable for rectal administration are, for example, suppositories comprising a combination of the active ingredient and a suppository base.
  • Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols.
  • compositions suitable for parenteral administration may comprise aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers.
  • the active ingredient optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents. Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions.
  • the manufacture of injectable preparations is usually carried out under sterile conditions, as is the filling, for example, into ampoules or vials, and the sealing of the containers.
  • the disclosure also provides for a pharmaceutical combination, e.g. a kit, comprising a) a first agent which is a compound of the disclosure as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.
  • a pharmaceutical combination e.g. a kit, comprising a) a first agent which is a compound of the disclosure as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.
  • the kit can comprise instructions for its administration.
  • the compounds or pharmaceutical acceptable salts of the disclosure may be administered as the sole therapy, or together with other therapeutic agent or agents.
  • the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e. by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the individual is enhanced) .
  • the benefit experienced by an individual may be increased by administering one of the compounds described herein with another therapeutic agent that also has therapeutic benefit.
  • increased therapeutic benefit may result by also providing the individual with another therapeutic agent for gout.
  • the additional therapy or therapies include, but are not limited to physiotherapy, psychotherapy, radiation therapy, application of compresses to a diseased area, rest, altered diet, and the like. Regardless of the disease, disorder or condition being treated, the overall benefit experienced by the individual may be additive of the two therapies or the individual may experience a synergistic benefit.
  • the compounds described herein may be administered in the same pharmaceutical composition as other therapeutic agents, or because of different physical and chemical characteristics, be administered by a different route.
  • the compounds described herein may be administered orally to generate and maintain good blood levels thereof, while the other therapeutic agent may be administered intravenously.
  • the compounds described herein may be administered concurrently, sequentially or dosed separately to other therapeutic agents.
  • a compound of formula (I) can also be prepared as a pharmaceutically acceptable acid addition salt by, for example, reacting the free base form of the at least one compound with a pharmaceutically acceptable inorganic or organic acid.
  • a pharmaceutically acceptable base addition salt of the at least one compound of formula (I) can be prepared by, for example, reacting the free acid form of the at least one compound with a pharmaceutically acceptable inorganic or organic base.
  • Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds of formula (I) are set forth in the definitions section of this Application.
  • the salt forms of the compounds of formula (I) can be prepared using salts of the starting materials or intermediates.
  • the free acid or free base forms of the compounds of formula (I) can be prepared from the corresponding base addition salt or acid addition salt form.
  • a compound of formula (I) in an acid addition salt form can be converted to the corresponding free base thereof by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like) .
  • a compound of formula (I) in a base addition salt form can be converted to the corresponding free acid thereof by, for example, treating with a suitable acid (e.g., hydrochloric acid, etc) .
  • N-oxides of a compound of formula (I) or a pharmaceutically acceptable salt thereof can be prepared by methods known to those of ordinary skill in the art.
  • N-oxides can be prepared by treating an unoxidized form of the compound of formula (I) with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 to 80°C.
  • an oxidizing agent e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like
  • a suitable inert organic solvent e.g., a halogenated hydrocarbon such as dichloromethane
  • the N-oxides of the compounds of formula (I) can
  • Compounds of formula (I) in an unoxidized form can be prepared from N-oxides of compounds of formula (I) by, for example, treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, and the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, and the like) at 0 to 80°C.
  • a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, and the like
  • an inert organic solvent e.g., acetonitrile, ethanol, aqueous dioxane, and the like
  • Protected derivatives of the compounds of formula (I) can be made by methods known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley &Sons, Inc. 1999.
  • references to ether or Et 2 O are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in °C (degrees Centigrade) . All reactions were conducted under an inert atmosphere at RT unless otherwise noted.
  • MS mass spectra
  • ESI electrospray ionization
  • UV detector (220 and 254 nm)
  • ELSD evaporative light scattering detector
  • Thin-layer chromatography was performed on 0.25 mm Superchemgroup silica gel plates (60F-254) , visualized with UV light, 5%ethanolic phosphomolybdic acid, ninhydrin, or p-anisaldehyde solution. Flash column chromatography was performed on silica gel (200-300 mesh, Branch of Qingdao Haiyang Chemical Co., Ltd) .
  • Examples 4-538 listed in Table 1 were prepared from the appropriate starting materials which are commercially available or known in the literature. The structures and names of Examples 4-538 are given in Table 1.
  • MTS testing kit was purchased from Promega (Madison, WI, USA) .
  • the RPMI-1640, Penicillin-Streptomycin and Trypsin-EDTA (0.25%) were purchased from BI (Biological Industries, Beit Haemek, Israel) .
  • Fetal bovine serum was purchased from GIBCO (Grand Island, NY, USA) .
  • Dimethyl sulfoxide (DMSO) were purchased from Sigma (St. Louis., MO, USA) .
  • MDA-MB-436 (CAS, Cat. No: TCHu184) cells were cultured in RPMI-1640 supplemented with Penicillin-Streptomycin and 10%FBS.
  • MDA-MB-436 BRCA1-deficient lines
  • the inhibition of PARP1 was reflected by the inhibition of cell proliferation of MDA-MB-436 cells.
  • Cells were plated into 96-well plates at the optimized cell density of 2000 cells/well. Plates were incubated at 37°C, with 5 %CO 2 for 24 h.
  • Compounds were serially diluted and added to the plates with the final concentrations of 10000, 3333.3, 1111.1, 370.4, 123.5, 41.2, 13.7, 4.6 and 1.5 nM. Plates were incubated at 37°C, with 5%CO 2 for 120 h.
  • Example IC 50 (nM) Example IC 50 (nM) 2 1 192 1 4 5 195 1 13 1 193 1 44 1 194b 3 61 1 220 1 71 1 221 1 118 1 224 1 119 1 226 1 121 1 246 1 126 1 247 1 141 1 249 1 149 1 252 1 150 1 271 1 178 1 285 1 179 1 289 3 213 1 290 1 181b 1 291 2 191 1 / /
  • MTS testing kit was purchased from Promega (Madison, WI, USA) .
  • the RPMI-1640, IMDM, Penicillin-Streptomycin and Trypsin-EDTA (0.25%) were purchased from BI (Biological Industries, Beit Haemek, Israel) .
  • Fetal bovine serum was purchased from GIBCO (Grand Island, NY, USA) .
  • Dimethyl sulfoxide (DMSO) were purchased from Sigma (St. Louis., MO, USA) .
  • Capan-1 (ATCC, Cat. No: HTB-79) cells were cultured in IMDM supplemented with 20%FBS and 100 U/mL Penicillin-Streptomycin and MX-1 (Cobioer, Cat. No: CBP60640) cells were cultured in RPMI-1640 supplemented with 10%FBS and 100 U/mL Penicillin-Streptomycin.
  • Example MX-1 IC 50 (nM) Example MX-1 IC 50 (nM) 2 1 221 2 4 1 246 1 13 3 247 2 194b 3 285 3 213 1 289 1 220 2 291 2
  • Animals in Group 1 were administered with Compound 2 by single intravenous bolus injection at 1 mg/kg, which was formulated in 10%DMSO (Sigma, Batch#LPC0S181) : 60%PEG400 (Sigma, Batch#MKCH6281) : 30%water at 1 mg/mL as a solution.
  • Animals in Group 2 were administered with Compound 2 by single oral gavage (PO) administration at 3 mg/kg, which was formulated in 10%DMSO (Sigma, Batch#BCCG0331) : 60%PEG400 (Sigma, Batch#MKCN6245) : 30%water at 1 mg/mL as a solution.
  • Blood samples were collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose. Concentrations of Compound 2 in plasma were determined by LC/MS/MS (LC: Waters UPLC; MS: Triple Quad 6500 plus) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are certain PARP inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Description

COMPOUNDS AS PARP INHIBITORS
This application claims the priority to the U.S. provisional application No. 63/180,058, 63/218,222, 63/248,264, 63/278,953, 63/320,162 and 63/331,810, each of which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit enzymatic activity of poly (ADP-ribose) polymerase (PARP) and may be useful for the treatment of diseases and disorders mediated by PARP, such as hyper-proliferative diseases like cancer and inflammation.
BACKGROUND OF THE INVENTION
Hyper-proliferative diseases like cancer and inflammation are attracting the scientific community to provide therapeutic benefits. In this regard efforts have been made to identify and target specific mechanisms which play a role in proliferating the diseases.
Tumor development is closely associated with genetic alteration and deregulation of Poly (ADP-Ribose) Polymerase (PARP) and their regulators, suggesting that inhibitors of PARP may be useful anti-cancer therapeutics.
PARPs belong to a protein family that contains PARP catalytic domains, and approximately 18 members have been discovered so far. PARP can be activated by damaged DNA fragments and catalyzes the attachment of poly (ADP-ribose) to various target proteins, which results in the modulation of catalytic activity and protein-protein interactions of the target proteins. PARP has been implicated in several biological processes, including DNA repair, gene transcription, cell cycle progression (including proliferation and differentiation) , cell death, chromatin functions, genomic (e.g. chromosomal) stability and telomere length.
Activation of PARP and the resultant formation of poly (ADP-ribose) can be induced by DNA strand breaks after exposure to chemotherapy, ionizing radiation, oxygen free radicals, or nitric oxide (NO) . Because this cellular ADP-ribose transfer process is associated with the repair of DNA strand breakage in response to DNA damage caused by radiotherapy or chemotherapy, it can contribute to the resistance that often develops to various types of cancer therapies. Consequently, inhibition of PARP is expected to retard intracellular DNA repair and enhance the antitumor effects of cancer therapies.
In cancer models, PARP inhibitors have been shown to potentiate radiation and chemotherapy by increasing apoptosis of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals.
Therefore, a compound having an inhibitory activity on PARP will be useful for the prevention or treatment of cancer. Although PARP inhibitors were disclosed in the arts, e.g. WO 2004080976 and WO 2009050469, many suffer from having short half-life or toxicity. Therefore, there is a need for new PARP inhibitors that have at least one advantageous property selected from solubility, drug-drug interactions, potency, stability, selectivity, toxicity, drug resistance, pharmacokinetics and pharmacodynamics properties as an alternative for the treatment of hyper-proliferative diseases. In this regard, a novel class of PARP inhibitors is provided herein.
DISCLOSURE OF THE INVENTION
Disclosed herein are certain novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, and their use as pharmaceuticals.
In one aspect, disclosed herein is a compound of formula (I) :
Figure PCTCN2022088989-appb-000001
or a pharmaceutically acceptable salt thereof, wherein:
X 1 is selected from N and CR 6;
X 2 is selected from N and CR 7;
X 3 is selected from N and CR 8;
X 4 is selected from N and CR 9;
Ring Q 1 is selected from C 3-10 cycloalkyl, heterocyclyl, and heteroaryl;
Ring Q 2 is selected from heterocyclyl, aryl, and heteroaryl;
L is selected from a bond, - (CR C0R D0)  u-, - (CR C0R D0)  uO (CR C0R D0)  t-, - (CR C0R D0)  uNR A0 (CR C0R D0)  t-, and - (CR C0R D0)  uS (CR C0R D0)  t-;
each R 1 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2- 10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A1R B1, -OR A1, -C (O) R A1, -C (=NR E1) R A1, -C (=N-OR B1) R A1, -C (O) OR A1, -OC (O) R A1, -C (O) NR A1R B1, -C (O) NR A1S (O)  rR A1, -C (O) NR A1S (O)  2OR A1, -C (O) NR A1S (O)  rNR A1R B1, -C (O) NR A1S (O) (=NR E1) R B1, -C (O) NR A1S (O) (=NR E1) NR A1R B1, -NR A1C (O) R B1, -C (=NR E1) NR A1R B1, -NR A1C (=NR E1) R B1, -OC (O) NR A1R B1, -NR A1C (O) OR B1, -NR A1C (O) NR A1R B1, -NR A1C (S) NR A1R B1, -NR A1C (=NR E1) NR A1R B1, -S (O)  rR A1, -S (O) (=NR E1) R B1, -N=S (O) R A1R B1, -S (O)  2OR A1, -OS (O)  2R A1, -NR A1S (O)  rR B1, -NR A1S (O) (=NR E1) R B1, -S (O)  rNR A1R B1, -S (O) (=NR E1) NR A1R B1, -NR A1S (O)  2NR A1R B1, -NR A1S (O) (=NR E1) NR A1R B1, -P (O) R A1R B1 and -P (O) (OR A1) (OR B1) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X1;
each R 2 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2- 10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A2R B2, -OR A2, -C (O) R A2, -C (=NR E2) R A2, -C (=N-OR B2) R A2, -C (O) OR A2, -OC (O) R A2, -C (O) NR A2R B2, -NR A2C (O) R B2, -C (=NR E2) NR A2R B2, -NR A2C (=NR E2) R B2, -OC (O) NR A2R B2, -NR A2C (O) OR B2, -NR A2C (O) NR A2R B2, -NR A2C (S) NR A2R B2, -NR A2C (=NR E2) NR A2R B2, -S (O)  rR A2, -S (O) (=NR E2) R B2, -N=S (O) R A2R B2, -S (O)  2OR A2, -OS (O)  2R A2, -NR A2S (O)  rR B2, -NR A2S (O) (=NR E2) R B2, -S (O)  rNR A2R B2, -S (O) (=NR E2) NR A2R B2, -NR A2S (O)  2NR A2R B2, -NR A2S (O) (=NR E2) NR A2R B2, -P (O) R A2R B2 and -P (O) (OR A2) (OR B2) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X2;
R 3 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, CN, NO 2, -NR A3R B3, -OR A3 and -C (O) R A3, wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R X3;
R 4 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, CN, NO 2, -NR A4R B4, -OR A4, -C (O) R A4, wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R X4;
or R 3 and R 4 together with the atoms to which they are attached form a C 3-10 cycloalkyl or heterocyclic ring of 4 to 12 members containing 1, 2 or 3 heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups;
R 5 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A5R B5, -OR A5, -C (O) R A5, -C (=NR E5) R A5, -C (=N-OR B5) R A5, -C (O) OR A5, -OC (O) R A5, -C (O) NR A5R B5, -NR A5C (O) R B5, -C (=NR E5) NR A5R B5, -NR A5C (=NR E5) R B5, -OC (O) NR A5R B5, -NR A5C (O) OR B5, -NR A5C (O) NR A5R B5, -NR A5C (S) NR A5R B5, -NR A5C (=NR E5) NR A5R B5, -S (O)  rR A5, -S (O) (=NR E5) R B5, -N=S (O) R A5R B5, -S (O)  2OR A5, -OS (O)  2R A5, -NR A5S (O)  rR B5, -NR A5S (O) (=NR E5) R B5, -S (O)  rNR A5R B5, -S (O) (=NR E5) NR A5R B5, -NR A5S (O)  2NR A5R B5, -NR A5S (O) (=NR E5) NR A5R B5, -P (O) R A5R B5 and -P (O) (OR A5) (OR B5) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X5;
R 6 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A6R B6, -OR A6, -C (O) R A6, -C (=NR E6) R A6, -C (=N-OR B6) R A6, -C (O) OR A6, -OC (O) R A6, -C (O) NR A6R B6, -NR A6C (O) R B6, -C (=NR E6) NR A6R B6, -NR A6C (=NR E6) R B6, -OC (O) NR A6R B6, -NR A6C (O) OR B6, -NR A6C (O) NR A6R B6, -NR A6C (S) NR A6R B6, -NR A6C (=NR E6) NR A6R B6, -S (O)  rR A6, -S (O) (=NR E6) R B6, -N=S (O) R A6R B6, -S (O)  2OR A6, -OS (O)  2R A6, -NR A6S (O)  rR B6, -NR A6S (O) (=NR E6) R B6, -S (O)  rNR A6R B6, -S (O) (=NR E6) NR A6R B6, -NR A6S (O)  2NR A6R B6, -NR A6S (O) (=NR E6) NR A6R B6, -P (O) R A6R B6 and -P (O) (OR A6) (OR B6) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X6;
R 7 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A7R B7, -OR A7, -C (O) R A7, -C (=NR E7) R A7, -C (=N-OR B7) R A7, -C (O) OR A7, -OC (O) R A7, -C (O) NR A7R B7, -NR A7C (O) R B7, -C (=NR E7) NR A7R B7, -NR A7C (=NR E7) R B7, -OC (O) NR A7R B7, -NR A7C (O) OR B7, -NR A7C (O) NR A7R B7, -NR A7C (S) NR A7R B7, -NR A7C (=NR E7) NR A7R B7, -S (O)  rR A7, -S (O) (=NR E7) R B7, -N=S (O) R A7R B7, -S (O)  2OR A7, -OS (O)  2R A7, -NR A7S (O)  rR B7, -NR A7S (O) (=NR E7) R B7, -S (O)  rNR A7R B7, -S (O) (=NR E7) NR A7R B7, -NR A7S (O)  2NR A7R B7, -NR A7S (O) (=NR E7) NR A7R B7, -P (O) R A7R B7 and -P (O) (OR A7) (OR B7) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X7;
R 8 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4  alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A8R B8, -OR A8, -C (O) R A8, -C (=NR E8) R A8, -C (=N-OR B8) R A8, -C (O) OR A8, -OC (O) R A8, -C (O) NR A8R B8, -NR A8C (O) R B8, -C (=NR E8) NR A8R B8, -NR A8C (=NR E8) R B8, -OC (O) NR A8R B8, -NR A8C (O) OR B8, -NR A8C (O) NR A8R B8, -NR A8C (S) NR A8R B8, -NR A8C (=NR E8) NR A8R B8, -S (O)  rR A8, -S (O) (=NR E8) R B8, -N=S (O) R A8R B8, -S (O)  2OR A8, -OS (O)  2R A8, -NR A8S (O)  rR B8, -NR A8S (O) (=NR E8) R B8, -S (O)  rNR A8R B8, -S (O) (=NR E8) NR A8R B8, -NR A8S (O)  2NR A8R B8, -NR A8S (O) (=NR E8) NR A8R B8, -P (O) R A8R B8 and -P (O) (OR A8) (OR B8) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X8;
R 9 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A9R B9, -OR A9, -C (O) R A9, -C (=NR E9) R A9, -C (=N-OR B9) R A9, -C (O) OR A9, -OC (O) R A9, -C (O) NR A9R B9, -NR A9C (O) R B9, -C (=NR E9) NR A9R B9, -NR A9C (=NR E9) R B9, -OC (O) NR A9R B9, -NR A9C (O) OR B9, -NR A9C (O) NR A9R B9, -NR A9C (S) NR A9R B9, -NR A9C (=NR E9) NR A9R B9, -S (O)  rR A9, -S (O) (=NR E9) R B9, -N=S (O) R A9R B9, -S (O)  2OR A9, -OS (O)  2R A9, -NR A9S (O)  rR B9, -NR A9S (O) (=NR E9) R B9, -S (O)  rNR A9R B9, -S (O) (=NR E9) NR A9R B9, -NR A9S (O)  2NR A9R B9, -NR A9S (O) (=NR E9) NR A9R B9, -P (O) R A9R B9 and -P (O) (OR A9) (OR B9) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X9;
wherein
when X 1 is CH, X 2 is selected from N, CH and CF, X 3 and X 4 are independently selected from N or CH, the moiety
Figure PCTCN2022088989-appb-000002
in Formula (I) is
Figure PCTCN2022088989-appb-000003
and R B1 is selected from hydrogen and C 1-4 alkyl, the moiety
Figure PCTCN2022088989-appb-000004
in Formula (I) is not
Figure PCTCN2022088989-appb-000005
wherein L, Q 1, Q 2, R 1, R 2, R 3, R 4, m and n are as defined in formula (I) ;
each R A0 is independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1- 4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X0;
each R A1 and R B1 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X1;
or each “R A1 and R B1” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X1 groups;
each R A2 and R B2 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein  alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X2;
or each “R A2 and R B2” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X2 groups;
each R A3 and R B3 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X3;
or each “R A3 and R B3” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups;
each R A4 and R B4 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X4;
or each “R A4 and R B4” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X4 groups;
each R A5 and R B5 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X5;
or each “R A5 and R B5” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X5 groups;
each R A6 and R B6 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X6;
or each “R A6 and R B6” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X6 groups;
each R A7 and R B7 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X7;
or each “R A7 and R B7” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X7 groups;
each R A8 and R B8 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X8;
or each “R A8 and R B8” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X8 groups;
each R A9 and R B9 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X9;
or each “R A9 and R B9” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X9 groups;
each R C0 and R D0 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X0;
or R C0 and R D0 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen and optionally substituted with 1, 2 or 3 R X0 groups;
each R E1, R E2, R E5, R E6, R E7, R E8 and R E9 are independently selected from hydrogen, C 1- 10 alkyl, CN, NO 2, -OR a1, -SR a1, -S (O)  rR a1, -C (O) R a1, -C (O) OR a1, -C (O) NR a1R b1 and -S (O)  rNR a1R b1;
each R X0, R X1, R X2, R X3, R X4, R X5, R X6, R X7, R X8 and R X9 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, halogen, CN, NO 2, - (CR c1R d1)  tNR a1R b1, - (CR c1R d1)  tOR b1, - (CR c1R d1)  tC (O) R a1, - (CR c1R d1)  tC (=NR e1) R a1, - (CR c1R d1)  tC (=N-OR b1) R a1, - (CR c1R d1)  tC (O) OR b1, - (CR c1R d1)  tOC (O) R b1, - (CR c1R d1)  tC (O) NR a1R b1, - (CR c1R d1)  tNR a1C (O) R b1, - (CR c1R d1)  tC (=NR e1) NR a1R b1, - (CR c1R d1)  tNR a1C (=NR e1) R b1, - (CR c1R d1)  tOC (O) NR a1R b1, - (CR c1R d1)  tNR a1C (O) OR b1, - (CR c1R d1)  tNR a1C (O) NR a1R b1, - (CR c1R d1)  tNR a1C (S) NR a1R b1, - (CR c1R d1)  tNR a1C (=NR e1) NR a1R b1, - (CR c1R d1)  tS (O)  rR b1, - (CR c1R d1)  tS (O) (=NR e1) R b1, - (CR c1R d1)  tN=S (O) R a1R b1, - (CR c1R d1)  tS (O)  2OR b1, - (CR c1R d1)  tOS (O)  2R b1, - (CR c1R d1)  tNR a1S (O)  rR b1, - (CR c1R d1)  tNR a1S (O) (=NR e1) R b1, - (CR c1R d1)  tS (O)  rNR a1R b1, - (CR c1R d1)  tS (O) (=NR e1) NR a1R b1, - (CR c1R d1)  tNR a1S (O)  2NR a1R b1, - (CR c1R d1)  tNR a1S (O) (=NR e1) NR a1R b1, - (CR c1R d1)  tP (O) R a1R b1 and - (CR c1R d1)  tP (O) (OR a1) (OR b1) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl  and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y;
each R a1 and each R b1 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y;
or R a1 and R b1 together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R Y groups;
each R c1 and each R d1 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y;
or R c1 and R d1 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1, 2 or 3 R Y groups;
each R e1 is independently selected from hydrogen, C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, CN, NO 2, -OR a2, -SR a2, -S (O)  rR a2, -C (O) R a2, -C (O) OR a2, -S (O)  rNR a2R b2 and -C (O) NR a2R b2;
each R Y is independently selected from C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, halogen, CN, -NO 2, -NR a2R b2, -OR a2, -SR a2, -S (O)  rR a2, -S (O)  2OR a2, -OS (O)  2R b2, -S (O)  rNR a2R b2, -P (O) R a2R b2, -P (O) (OR a2) (OR b2) , - (CR c2R d2)  tNR a2R b2, - (CR c2R d2)  tOR b2, - (CR c2R d2)  tSR b2, - (CR c2R d2)  tS (O)  rR b2, - (CR c2R d2)  tP (O) R a2R b2, - (CR c2R d2)  tP (O) (OR a2) (OR b2) , - (CR c2R d2)  tCO 2R b2, - (CR c2R d2)  tC (O) NR a2R b2, - (CR c2R d2)  tNR a2C (O) R b2, - (CR c2R d2)  tNR a2CO 2R b2, - (CR c2R d2)  tOC (O) NR a2R b2, - (CR c2R d2)  tNR a2C (O) NR a2R b2, - (CR c2R d2)  tNR a2SO 2NR a2R b2, - NR a2 (CR c2R d2)  tNR a2R b2, -O (CR c2R d2)  tNR a2R b2, -S (CR c2R d2)  tNR a2R b2, -S (O)  r (CR c2R d2)  tNR a2R b2, -C (O) R a2, -C (O) (CR c2R d2)  tOR b2, -C (O) (CR c2R d2)  tNR a2R b2, -C (O) (CR c2R d2)  tSR b2, -C (O) (CR c2R d2)  tS (O)  rR b2, -CO 2R b2, -CO 2 (CR c2R d2)  tC (O) NR a2R b2, -OC (O) R a2, -CN, -C (O) NR a2R b2, -NR a2C (O) R b2, -OC (O) NR a2R b2, -NR a2C (O) OR b2, -NR a2C (O) NR a2R b2, -NR a2S (O)  rR b2, -CR a2 (=N-OR b2) , -C (=NR e2) R a2, -C (=NR e2) NR a2R b2, -NR a2C (=NR e2) NR a2R b2, -CHF 2, -CF 3, -OCHF 2 and -OCF 3, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from OH, CN, amino, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
each R a2 and each R b2 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1- 10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino, di (C 1-10 alkyl) amino, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10  alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
or R a2 and R b2 together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
each R c2 and each R d2 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino, di (C 1-10 alkyl) amino, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
or R c2 and R d2 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
each R e2 is independently selected from hydrogen, CN, NO 2, C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, -C (O) C 1-4 alkyl, -C (O) C 3-10 cycloalkyl, -C (O) OC 1-4 alkyl, -C (O) OC 3-10 cycloalkyl, -C (O) N (C 1-4 alkyl)  2, -C (O) N (C 3-10 cycloalkyl)  2, -S (O)  2C 1-4 alkyl, -S (O)  2C 3-10 cycloalkyl, -S (O)  2N (C 1-4 alkyl)  2 and -S (O)  2N (C 3-10 cycloalkyl)  2;
m is selected from 0, 1, 2, 3 and 4;
n is selected from 0, 1, 2, 3 and 4;
each r is independently selected from 0, 1 and 2;
each t is independently selected from 0, 1, 2, 3 and 4;
each u is independently selected from 0, 1, 2, 3 and 4.
In yet another aspect, the present disclosure provides pharmaceutical compositions comprising a compound of formula (I) or at least one pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
In yet another aspect, the disclosure provides methods for modulating PARP1, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, thereby modulating said PARP1.
In yet another aspect, disclosed is a method to treat, ameliorate or prevent a condition which responds to inhibition of PARP1 comprising administering to a system or subject in need of such treatment an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said condition.
Alternatively, the present disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a condition mediated by PARP1. In particular embodiments, the compounds of the disclosure may be used alone or in combination with a second therapeutic agent to treat a condition mediated by PARP1.
Alternatively, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating a condition mediated by PARP1.
Specifically, the condition herein includes but not limited to, an autoimmune disease, a transplantation disease, an infectious disease or a cell proliferative disorder.
Furthermore, the disclosure provides methods for treating a cell proliferative disorder, comprising administering to a system or subject in need of such treatment an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said condition.
Alternatively, the present disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a cell-proliferative disorder. In particular examples, the compounds of the disclosure may be used alone or in combination with a chemotherapeutic agent to treat a cell proliferative disorder.
Specifically, the cell proliferative disorder disclosed herein includes but not limited to, lymphoma, osteosarcoma, melanoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.
In the above methods for using the compounds of the disclosure, a compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered to a system comprising cells or tissues, or to a subject including a mammalian subject such as a human or animal subject.
Certain Terminology
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. All patents, patent applications, published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there is a plurality of definitions for terms herein, those in this section prevail.
It is to be understood that the foregoing general description and the following detailed description are explanatory only and are not restrictive of any subject matter claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification and the appended claims, the singular forms “a” , “an” and “the” include plural referents unless the context clearly dictates otherwise. It should also be noted that use of “or” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “include” , “includes” , and “included” is not limiting. Likewise, use of the term “comprising” as well as other forms, such as “comprise” , “comprises” , and “comprised” is not limiting.
Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, IR and UV/Vis spectroscopy and pharmacology, within the skill of the art are employed. Unless specific definitions are provided, the nomenclature employed in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those known in the art. Standard techniques can be  used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. Reactions and purification techniques can be performed e.g., using kits of manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures can be generally performed of conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. Throughout the specification, groups and substituents thereof can be chosen by one skilled in the field to provide stable moieties and compounds.
Where substituent groups are specified by their conventional chemical formulas, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left. As a non-limiting example, CH 2O is equivalent to OCH 2.
The term “substituted” means that a hydrogen atom is replaced by a substituent. It is to be understood that substitution at a given atom is limited by valency.
The term “C i-j” or “i-j membered” used herein means that the moiety has i-j carbon atoms or i-j atoms. For example, “C 1-6 alkyl” means said alkyl has 1-6 carbon atoms. Likewise, C 3-10 cycloalkyl means said cycloalkyl has 3-10 carbon atoms.
When any variable (e.g. R) occurs at the structure of a compound over one time, it is defined independently at each case. Therefore, for example, if a group is substituted by 0-2 R, the group may be optionally substituted by at most two R and R has independent option at each case. Additionally, a combination of substituents and/or the variants thereof are allowed only if such a combination will result in a stable compound.
The expression “one or more” or “at least one” refers to one, two, three, four, five, six, seven, eight, nine or more.
Unless stated otherwise, the term “hetero” means heteroatom or heteroatom radical (i.e. a radical containing heteroatom) , i.e. the atoms beyond carbon and hydrogen atoms or the radical containing such atoms. Preferably, the heteroatom (s) is independently selected from the group consisting of O, N, S, P and the like. In an embodiment wherein two or more heteroatoms are involved, the two or more heteroatoms may be the same, or part or all of the two or more heteroatoms may be different.
The term “alkyl” , employed alone or in combination with other terms, refers to branched or straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Unless otherwise specified, “alkyl” refers to C l-10 alkyl. For example, C 1-6, as in “C l-6 alkyl” is defined to include groups having 1, 2, 3, 4, 5, or 6 carbons in a linear or branched arrangement. For example, “C l-8 alkyl” includes but is not limited to methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl, pentyl, hexyl, heptyl, and octyl.
The term “cycloalkyl” , employed alone or in combination with other terms, refers to a saturated monocyclic or multicyclic (e.g. bicyclic or tricyclic) hydrocarbon ring system, usually with 3 to 16 ring atoms. The ring atoms of cycloalkyl are all carbon and the cycloalkyl contains zero heteroatoms and zero double bonds. In a multicyclic cycloalkyl, two or more rings can be fused or bridged or spiro together. Examples of monocyclic ring systems include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The bridged cycloalkyl is a polycyclic ring system containing 3-10 carbon atoms, which contains one or two alkylene bridges, each alkylene bridge consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. Cycloalkyl can be fused with aryl or heteroaryl group. In some embodiments, cycloalkyl is benzocondensed. Representative examples of such bridged cycloalkyl ring systems include, but are not limited to, bicyclo [1.1.1] pentane, bicyclo [3.1.1] heptane, bicyclo [2.2.1] heptane,  bicyclo [2.2.2] octane, bicyclo [3.2.2] nonane, bicyclo [3.3.1] nonane, bicyclo [4.2.1] nonane, tricyclo [3.3.1.03, 7] nonane and tricyclo [3.3.1.13, 7] decane (adamantane) . The cycloalkyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring system.
The term “alkenyl” , employed alone or in combination with other terms, refers to a non-aromatic hydrocarbon radical, straight, branched or cyclic, containing 2-10 carbon atoms and at least one carbon to carbon double bond. In some embodiments, the cyclic refers to monocyclic or multicyclic. In a multicyclic alkenyl, two or more rings can be fused or bridged or spiro together. In some embodiments, one carbon to carbon double bond is present, and up to four non-aromatic carbon-carbon double bonds may be present. Thus, “C 2-6 alkenyl” means an alkenyl radical having 2-6 carbon atoms. Alkenyl groups include but are not limited to ethenyl, propenyl, butenyl, 2-methylbutenyl, cyclopentenyl and cyclohexenyl. The straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated.
The term “alkynyl” , employed alone or in combination with other terms, refers to a hydrocarbon radical, straight, branched or cyclic, containing 2-10 carbon atoms and at least one carbon to carbon triple bond. In some embodiments, up to three carbon-carbon triple bonds may be present. Thus, “C 2-6 alkynyl” means an alkynyl radical having 2-6 carbon atoms. Alkynyl groups include but are not limited to ethynyl, propynyl, butynyl, and 3-methylbutynyl. The straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated.
The term “halogen” (or “halo” ) refers to fluorine, chlorine, bromine and iodine.
The term “alkoxy” , employed alone or in combination with other terms, refers to an alkyl as defined above, which is single bonded to an oxygen atom. The attachment point of an alkoxy radical to a molecule is through the oxygen atom. An alkoxy radical may be depicted as -O-alkyl. The term “C 1-10 alkoxy” refers to an alkoxy radical containing 1-10 carbon atoms, having straight or branched moieties. Alkoxy group includes but is not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy, hexyloxy, and the like.
The term “cycloalkoxy” , employed alone or in combination with other terms, refers to cycloalkyl as defined above, which is single bonded to an oxygen atom. The attachment point of a cycloalkoxy radical to a molecule is through the oxygen atom. A cycloalkoxy radical may be depicted as -O-cycloalkyl. “C 3-10 cycloalkoxy” refers to a cycloalkoxy radical containing 3-10 carbon atoms. Cycloalkoxy can be fused with aryl or heteroaryl group. In some embodiments, cycloalkoxy is benzocondensed. Cycloalkoxy group includes but is not limited to, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like.
The term “alkylthio” , employed alone or in combination with other terms, refers to an alkyl radical as defined above, which is single bonded to a sulfur atom. The attachment point of an alkylthio radical to a molecule is through the sulfur atom. An alkylthio radical may be depicted as -S-alkyl. The term “C 1-10 alkylthio” refers to an alkylthio radical containing 1-10 carbon atoms, having straight or branched moieties. Alkylthio group includes but is not limited to, methylthio, ethylthio, propylthio, isopropylthio, butylthio, hexylthio, and the like.
The term “cycloalkylthio” , employed alone or in combination with other terms, refers to cycloalkyl as defined above, which is single bonded to a sulfur atom. The attachment point of a cycloalkylthio radical to a molecule is through the sulfur atom. A cycloalkylthio radical may be depicted as -S-cycloalkyl. “C 3-10 cycloalkylthio” refers to a cycloalkylthio radical containing 3-10 carbon atoms. Cycloalkylthio can be fused with aryl or heteroaryl group.  In some embodiments, cycloalkylthio is benzocondensed. Cycloalkylthio group includes but is not limited to, cyclopropylthio, cyclobutylthio, cyclohexylthio, and the like.
The term “alkylamino” , employed alone or in combination with other terms, refers to an alkyl as defined above, which is single bonded to a nitrogen atom. The attachment point of an alkylamino radical to a molecule is through the nitrogen atom. An alkylamino radical may be depicted as -NH (alkyl) . The term “C 1-10 alkylamino” refers to an alkylamino radical containing 1-10 carbon atoms, having straight or branched moieties. Alkylamino group includes but is not limited to, methylamino, ethylamino, propylamino, isopropylamino, butylamino, hexylamoino, and the like.
The term “cycloalkylamino” , employed alone or in combination with other terms, refers to cycloalkyl as defined above, which is single bonded to a nitrogen atom. The attachment point of a cycloalkylamino radical to a molecule is through the nitrogen atom. A cycloalkylamino radical may be depicted as -NH (cycloalkyl) . “C 3-10 cycloalkylamino” refers to a cycloalkylamino radical containing 3-10 carbon atoms. Cycloalkylamino can be fused with aryl or heteroaryl group. In some embodiments, cycloalkylamino is benzocondensed. Cycloalkylamino group includes but is not limited to, cyclopropylamino, cyclobutylamino, cyclohexylamino, and the like.
The term “di (alkyl) amino” , employed alone or in combination with other terms, refers to two alkyl as defined above, which are single bonded to a nitrogen atom. The attachment point of an di (alkyl) amino radical to a molecule is through the nitrogen atom. A di (alkyl) amino radical may be depicted as -N (alkyl)  2. The term “di (C 1-10 alkyl) amino” refers to a di (C 1-10 alkyl) amino radical wherein the alkyl radicals each independently contains 1-10 carbon atoms, having straight or branched moieties.
The term “aryl” , employed alone or in combination with other terms, refers to a monovalent, monocyclic-, bicyclic-or tricyclic aromatic hydrocarbon ring system having 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms (a “C 6-14 aryl” group) , particularly a ring having 6 carbon atoms (a “C 6 aryl” group) , e.g. a phenyl group; or a ring having 10 carbon atoms (a “C 10 aryl” group) , e.g. a naphthyl group; or a ring having 14 carbon atoms, (a “C 14 aryl” group) , e.g. an anthranyl group. Aryl can be fused with cycloalkyl or heterocycle group.
Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals. Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in “-yl” by removal of one hydrogen atom from the carbon atom with the free valence are named by removing “-yl” and adding “-idene” to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene.
The term “heteroaryl” , employed alone or in combination with other terms, refers to a monovalent, monocyclic-, bicyclic-or tricyclic aromatic ring system having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms (a “5-to 14-membered heteroaryl” group) , particularly 5 or 6 or 9 or 10 atoms, and which contains at least one heteroatom which may be identical or different, said heteroatom selected from N, O and S. Heteroaryl can be fused with cycloalkyl or heterocycle group. In some embodiments, “heteroaryl” refers to
a 5-to 8-membered monocyclic aromatic ring containing one or more, for example, from 1 to 4, or, in some embodiments, from 1 to 3, heteroatoms selected from N, O and S, with the remaining ring atoms being carbon; or
a 8-to 12-membered bicyclic aromatic ring system containing one or more, for example, from 1 to 6, or, in some embodiments, from 1 to 4, or, in some embodiments, from 1 to 3, heteroatoms selected from N, O and S, with the remaining ring atoms being  carbon; or
a 11-to 14-membered tricyclic aromatic ring system containing one or more, for example, from 1 to 8, or, in some embodiments, from 1 to 6, or, in some embodiments, from 1 to 4, or in some embodiments, from 1 to 3, heteroatoms selected from N, O and S, with the remaining ring atoms being carbon.
When the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1.
Examples of heteroaryl groups include, but are not limited to, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, pyrazin-2-yl, pyrazin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, pyridazinyl, triazinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, triazolyl, tetrazolyl, thienyl, furyl.
Further heteroaryl groups include but are not limited to indolyl, benzothienyl, benzofuryl, benzoimidazolyl, benzotriazolyl, quinoxalinyl, quinolinyl, and isoquinolinyl. “Heteroaryl” is also understood to include the N-oxide derivative of any nitrogen-containing heteroaryl.
Bivalent radicals derived from univalent heteroaryl radicals whose names end in “-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylidene.
The term “heterocycle” , employed alone or in combination with other terms, (and variations thereof such as “heterocyclic” , or “heterocyclyl” ) broadly refers to a saturated or unsaturated mono-or multicyclic (e.g. bicyclic or tricyclic) aliphatic ring system, usually with 3 to 16 ring atoms, wherein at least one (e.g. 2, 3 or 4) ring atom is heteroatom independently selected from O, S, N and P (preferably O, S, N) . In a multicyclic heterocycle, two or more rings can be fused or bridged or spiro together. Heterocycle can be fused with aryl or heteroaryl group. In some embodiments, heterocycle is benzocondensed. Heterocycle also includes ring systems substituted with one or more oxo or imino moieties. In some embodiments, the C, N, S and P atoms in the heterocycle ring are optionally substituted by oxo. In some embodiments, the C, S and P atoms in the heterocycle ring are optionally substituted by imino, and imino can be unsubstituted or substituted. The point of the attachment may be carbon atom or heteroatom in the heterocyclic ring, provided that attachment results in the creation of a stable structure. When the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure result.
Suitable heterocycles include, for example, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-3-yl, imidazolidin-4-yl, imidazolidin-5-yl, pyrazolidin-1-yl, pyrazolidin-2-yl, pyrazolidin-3-yl, pyrazolidin-4-yl, pyrazolidin-5-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, hexahydropyridazin-1-yl, hexahydropyridazin-3-yl, hexahydropyridazin-4-yl and tetrahydropyridyl. Morpholinyl groups are also contemplated, such as morpholin-1-yl, morpholin-2-yl, morpholin-3-yl and morpholin-4-yl. Examples of heterocycle with one or more oxo moieties include but are not limited to, piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-thiomorpholinyl and 1, 1-dioxo-thiomorpholinyl. Bicyclic heterocycles include, for example:
Figure PCTCN2022088989-appb-000006
As used herein, “aryl-alkyl” refers to an alkyl moiety as defined above substituted by an aryl group as defined above. Exemplary aryl-alkyl groups include but are not limited to benzyl, phenethyl and naphthylmethyl groups. In some embodiments, aryl-alkyl groups have 7-20 or 7-11 carbon atoms. When used in the phrase “aryl-C l-4 alkyl” , the term “C 1-4” refers to the alkyl portion of the moiety and does not describe the number of atoms in the aryl portion of the moiety.
As used herein, “heterocyclyl-alkyl” refers to alkyl as defined above substituted by heterocyclyl as defined above. When used in the phrase “heterocyclyl-C 1-4 alkyl” , the term “C 1-4” refers to the alkyl portion of the moiety and does not describe the number of atoms in the heterocyclyl portion of the moiety.
As used herein, “cycloalkyl-alkyl” refers to alkyl as defined above substituted by cycloalkyl as defined above. When used in the phrase “C 3-10 cycloalkyl-C l-4 alkyl” , the term “C 3-10” refers to the cycloalkyl portion of the moiety and does not describe the number of atoms in the alkyl portion of the moiety, and the term “C 1-4” refers to the alkyl portion of the moiety and does not describe the number of atoms in the cycloalkyl portion of the moiety.
As used herein, “heteroaryl-alkyl” refers to alkyl as defined above substituted by heteroaryl as defined above. When used in the phrase “heteroaryl-C l-4 alkyl” , the term “C 1- 4” refers to the alkyl portion of the moiety and does not describe the number of atoms in the heteroaryl portion of the moiety.
For avoidance of doubt, reference, for example, to substitution of alkyl, cycloalkyl, heterocyclyl, aryl and/or heteroaryl refers to substitution of each of those groups individually as well as to substitutions of combinations of those groups. That is, if R is aryl-C l- 4 alkyl and may be unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R X, it should be understood that the aryl portion may be unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R X and the alkyl portion may also be unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituens, independently selected from R X.
The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases may be selected, for example, from aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium and zinc salts. Further, for example, the pharmaceutically acceptable salts derived from inorganic bases may be selected from ammonium, calcium, magnesium, potassium and sodium salts. Salts in the solid form may exist in one or more crystalline forms, or polymorphs, and may also be in the form of solvates, such as hydrates. Salts derived from pharmaceutically acceptable organic non-toxic bases may be selected, for example, from salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N, N'-dibenzylethylene-diamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine and tripropylamine, tromethamine.
When the compound disclosed herein is basic, salts may be prepared using at least one pharmaceutically acceptable non-toxic acid, selected from inorganic and organic acids. Such acid may be selected, for example, from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric and p-toluenesulfonic acids. In some embodiments, such acid may be selected, for example, from citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric and tartaric acids.
The terms “administration of” and or “administering” a compound or a pharmaceutically acceptable salt should be understood to mean providing a compound or a pharmaceutically acceptable salt thereof to the individual in recognized need of treatment.
The term “effective amount” means the amount of the a compound or a pharmaceutically acceptable salt that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
The term “composition” as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Such term in relation to a pharmaceutical composition is intended to encompass a product comprising the active ingredient (s) and the inert ingredient (s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
The term “pharmaceutically acceptable” it is meant compatible with the other ingredients of the formulation and not unacceptably deleterious to the recipient thereof.
The term “subject” as used herein in reference to individuals suffering from a disorder, a condition, and the like, encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like. In one embodiment of the methods and compositions provided herein, the mammal is a human.
The terms “treat, ” “treating” or “treatment, ” and other grammatical equivalents as used herein, include alleviating, abating or ameliorating a disease or condition, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition, and are intended to include prophylaxis. The terms further include achieving a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For prophy-lactic benefit, the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
The term “protecting group” or “Pg” refers to a substituent that can be commonly employed to block or protect a certain functionality while reacting other functional groups on the compound. For example, an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include but are not limited to acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC) , benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc) . Similarly, a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include but are not limited to acetyl and silyl. A “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Common carboxy-protecting groups include -CH 2CH 2SO 2Ph, cyanoethyl, 2- (trimethylsilyl) ethyl, 2- (trimethylsilyl) ethoxymethyl, 2- (p-toluenesulfonyl) ethyl, 2- (p-nitrophenylsulfenyl) ethyl, 2- (diphenylphosphino) -ethyl, nitroethyl and the like. For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley &Sons, New York, 1991.
The term “NH protecting group” as used herein includes, but not limited to, trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycarbonyl, para-nitrobenzylcarbonyl, ortho-bromobenzyloxycarbonyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, para-methoxybenzyloxycarbonyl, 3, 4-dimethoxybenzyl-oxycarbonyl, 4- (phenylazo) -benzyloxycarbonyl, 2-furfuryloxycarbonyl, diphenylmethoxycarbonyl, 1, 1-dimethylpropoxy-carbonyl, isopropoxycarbonyl, phthaloyl, succinyl, alanyl, leucyl, 1-adamantyloxycarbonyl, 8-quinolyloxycarbonyl, benzyl, diphenylmethyl, triphenylmethyl, 2-nitrophenylthio, methanesulfonyl, para-toluenesulfonyl, N, N-dimethylaminomethylene, benzylidene, 2-hydroxybenzylidene, 2-hydroxy-5-chlorobenzylidene, 2-hydroxy-l-naphthylmethylene, 3-hydroxy-4-pyridylmethylene, cyclohexylidene, 2-ethoxycarbonylcyclohexylidene, 2-ethoxycarbonylcyclopentylidene, 2-acetylcyclohexylidene,  3,3-dimethyl-5-oxycyclo-hexylidene, diphenylphosphoryl, dibenzylphosphoryl, 5-methyl-2-oxo-2H-1, 3-dioxol-4-yl-methyl, trimethylsilyl, triethylsilyl and triphenylsilyl.
The term “C (O) OH protecting group” as used herein includes, but not limited to, methyl, ethyl, n-propyl, isopropyl, 1, 1-dimethylpropyl, n-butyl, tert-butyl, phenyl, naphthyl, benzyl, diphenylmethyl, triphenylmethyl, para-nitrobenzyl, para-methoxybenzyl, bis (para-methoxyphenyl) methyl, acetylmethyl, benzoylmethyl, para-nitrobenzoylmethyl, para-bromobenzoylmethyl, para-methanesulfonylbenzoylmethyl, 2-tetrahydropyranyl, 2-tetrahydrofuranyl, 2, 2, 2-trichloro-ethyl, 2- (trimethylsilyl) ethyl, acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, phthalimidomethyl, succinimidomethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxymethyl, methoxyethoxymethyl, 2- (trimethylsilyl) ethoxymethyl, benzyloxymethyl, methylthiomethyl, 2-methylthioethyl, phenylthiomethyl, 1, 1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl and tert-butylmethoxyphenylsilyl.
The term “OH or SH protecting group” as used herein includes, but not limited to, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3, 4-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 1, 1-dimethylpropoxycarbonyl, isopropoxycarbonyl, isobutyloxycarbonyl, diphenylmethoxycarbonyl, 2, 2, 2-trichloroethoxycarbonyl, 2, 2, 2-tribromoethoxycarbonyl, 2- (trimethylsilyl) ethoxycarbonyl, 2- (phenylsulfonyl) ethoxycarbonyl, 2- (triphenylphosphonio) ethoxycarbonyl, 2-furfuryloxycarbonyl, 1-adamantyloxycarbonyl, vinyloxycarbonyl, allyloxycarbonyl, 4-ethoxy-1-naphthyloxycarbonyl, 8-quinolyloxycarbonyl, acetyl, formyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, pivaloyl, benzoyl, methyl, tert-butyl, 2, 2, 2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl (phenylmethyl) , para-methoxybenzyl, 3, 4-dimethoxybenzyl, diphenylmethyl, triphenylmethyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2, 2, 2-trichloro-ethoxymethyl, 2- (trimethylsilyl) ethoxymethyl, 1-ethoxyethyl, methanesulfonyl, para-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl and tert-butylmethoxyphenylsilyl.
Geometric isomers may exist in the present compounds. Compounds of this invention may contain carbon-carbon double bonds or carbon-nitrogen double bonds in the E or Z configuration, wherein the term "E" represents higher order substituents on opposite sides of the carbon-carbon or carbon-nitrogen double bond and the term "Z" represents higher order substituents on the same side of the carbon-carbon or carbon-nitrogen double bond as determined by the Cahn-Ingold-Prelog Priority Rules. The compounds of this invention may also exist as a mixture of "E" and "Z" isomers. Substituents around a cycloalkyl or heterocycloalkyl are designated as being of cis or trans configuration. Furthermore, the invention contemplates the various isomers and mixtures thereof resulting from the disposal of substituents around an adamantane ring system. Two substituents around a single ring within an adamantane ring system are designated as being of Z or E relative configuration. For examples, see C. D. Jones, M. Kaselj, R. N. Salvatore, W. J. le Noble J. Org. Chem. 1998, 63, 2758-2760.
Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, in which the terms "R" and "S" are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10. Compounds having asymmetrically substituted carbon atoms with equal amounts of  R and S configurations are racemic at those carbon atoms. Atoms with an excess of one configuration over the other are assigned the configuration present in the higher amount, preferably an excess of about 85-90%, more preferably an excess of about 95-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers.
Isotope Enriched or Labeled Compounds.
Compounds of the invention can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature. Isotopes can be radioactive or non-radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine include, but are not limited to,  2H,  3H,  13C,  14C,  15N,  18O,  32P,  35S,  18F,  36Cl and  125I. Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.
In another embodiment, the isotope-labeled compounds contain deuterium ( 2H) , tritium ( 3H) or  14C isotopes. Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope-labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope-labeled reagent for a non-labeled reagent. In some instances, compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuterated acid such as D 2SO 4/D 2O.
The isotope-labeled compounds of the invention may be used as standards to determine the effectiveness of PARP1 inhibitors in binding assays. Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975) ) . Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al, J. Labelled Compounds. Radiopharmaceuticals. 36 (10) , 927-932 (1995) ; Kushner et al., Can. J. Physiol. Pharmacology, 77, 79-88 (1999) .
In addition, non-radioactive isotope containing drugs, such as deuterated drugs called "heavy drugs" can be used for the treatment of diseases and conditions related to PARP1 activity. Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment. Examples of the amount of enrichment include but are not limited to from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %.
Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site  of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmacokinetic profile or efficacy relative to the non-isotopic compound.
In an Embodiment (1) , this invention provides to a compound of formula (I) :
Figure PCTCN2022088989-appb-000007
or a pharmaceutically acceptable salt thereof, wherein:
X 1 is selected from N and CR 6;
X 2 is selected from N and CR 7;
X 3 is selected from N and CR 8;
X 4 is selected from N and CR 9;
Ring Q 1 is selected from C 3-10 cycloalkyl, heterocyclyl, and heteroaryl;
Ring Q 2 is selected from heterocyclyl, aryl, and heteroaryl;
L is selected from a bond, - (CR C0R D0)  u-, - (CR C0R D0)  uO (CR C0R D0)  t-, - (CR C0R D0)  uNR A0 (CR C0R D0)  t-, and - (CR C0R D0)  uS (CR C0R D0)  t-;
each R 1 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2- 10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A1R B1, -OR A1, -C (O) R A1, -C (=NR E1) R A1, -C (=N-OR B1) R A1, -C (O) OR A1, -OC (O) R A1, -C (O) NR A1R B1, -C (O) NR A1S (O)  rR A1, -C (O) NR A1S (O)  2OR A1, -C (O) NR A1S (O)  rNR A1R B1, -C (O) NR A1S (O) (=NR E1) R B1, -C (O) NR A1S (O) (=NR E1) NR A1R B1, -NR A1C (O) R B1, -C (=NR E1) NR A1R B1, -NR A1C (=NR E1) R B1, -OC (O) NR A1R B1, -NR A1C (O) OR B1, -NR A1C (O) NR A1R B1, -NR A1C (S) NR A1R B1, -NR A1C (=NR E1) NR A1R B1, -S (O)  rR A1, -S (O) (=NR E1) R B1, -N=S (O) R A1R B1, -S (O)  2OR A1, -OS (O)  2R A1, -NR A1S (O)  rR B1, -NR A1S (O) (=NR E1) R B1, -S (O)  rNR A1R B1, -S (O) (=NR E1) NR A1R B1, -NR A1S (O)  2NR A1R B1, -NR A1S (O) (=NR E1) NR A1R B1, -P (O) R A1R B1 and -P (O) (OR A1) (OR B1) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X1;
each R 2 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2- 10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A2R B2, -OR A2, -C (O) R A2, -C (=NR E2) R A2, -C (=N-OR B2) R A2, -C (O) OR A2, -OC (O) R A2, -C (O) NR A2R B2, -NR A2C (O) R B2, -C (=NR E2) NR A2R B2, -NR A2C (=NR E2) R B2, -OC (O) NR A2R B2, -NR A2C (O) OR B2, -NR A2C (O) NR A2R B2, -NR A2C (S) NR A2R B2, -NR A2C (=NR E2) NR A2R B2, -S (O)  rR A2, -S (O) (=NR E2) R B2, -N=S (O) R A2R B2, -S (O)  2OR A2, -OS (O)  2R A2, -NR A2S (O)  rR B2, -NR A2S (O) (=NR E2) R B2, -S (O)  rNR A2R B2, -S (O) (=NR E2) NR A2R B2, -NR A2S (O)  2NR A2R B2, -NR A2S (O) (=NR E2) NR A2R B2, -P (O) R A2R B2 and -P (O) (OR A2) (OR B2) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X2;
R 3 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, CN, NO 2, - NR A3R B3, -OR A3 and -C (O) R A3, wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R X3;
R 4 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, CN, NO 2, -NR A4R B4, -OR A4, -C (O) R A4, wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R X4;
or R 3 and R 4 together with the atoms to which they are attached form a C 3-10 cycloalkyl or heterocyclic ring of 4 to 12 members containing 1, 2 or 3 heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups;
R 5 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A5R B5, -OR A5, -C (O) R A5, -C (=NR E5) R A5, -C (=N-OR B5) R A5, -C (O) OR A5, -OC (O) R A5, -C (O) NR A5R B5, -NR A5C (O) R B5, -C (=NR E5) NR A5R B5, -NR A5C (=NR E5) R B5, -OC (O) NR A5R B5, -NR A5C (O) OR B5, -NR A5C (O) NR A5R B5, -NR A5C (S) NR A5R B5, -NR A5C (=NR E5) NR A5R B5, -S (O)  rR A5, -S (O) (=NR E5) R B5, -N=S (O) R A5R B5, -S (O)  2OR A5, -OS (O)  2R A5, -NR A5S (O)  rR B5, -NR A5S (O) (=NR E5) R B5, -S (O)  rNR A5R B5, -S (O) (=NR E5) NR A5R B5, -NR A5S (O)  2NR A5R B5, -NR A5S (O) (=NR E5) NR A5R B5, -P (O) R A5R B5 and -P (O) (OR A5) (OR B5) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X5;
R 6 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A6R B6, -OR A6, -C (O) R A6, -C (=NR E6) R A6, -C (=N-OR B6) R A6, -C (O) OR A6, -OC (O) R A6, -C (O) NR A6R B6, -NR A6C (O) R B6, -C (=NR E6) NR A6R B6, -NR A6C (=NR E6) R B6, -OC (O) NR A6R B6, -NR A6C (O) OR B6, -NR A6C (O) NR A6R B6, -NR A6C (S) NR A6R B6, -NR A6C (=NR E6) NR A6R B6, -S (O)  rR A6, -S (O) (=NR E6) R B6, -N=S (O) R A6R B6, -S (O)  2OR A6, -OS (O)  2R A6, -NR A6S (O)  rR B6, -NR A6S (O) (=NR E6) R B6, -S (O)  rNR A6R B6, -S (O) (=NR E6) NR A6R B6, -NR A6S (O)  2NR A6R B6, -NR A6S (O) (=NR E6) NR A6R B6, -P (O) R A6R B6 and -P (O) (OR A6) (OR B6) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X6;
R 7 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A7R B7, -OR A7, -C (O) R A7, -C (=NR E7) R A7, -C (=N-OR B7) R A7, -C (O) OR A7, -OC (O) R A7, -C (O) NR A7R B7, -NR A7C (O) R B7, -C (=NR E7) NR A7R B7, -NR A7C (=NR E7) R B7, -OC (O) NR A7R B7, -NR A7C (O) OR B7, -NR A7C (O) NR A7R B7, -NR A7C (S) NR A7R B7, -NR A7C (=NR E7) NR A7R B7, -S (O)  rR A7, -S (O) (=NR E7) R B7, -N=S (O) R A7R B7, -S (O)  2OR A7, -OS (O)  2R A7, -NR A7S (O)  rR B7, -NR A7S (O) (=NR E7) R B7, -S (O)  rNR A7R B7, -S (O) (=NR E7) NR A7R B7, -NR A7S (O)  2NR A7R B7, -NR A7S (O) (=NR E7) NR A7R B7, -P (O) R A7R B7 and -P (O) (OR A7) (OR B7) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X7;
R 8 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A8R B8, -OR A8, -C (O) R A8, -C (=NR E8) R A8, -C (=N-OR B8) R A8, -C (O) OR A8, -OC (O) R A8, -C (O) NR A8R B8, -NR A8C (O) R B8, - C (=NR E8) NR A8R B8, -NR A8C (=NR E8) R B8, -OC (O) NR A8R B8, -NR A8C (O) OR B8, -NR A8C (O) NR A8R B8, -NR A8C (S) NR A8R B8, -NR A8C (=NR E8) NR A8R B8, -S (O)  rR A8, -S (O) (=NR E8) R B8, -N=S (O) R A8R B8, -S (O)  2OR A8, -OS (O)  2R A8, -NR A8S (O)  rR B8, -NR A8S (O) (=NR E8) R B8, -S (O)  rNR A8R B8, -S (O) (=NR E8) NR A8R B8, -NR A8S (O)  2NR A8R B8, -NR A8S (O) (=NR E8) NR A8R B8, -P (O) R A8R B8 and -P (O) (OR A8) (OR B8) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X8;
R 9 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A9R B9, -OR A9, -C (O) R A9, -C (=NR E9) R A9, -C (=N-OR B9) R A9, -C (O) OR A9, -OC (O) R A9, -C (O) NR A9R B9, -NR A9C (O) R B9, -C (=NR E9) NR A9R B9, -NR A9C (=NR E9) R B9, -OC (O) NR A9R B9, -NR A9C (O) OR B9, -NR A9C (O) NR A9R B9, -NR A9C (S) NR A9R B9, -NR A9C (=NR E9) NR A9R B9, -S (O)  rR A9, -S (O) (=NR E9) R B9, -N=S (O) R A9R B9, -S (O)  2OR A9, -OS (O)  2R A9, -NR A9S (O)  rR B9, -NR A9S (O) (=NR E9) R B9, -S (O)  rNR A9R B9, -S (O) (=NR E9) NR A9R B9, -NR A9S (O)  2NR A9R B9, -NR A9S (O) (=NR E9) NR A9R B9, -P (O) R A9R B9 and -P (O) (OR A9) (OR B9) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X9;
wherein
when X 1 is CH, X 2 is selected from N, CH and CF, X 3 and X 4 are independently selected from N or CH, the moiety
Figure PCTCN2022088989-appb-000008
in Formula (I) is
Figure PCTCN2022088989-appb-000009
and R B1 is selected from hydrogen and C 1-4 alkyl, the moiety
Figure PCTCN2022088989-appb-000010
in Formula (I) is not
Figure PCTCN2022088989-appb-000011
wherein L, Q 1, Q 2, R 1, R 2, R 3, R 4, m and n are as defined in formula (I) ;
each R A0 is independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1- 4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X0;
each R A1 and R B1 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X1;
or each “R A1 and R B1” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X1 groups;
each R A2 and R B2 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X2;
or each “R A2 and R B2” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X2 groups;
each R A3 and R B3 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X3;
or each “R A3 and R B3” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups;
each R A4 and R B4 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X4;
or each “R A4 and R B4” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X4 groups;
each R A5 and R B5 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X5;
or each “R A5 and R B5” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X5 groups;
each R A6 and R B6 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X6;
or each “R A6 and R B6” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X6 groups;
each R A7 and R B7 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X7;
or each “R A7 and R B7” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently  selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X7 groups;
each R A8 and R B8 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X8;
or each “R A8 and R B8” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X8 groups;
each R A9 and R B9 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X9;
or each “R A9 and R B9” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X9 groups;
each R C0 and R D0 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X0;
or R C0 and R D0 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen and optionally substituted with 1, 2 or 3 R X0 groups;
each R E1, R E2, R E5, R E6, R E7, R E8 and R E9 are independently selected from hydrogen, C 1- 10 alkyl, CN, NO 2, -OR a1, -SR a1, -S (O)  rR a1, -C (O) R a1, -C (O) OR a1, -C (O) NR a1R b1 and -S (O)  rNR a1R b1;
each R X0, R X1, R X2, R X3, R X4, R X5, R X6, R X7, R X8 and R X9 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, halogen, CN, NO 2, - (CR c1R d1)  tNR a1R b1, - (CR c1R d1)  tOR b1, - (CR c1R d1)  tC (O) R a1, - (CR c1R d1)  tC (=NR e1) R a1, - (CR c1R d1)  tC (=N-OR b1) R a1, - (CR c1R d1)  tC (O) OR b1, - (CR c1R d1)  tOC (O) R b1, - (CR c1R d1)  tC (O) NR a1R b1, - (CR c1R d1)  tNR a1C (O) R b1, - (CR c1R d1)  tC (=NR e1) NR a1R b1, - (CR c1R d1)  tNR a1C (=NR e1) R b1, - (CR c1R d1)  tOC (O) NR a1R b1, - (CR c1R d1)  tNR a1C (O) OR b1, - (CR c1R d1)  tNR a1C (O) NR a1R b1, - (CR c1R d1)  tNR a1C (S) NR a1R b1, - (CR c1R d1)  tNR a1C (=NR e1) NR a1R b1, - (CR c1R d1)  tS (O)  rR b1, - (CR c1R d1)  tS (O) (=NR e1) R b1, - (CR c1R d1)  tN=S (O) R a1R b1, - (CR c1R d1)  tS (O)  2OR b1, - (CR c1R d1)  tOS (O)  2R b1, - (CR c1R d1)  tNR a1S (O)  rR b1, - (CR c1R d1)  tNR a1S (O) (=NR e1) R b1, - (CR c1R d1)  tS (O)  rNR a1R b1, - (CR c1R d1)  tS (O) (=NR e1) NR a1R b1, - (CR c1R d1)  tNR a1S (O)  2NR a1R b1, - (CR c1R d1)  tNR a1S (O) (=NR e1) NR a1R b1, - (CR c1R d1)  tP (O) R a1R b1 and - (CR c1R d1)  tP (O) (OR a1) (OR b1) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y;
each R a1 and each R b1 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y;
or R a1 and R b1 together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R Y groups;
each R c1 and each R d1 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y;
or R c1 and R d1 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1, 2 or 3 R Y groups;
each R e1 is independently selected from hydrogen, C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, CN, NO 2, -OR a2, -SR a2, -S (O)  rR a2, -C (O) R a2, -C (O) OR a2, -S (O)  rNR a2R b2 and -C (O) NR a2R b2;
each R Y is independently selected from C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, halogen, CN, -NO 2, -NR a2R b2, -OR a2, -SR a2, -S (O)  rR a2, -S (O)  2OR a2, -OS (O)  2R b2, -S (O)  rNR a2R b2, -P (O) R a2R b2, -P (O) (OR a2) (OR b2) , - (CR c2R d2)  tNR a2R b2, - (CR c2R d2)  tOR b2, - (CR c2R d2)  tSR b2, - (CR c2R d2)  tS (O)  rR b2, - (CR c2R d2)  tP (O) R a2R b2, - (CR c2R d2)  tP (O) (OR a2) (OR b2) , - (CR c2R d2)  tCO 2R b2, - (CR c2R d2)  tC (O) NR a2R b2, - (CR c2R d2)  tNR a2C (O) R b2, - (CR c2R d2)  tNR a2CO 2R b2, - (CR c2R d2)  tOC (O) NR a2R b2, - (CR c2R d2)  tNR a2C (O) NR a2R b2, - (CR c2R d2)  tNR a2SO 2NR a2R b2, - NR a2 (CR c2R d2)  tNR a2R b2, -O (CR c2R d2)  tNR a2R b2, -S (CR c2R d2)  tNR a2R b2, -S (O)  r (CR c2R d2)  tNR a2R b2, -C (O) R a2, -C (O) (CR c2R d2)  tOR b2, -C (O) (CR c2R d2)  tNR a2R b2, -C (O) (CR c2R d2)  tSR b2, -C (O) (CR c2R d2)  tS (O)  rR b2, -CO 2R b2, -CO 2 (CR c2R d2)  tC (O) NR a2R b2, -OC (O) R a2, -CN, -C (O) NR a2R b2, -NR a2C (O) R b2, -OC (O) NR a2R b2, -NR a2C (O) OR b2, -NR a2C (O) NR a2R b2, -NR a2S (O)  rR b2, -CR a2 (=N-OR b2) , -C (=NR e2) R a2, -C (=NR e2) NR a2R b2, -NR a2C (=NR e2) NR a2R b2, -CHF 2, -CF 3, -OCHF 2 and -OCF 3, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from OH, CN, amino, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
each R a2 and each R b2 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1- 10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino, di (C 1-10 alkyl) amino, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
or R a2 and R b2 together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
each R c2 and each R d2 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino, di (C 1-10 alkyl) amino, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
or R c2 and R d2 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
each R e2 is independently selected from hydrogen, CN, NO 2, C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, -C (O) C 1-4 alkyl, -C (O) C 3-10 cycloalkyl, -C (O) OC 1-4 alkyl, -C (O) OC 3-10 cycloalkyl, -C (O) N (C 1-4 alkyl)  2, -C (O) N (C 3-10 cycloalkyl)  2, -S (O)  2C 1-4 alkyl, -S (O)  2C 3-10 cycloalkyl, -S (O)  2N (C 1-4 alkyl)  2 and -S (O)  2N (C 3-10 cycloalkyl)  2;
m is selected from 0, 1, 2, 3 and 4;
n is selected from 0, 1, 2, 3 and 4;
each r is independently selected from 0, 1 and 2;
each t is independently selected from 0, 1, 2, 3 and 4;
each u is independently selected from 0, 1, 2, 3 and 4.
In another Embodiment (2) , the invention provides a compound of Embodiment (1) or a pharmaceutically acceptable salt thereof, wherein X 1 is N.
In another Embodiment (3) , the invention provides a compound of Embodiment (1) or a pharmaceutically acceptable salt thereof, wherein X 1 is CR 6.
In another Embodiment (4) , the invention provides a compound of any one of Embodiments (1) - (3) or a pharmaceutically acceptable salt thereof, wherein X 2 is N.
In another Embodiment (5) , the invention provides a compound of any one of Embodiments (1) - (3) or a pharmaceutically acceptable salt thereof, wherein X 2 is CR 7.
In another Embodiment (6) , the invention provides a compound of any one of Embodiments (1) - (5) or a pharmaceutically acceptable salt thereof, wherein X 3 is N.
In another Embodiment (7) , the invention provides a compound of any one of Embodiments (1) - (5) or a pharmaceutically acceptable salt thereof, wherein X 3 is CR 8.
In another Embodiment (8) , the invention provides a compound of any one of Embodiments (1) - (7) or a pharmaceutically acceptable salt thereof, wherein X 4 is N.
In another Embodiment (9) , the invention provides a compound of any one of Embodiments (1) - (7) or a pharmaceutically acceptable salt thereof, wherein X 4 is CR 9.
In another Embodiment (10) , the invention provides a compound of any one of Embodiment (1) and (3) - (9) or a pharmaceutically acceptable salt thereof, wherein R 6 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A6R B6, -OR A6, -C (O) R A6, -C (O) OR A6, -OC (O) R A6, -C (O) NR A6R B6, -NR A6C (O) R B6, -OC (O) NR A6R B6, -NR A6C (O) OR B6, -NR A6C (O) NR A6R B6, -NR A6C (S) NR A6R B6, -S (O)  2OR A6, -OS (O)  2R A6, -NR A6S (O)  rR B6, -S (O)  rNR A6R B6 and -NR A6S (O)  2NR A6R B6, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X6, preferably, wherein R 6 is selected from hydrogen, halogen, C 1-10 alkyl, C 2- 10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A6R B6 and -OR A6, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X6. In another Embodiment, R 6 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2, -OH and -NH 2. In another Embodiment, R 6 is selected from hydrogen F, Cl, CN, and methyl.
In another Embodiment (11) , the invention provides a compound of any one of Embodiment (1) - (3) and (5) - (10) or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A7R B7, -OR A7, -C (O) R A7, -C (O) OR A7, -OC (O) R A7, -C (O) NR A7R B7, -NR A7C (O) R B7, -OC (O) NR A7R B7, -NR A7C (O) OR B7, -NR A7C (O) NR A7R B7, -NR A7C (S) NR A7R B7, -S (O)  2OR A7, -OS (O)  2R A7, -NR A7S (O)  rR B7, -S (O)  rNR A7R B7 and -NR A7S (O)  2NR A7R B7, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X7.
In another Embodiment (12) , the invention provides a compound of Embodiment (11) or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A7R B7 and -OR A7, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X7. In another Embodiment, R 7 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2, -OH and -NH 2. In another Embodiment, R 7 is selected from hydrogen and F.
In another Embodiment (13) , the invention provides a compound of any one of Embodiment (1) - (5) and (7) - (12) or a pharmaceutically acceptable salt thereof, wherein R 8 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A8R B8, -OR A8, -C (O) R A8, -C (O) OR A8, -OC (O) R A8, -C (O) NR A8R B8, -NR A8C (O) R B8, -OC (O) NR A8R B8, -NR A8C (O) OR B8, -NR A8C (O) NR A8R B8, -NR A8C (S) NR A8R B8, -S (O)  2OR A8, -OS (O)  2R A8, -NR A8S (O)  rR B8, -S (O)  rNR A8R B8 and -NR A8S (O)  2NR A8R B8, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X8.
In another Embodiment (14) , the invention provides a compound of Embodiment (13) or a pharmaceutically acceptable salt thereof, wherein R 8 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A8R B8 and -OR A8, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X8. In another Embodiment, R 8 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl,  cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2, -OH and -NH 2. In another Embodiment, R 8 is hydrogen.
In another Embodiment (15) , the invention provides a compound of any one of Embodiment (1) - (7) and (9) - (14) or a pharmaceutically acceptable salt thereof, wherein R 9 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A9R B9, -OR A9, -C (O) R A9, -C (O) OR A9, -OC (O) R A9, -C (O) NR A9R B9, -NR A9C (O) R B9, -OC (O) NR A9R B9, -NR A9C (O) OR B9, -NR A9C (O) NR A9R B9, -NR A9C (S) NR A9R B9, -S (O)  2OR A9, -OS (O)  2R A9, -NR A9S (O)  rR B9, -S (O)  rNR A9R B9 and -NR A9S (O)  2NR A9R B9, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X9.
In another Embodiment (16) , the invention provides a compound of Embodiment (15) or a pharmaceutically acceptable salt thereof, wherein R 9 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A9R B9 and -OR A9, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X9. In another Embodiment, R 9 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2, -OH and -NH 2. In another Embodiment, R 9 is hydrogen.
In another Embodiment (17) , the invention provides a compound of any one of Embodiments (1) - (16) or a pharmaceutically acceptable salt thereof, wherein the moiety 
Figure PCTCN2022088989-appb-000012
in Formula (I) is selected from
Figure PCTCN2022088989-appb-000013
Figure PCTCN2022088989-appb-000014
Figure PCTCN2022088989-appb-000015
In another Embodiment, 
Figure PCTCN2022088989-appb-000016
in Formula (I) is
Figure PCTCN2022088989-appb-000017
Figure PCTCN2022088989-appb-000018
In another Embodiment (18) , the invention provides a compound of any one of Embodiments (1) - (17) or a pharmaceutically acceptable salt thereof, wherein R 5 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A5R B5, -OR A5, -C (O) R A5, -C (O) OR A5, -OC (O) R A5, -C (O) NR A5R B5, -NR A5C (O) R B5, -OC (O) NR A5R B5, -NR A5C (O) OR B5, -NR A5C (O) NR A5R B5, -NR A5C (S) NR A5R B5, -S (O)  rR A5, -S (O)  2OR A5, -OS (O)  2R A5, -NR A5S (O)  rR B5 and -S (O)  rNR A5R B5, wherein alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X5.
In another Embodiment (19) , the invention provides a compound of Embodiment (18) or a pharmaceutically acceptable salt thereof, wherein R 5 is selected from hydrogen, halogen, methyl, ethyl, methoxy, ethoxy, isopropyl, cyclopropyl, phenyl, CN, NO 2, -NH 2 and -OH, wherein methyl, ethyl, isopropyl, cyclopropyl and phenyl are each unsubstituted or substituted with at least one substituent, independently selected from R X5. In another Embodiment, wherein R 5 is selected from hydrogen, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, methoxy, ethoxy, isopropyl, methoxymethyl, cyclopropyl and phenyl.
In another Embodiment (20) , the invention provides a compound of any one of Embodiments (1) - (19) or a pharmaceutically acceptable salt thereof, wherein Q 1 is heterocyclyl.
In another Embodiment (21) , the invention provides a compound of Embodiment (20) or a pharmaceutically acceptable salt thereof, wherein Q 1 is selected from 
Figure PCTCN2022088989-appb-000019
Figure PCTCN2022088989-appb-000020
In another Embodiment, Q 1 is selected from
Figure PCTCN2022088989-appb-000021
Figure PCTCN2022088989-appb-000022
In another Embodiment (22) , the invention provides a compound of any one of Embodiments (1) - (21) or a pharmaceutically acceptable salt thereof, wherein each R 2 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, C 3- 10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A2R B2, -OR A2, -C (O) R A2, -C (O) OR A2, -OC (O) R A2, -C (O) NR A2R B2, -NR A2C (O) R B2, -OC (O) NR A2R B2, -NR A2C (O) OR B2, -NR A2C (O) NR A2R B2, -NR A2C (S) NR A2R B2, -S (O)  rR A2, -S (O) (=NR E2) R B2, -S (O)  2OR A2, -OS (O)  2R A2, -NR A2S (O)  rR B2, -S (O)  rNR A2R B2 and -NR A2S (O)  2NR A2R B2, wherein alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X2.
In another Embodiment (23) , the invention provides a compound of Embodiment (22) or a pharmaceutically acceptable salt thereof, wherein each R 2 is independently selected from hydrogen, F, Cl, Br, methyl, ethyl, isopropyl, cyclopropyl, methoxy, ethoxy, -OC (O) CH 3, -CN, -NO 2, -NH 2 and -OH, wherein methyl, ethyl, isopropyl and cyclopropyl are each unsubstituted or substituted with at least one substituent, independently selected from R X2. In another Embodiment, wherein each R 2 is independently selected from hydrogen, F, Cl, Br, methyl, ethyl, isopropyl, cyclopropyl, methoxy, ethoxy, -OC (O) CH 3, -CN, -NO 2, -NH 2 and -OH, wherein methyl, ethyl, isopropyl and cyclopropyl are each unsubstituted or substituted with at least one substituent, independently selected from methoxy, ethoxy, F, Cl, Br, -CN, -NO 2, -NH 2 and -OH.
In another Embodiment, wherein each R 2 is independently selected from hydrogen, F, Cl, Br, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, ethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, methoxy, ethoxy, methoxymethyl, 
Figure PCTCN2022088989-appb-000023
-OC (O) CH 3, -CN, -NO 2, -NH 2 and -OH.
In another Embodiment (24) , the invention provides a compound of any one of Embodiments (1) - (23) or a pharmaceutically acceptable salt thereof, wherein the moiety 
Figure PCTCN2022088989-appb-000024
in Formula (I) is selected from
Figure PCTCN2022088989-appb-000025
Figure PCTCN2022088989-appb-000026
In another Embodiment (25) , the invention provides a compound of any one of Embodiments (1) - (24) or a pharmaceutically acceptable salt thereof, wherein L is selected from a bond, -CR C0R D0-, - (CR C0R D0)  uO (CR C0R D0)  t-, - (CR C0R D0)  uNR A0 (CR C0R D0)  t-and - (CR C0R D0)  uS (CR C0R D0)  t-.
In another Embodiment (26) , the invention provides a compound of Embodiment (25) or a pharmaceutically acceptable salt thereof, wherein L is selected from a bond, -CH 2-, -O-, -NH-, and -S-. In another Embodiment, L is selected from a bond, -O-and -NH-.
In another Embodiment (27) , the invention provides a compound of any one of Embodiments (1) - (26) or a pharmaceutically acceptable salt thereof, wherein Q 2 is selected from 5-12 membered heterocyclyl, aryl, and heteroaryl.
In another Embodiment (28) , the invention provides a compound of Embodiment (27) or a pharmaceutically acceptable salt thereof, wherein Q 2 is selected from 
Figure PCTCN2022088989-appb-000027
Figure PCTCN2022088989-appb-000028
In another Embodiment, wherein Q 2 is selected from
Figure PCTCN2022088989-appb-000029
Figure PCTCN2022088989-appb-000030
In another Embodiment (29) , the invention provides a compound of any one of Embodiments (1) - (28) or a pharmaceutically acceptable salt thereof, wherein each R 1 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 3-10 cycloalkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, heteroaryl, CN, NO 2, -NR A1R B1, -OR A1, -C (O) R A1, -C (O) OR A1, -OC (O) R A1, -C (O) NR A1R B1, -C (O) NR A1S (O)  rR A1, -C (O) NR A1S (O)  rNR A1R B1, -C (O) NR A1S (O) (=NR E1) R B1, -NR A1C (O) R B1, -OC (O) NR A1R B1, -NR A1C (O) OR B1, -NR A1C (O) NR A1R B1, -S (O)  rNR A1R B1, -NR A1S (O)  rR B1, -NR A1S (O)  2NR A1R B1 and -NR A1C (S) NR A1R B1, wherein alkyl, cycloalkyl, heterocyclyl and heteroaryl, are each unsubstituted or substituted with at least one substituent, independently selected from R X1.
In another Embodiment (30) , the invention provides a compound of Embodiment (29) or a pharmaceutically acceptable salt thereof, each R 1 is independently selected from methyl, ethyl, isopropyl, cyclopropyl, F, Cl, 
Figure PCTCN2022088989-appb-000031
Figure PCTCN2022088989-appb-000032
CN, NO 2, -NR A1R B1, -NR A1C (O) R B1, -NR A1C (O) OR B1, -NR A1C (O) NR A1R B1, -NR A1S (O)  rR B1, -OR A1, -C (O) R A1, -C (O) OR A1, -OC (O) R A1, -C (O) NR A1R B1, -C (O) NR A1S (O)  rR A1, -C (O) NR A1S (O)  rNR A1R B1, -C (O) NR A1S (O) (=NR E1) R B1 and -S (O)  rNR A1R B1, wherein methyl, ethyl, isopropyl, cyclopropyl 
Figure PCTCN2022088989-appb-000033
Figure PCTCN2022088989-appb-000034
are each unsubstituted or substituted with at least one substituent, independently selected from R X1.
In another Embodiment (31) , the invention provides a compound of Embodiment (30) or a pharmaceutically acceptable salt thereof, wherein each R A1 and R B1 are independently selected from hydrogen, deuterium, C 1-10 alkyl, C 3-10 cycloalkyl, heterocyclyl and C 1-10 alkoxy, wherein alkyl, cycloalkyl, heterocyclyl and alkoxy are each unsubstituted or substituted with at least one substituent, independently selected from R X1. In another Embodiment, each R A1 and R B1 are independently selected from hydrogen, deuterium, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, methoxy and ethoxy, wherein methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, methoxy and ethoxy are each unsubstituted or substituted with at least one substituent, independently selected from R X1.
In another Embodiment (32) , the invention provides a compound of Embodiment (30) or a pharmaceutically acceptable salt thereof, wherein each “R A1 and R B1” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 8 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X1 groups.
In another Embodiment (33) , the invention provides a compound of any one of Embodiments (1) - (32) or a pharmaceutically acceptable salt thereof, wherein each R X1 is independently selected from C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, halogen, CN, NO 2, - (CR c1R d1)  tNR a1R b1, - (CR c1R d1)  tOR b1, - (CR c1R d1)  tNR a1C (O) R b1, - (CR c1R d1)  tNR a1C (O) OR b1 and - (CR c1R d1)  tNR a1S (O)  rR b1, wherein alkyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R Y.
In another Embodiment (34) , the invention provides a compound of Embodiment (33) or a pharmaceutically acceptable salt thereof, wherein each R X1 is independently selected from methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -OH, -NO 2, -NH 2, -NHCH 3, -NHCH 2CH 3, -NHC (O) CH 3, -NHC (O) OCH 3, 
Figure PCTCN2022088989-appb-000035
Figure PCTCN2022088989-appb-000036
wherein methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, methoxy and ethoxy are each unsubstituted or substituted with at least one substituent, independently selected from R Y. In another Embodiment, each R X1 is independently selected from methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, isopropyl, tert-butyl, cyclopropyl, methoxy, ethoxy, F, -CN, -NH 2, -NHCH 3, -NHCH 2CH 3, -NHC (O) CH 3, -NHC (O) OCH 3, 
Figure PCTCN2022088989-appb-000037
In another Embodiment (35) , the invention provides a compound of any one of Embodiments (1) - (34) or a pharmaceutically acceptable salt thereof, wherein the moiety 
Figure PCTCN2022088989-appb-000038
in Formula (I) is selected from
Figure PCTCN2022088989-appb-000039
Figure PCTCN2022088989-appb-000040
Figure PCTCN2022088989-appb-000041
Figure PCTCN2022088989-appb-000042
In another Embodiment (36) , the invention provides a compound of any one of Embodiments (1) - (35) or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, -NH 2 and -OH, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X3. In another Embodiment, wherein R 3 is selected from hydrogen and methyl, wherein methyl is unsubstituted or substituted with at least one substituent, independently selected from R X3.
In another Embodiment (37) , the invention provides a compound of Embodiment (36) or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from hydrogen and methyl.
In another Embodiment (38) , the invention provides a compound of any one of Embodiments (1) - (37) or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, -NH 2 and -OH, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X4. In another Embodiment, wherein R 4 is selected from hydrogen and methyl, which is unsubstituted or substituted with at least one substituent, independently selected from R X4.
In another Embodiment (39) , the invention provides a compound of Embodiment (38) or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from hydrogen and methyl.
In another Embodiment (40) , the invention provides a compound of any one of Embodiments (1) - (35) or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 together with the atoms to which they are attached form a C 3-10 cycloalkyl or heterocyclic ring of 4 to 8 members containing 1, 2 or 3 heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups.
In another Embodiment (41) , the invention provides a compound of Embodiment (40) or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 together with the atoms to which they are attached form a cyclopropyl, and optionally substituted with 1, 2 or 3 R X3 groups. In another Embodiment, wherein R 3 and R 4 together with the atoms to which they are attached form a cyclopropyl.
In another Embodiment (42) , the invention provides a compound selected from
Figure PCTCN2022088989-appb-000043
Figure PCTCN2022088989-appb-000044
Figure PCTCN2022088989-appb-000045
Figure PCTCN2022088989-appb-000046
Figure PCTCN2022088989-appb-000047
Figure PCTCN2022088989-appb-000048
Figure PCTCN2022088989-appb-000049
Figure PCTCN2022088989-appb-000050
Figure PCTCN2022088989-appb-000051
Figure PCTCN2022088989-appb-000052
Figure PCTCN2022088989-appb-000053
Figure PCTCN2022088989-appb-000054
Figure PCTCN2022088989-appb-000055
Figure PCTCN2022088989-appb-000056
Figure PCTCN2022088989-appb-000057
Figure PCTCN2022088989-appb-000058
and pharmaceutically acceptable salts thereof.
In another Embodiment (43) , the invention provides a compound selected from
Figure PCTCN2022088989-appb-000059
and pharmaceutically acceptable salts thereof.
In another Embodiment (44) , the invention provides a pharmaceutical composition comprising a compound of any one of Embodiments (1) - (43) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.
In another Embodiment (45) , the invention provides a method of treating, ameliorating or preventing a condition, which responds to inhibition of PARP1, comprising administering to a subject in need of such treatment an effective amount of a compound of any one of Embodiments (1) - (43) , or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent.
In another Embodiment (46) , the invention provides a use of a compound of any one of Embodiments (1) - (43) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a cell-proliferative disorder.
In an In another Embodiment (47) , the invention provides a use of a compound of Embodiment (46) or a pharmaceutically acceptable salt thereof, wherein the cell- proliferative disorder is includes but not limited to, breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, testicular cancer, lung cancer (including NSCLC, SCLC, squamous cell carcinoma or adenocarcinoma) , esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer (including RCC) , liver cancer (including HCC) , pancreatic cancer, stomach (i.e., gastric) cancer, thyroid cancer, chronic lymphocytic leukemia (CLL) , lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia and myeloma.
In another of its aspects, there is provided a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
In yet another of its aspects, there is provided a kit comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof; and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the composition is to be administered, storage information for the composition, dosing information and instructions regarding how to administer the composition. In one particular variation, the kit comprises the compound in a multiple dose form.
In still another of its aspects, there is provided an article of manufacture comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof; and packaging materials. In one variation, the packaging material comprises a container for housing the compound. In one particular variation, the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the compound. In another variation, the article of manufacture comprises the compound in a multiple dose form.
In a further of its aspects, there is provided a therapeutic method comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
In another of its aspects, there is provided a method of inhibiting a PARP1 comprising contacting the PARP1 with a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
In yet another of its aspects, there is provided a method of inhibiting a PARP1 comprising causing a compound disclosed herein, or a pharmaceutically acceptable salt thereof to be present in a subject in order to inhibit the PARP1 in vivo.
In a further of its aspects, there is provided a method of inhibiting PARP1 comprising administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits the PARP1 in vivo, the second compound being a compound according to any one of the above embodiments and variations.
In another of its aspects, there is provided a method of treating a disease state for which a PARP1 possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising causing a compound disclosed herein, or a pharmaceutically acceptable salt thereof to be present in a subject in a therapeutically effective amount for the disease state.
In a further of its aspects, there is provided a method of treating a disease state for which a PARP1 possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits the PARP1 in vivo. It is noted that the compounds of the present invention may be the first or second compounds.
In one variation of each of the above methods the disease state is selected from the group consisting of cancerous hyperproliferative disorders (e.g., brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, epidermoid, esophageal, testicular, gynecological or thyroid cancer) ; non-cancerous hyperproliferative disorders (e.g., benign hyperplasia of the skin (e.g., psoriasis) , restenosis, and benign prostatic hypertrophy (BPH) ) ; pancreatitis; kidney disease; pain; preventing blastocyte implantation; treating diseases related to vasculogenesis or angiogenesis (e.g., tumor angiogenesis, acute and chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer) ; asthma; neutrophil chemotaxis (e.g., reperfusion injury in myocardial infarction and stroke and inflammatory arthritis) ; septic shock; T-cell mediated diseases where immune suppression would be of value (e.g., the prevention of organ transplant rejection, graft versus host disease, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis) ; atherosclerosis; inhibition of keratinocyte responses to growth factor cocktails; chronic obstructive pulmonary disease (COPD) and other diseases.
In another of its aspects, there is provided a method of treating a disease state for which a mutation in the PARP1 gene contributes to the pathology and/or symptomology of the disease state including, for example, melanomas, lung cancer, colon cancer and other tumor types.
In still another of its aspects, the present invention relates to the use of a compound of any of the above embodiments and variations as a medicament. In yet another of its aspects, the present invention relates to the use of a compound according to any one of the above embodiments and variations in the manufacture of a medicament for inhibiting a PARP1.
In a further of its aspects, the present invention relates to the use of a compound according to any one of the above embodiments and variations in the manufacture of a medicament for treating a disease state for which a PARP1 possesses activity that contributes to the pathology and/or symptomology of the disease state.
Administration and Pharmaceutical Compositions
In general, compounds of the disclosure will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents. A therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors known to those of ordinary skill in the art. For example, for the treatment of neoplastic diseases and immune system disorders, the required dosage will also vary depending on the mode of administration, the particular condition to be treated and the effect desired.
In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.001 to about 100 mg/kg per body weight, or particularly, from about 0.03 to 2.5 mg/kg per body weight. An indicated daily dosage in the larger mammal, e.g. humans, may be in the range from about 0.5 mg to about 2000 mg, or more particularly, from about 0.5 mg to about 1000 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form. Suitable unit dosage forms for oral administration comprise from ca. 1 to 50 mg active ingredient.
Compounds of the disclosure may be administered as pharmaceutical compositions by any conventional route; for example, enterally, e.g., orally, e.g., in the form of tablets or capsules; parenterally, e.g., in the form of injectable solutions or suspensions; or topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form.
Pharmaceutical compositions comprising a compound of the present disclosure in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent may be manufactured in a conventional manner by mixing, granulating, coating, dissolving or lyophilizing processes. For example, pharmaceutical compositions comprising a compound of the disclosure in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance.
In one embodiment, the pharmaceutical compositions are solutions of the active ingredient, including suspensions or dispersions, such as isotonic aqueous solutions. In the case of lyophilized compositions comprising the active ingredient alone or together with a carrier such as mannitol, dispersions or suspensions can be made up before use. The pharmaceutical compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. Suitable preservatives include but are not limited to antioxidants such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid. The solutions or suspensions may further comprise viscosity-increasing agents, including but not limited to, sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, gelatins, or solubilizers, e.g. Tween 80 (polyoxyethylene (20) sorbitan mono-oleate) .
Suspensions in oil may comprise as the oil component the vegetable, synthetic, or semi-synthetic oils customary for injection purposes. Examples include but are not limited to liquid fatty acid esters that contain as the acid component a long-chained fatty acid having 8-22 carbon atoms, or in some embodiments, 12-22 carbon atoms. Suitable liquid fatty acid esters include but are not limited to lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brassidic acid and linoleic acid, and if desired, may contain antioxidants, for example vitamin E, 3-carotene or 3, 5-di-tert-butyl-hydroxytoluene. The alcohol component of these fatty acid esters may have six carbon atoms and may be monovalent or polyvalent, for example a mono-, di-or trivalent, alcohol. Suitable alcohol components include but are not limited to methanol, ethanol, propanol, butanol or pentanol or isomers thereof; glycol and glycerol.
Other suitable fatty acid esters include but are not limited ethyl-oleate, isopropyl myristate, isopropyl palmitate, 
Figure PCTCN2022088989-appb-000060
M 2375, (polyoxyethylene glycerol) , 
Figure PCTCN2022088989-appb-000061
M 1944 CS (unsaturated polyglycolized glycerides prepared by alcoholysis of apricot kernel oil and comprising glycerides and polyethylene glycol ester) , LABRASOL TM (saturated polyglycolized glycerides prepared by alcoholysis of TCM and comprising glycerides and polyethylene glycol ester; all available from GaKefosse, France) , and/or 
Figure PCTCN2022088989-appb-000062
812 (triglyceride of saturated fatty acids of chain length C8 to C12 from Hüls AG, Germany) , and vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil, or groundnut oil.
Pharmaceutical compositions for oral administration may be obtained, for example, by combining the active ingredient with one or more solid carriers, and if desired,  granulating a resulting mixture, and processing the mixture or granules by the inclusion of additional excipients, to form tablets or tablet cores.
Suitable carriers include but are not limited to fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starches, for example corn, wheat, rice or potato starch, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, carboxymethyl starch, crosslinked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate. Additional excipients include but are not limited to flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.
Tablet cores may be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arable, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient.
Pharmaceutical compositions for oral administration may also include hard capsules comprising gelatin or soft-sealed capsules comprising gelatin and a plasticizer, such as glycerol or sorbitol. The hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, such as corn starch, binders, and/or glidants, such as talc or magnesium stearate, and optionally stabilizers. In soft capsules, the active ingredient may be dissolved or suspended in suitable liquid excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type, may also be added.
Pharmaceutical compositions suitable for rectal administration are, for example, suppositories comprising a combination of the active ingredient and a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols.
Pharmaceutical compositions suitable for parenteral administration may comprise aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers. The active ingredient, optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents. Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions. The manufacture of injectable preparations is usually carried out under sterile conditions, as is the filling, for example, into ampoules or vials, and the sealing of the containers.
The disclosure also provides for a pharmaceutical combination, e.g. a kit, comprising a) a first agent which is a compound of the disclosure as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent. The kit can comprise instructions for its administration.
Combination therapies
The compounds or pharmaceutical acceptable salts of the disclosure may be administered as the sole therapy, or together with other therapeutic agent or agents.
For example, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e. by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the individual is enhanced) . Or, by way of example only, the benefit experienced by an individual may be increased by administering one of the compounds described herein with another therapeutic agent that also has therapeutic benefit. By way of example only, in a treatment for gout involving administration of one of the compounds described herein, increased therapeutic benefit may result by also providing the individual with another therapeutic agent for gout. Or, by way of example only, if one of the side effects experienced by an individual upon receiving one of the compounds described herein is nausea, then it may be appropriate to administer an anti-nausea agent in combination with the compound. Or, the additional therapy or therapies include, but are not limited to physiotherapy, psychotherapy, radiation therapy, application of compresses to a diseased area, rest, altered diet, and the like. Regardless of the disease, disorder or condition being treated, the overall benefit experienced by the individual may be additive of the two therapies or the individual may experience a synergistic benefit.
In the instances where the compounds described herein are administered in combination with other therapeutic agents, the compounds described herein may be administered in the same pharmaceutical composition as other therapeutic agents, or because of different physical and chemical characteristics, be administered by a different route. For example, the compounds described herein may be administered orally to generate and maintain good blood levels thereof, while the other therapeutic agent may be administered intravenously. Thus the compounds described herein may be administered concurrently, sequentially or dosed separately to other therapeutic agents.
EXAMPLES
Various methods may be developed for synthesizing a compound of formula (I) or a pharmaceutically acceptable salt thereof. Representative methods for synthesizing a compound of formula (I) or a pharmaceutically acceptable salt thereof are provided in the Examples. It is noted, however, that a compound of formula (I) or a pharmaceutically acceptable salt thereof may also be synthesized by other synthetic routes that others may devise.
It will be readily recognized that certain compounds of formula (I) have atoms with linkages to other atoms that confer a particular stereochemistry to the compound (e.g., chiral centers) . It is recognized that synthesis of a compound of formula (I) or a pharmaceutically acceptable salt thereof may result in the creation of mixtures of different stereoisomers (enantiomers, diastereomers) . Unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all of the different possible stereoisomers.
A compound of formula (I) can also be prepared as a pharmaceutically acceptable acid addition salt by, for example, reacting the free base form of the at least one compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of the at least one compound of formula (I) can be prepared by, for example, reacting the free acid form of the at least one compound with a pharmaceutically acceptable inorganic or organic base. Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds of formula  (I) are set forth in the definitions section of this Application. Alternatively, the salt forms of the compounds of formula (I) can be prepared using salts of the starting materials or intermediates.
The free acid or free base forms of the compounds of formula (I) can be prepared from the corresponding base addition salt or acid addition salt form. For example, a compound of formula (I) in an acid addition salt form can be converted to the corresponding free base thereof by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like) . A compound of formula (I) in a base addition salt form can be converted to the corresponding free acid thereof by, for example, treating with a suitable acid (e.g., hydrochloric acid, etc) .
The N-oxides of a compound of formula (I) or a pharmaceutically acceptable salt thereof can be prepared by methods known to those of ordinary skill in the art. For example, N-oxides can be prepared by treating an unoxidized form of the compound of formula (I) with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 to 80℃. Alternatively, the N-oxides of the compounds of formula (I) can be prepared from the N-oxide of an appropriate starting material.
Compounds of formula (I) in an unoxidized form can be prepared from N-oxides of compounds of formula (I) by, for example, treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, and the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, and the like) at 0 to 80℃.
Protected derivatives of the compounds of formula (I) can be made by methods known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley &Sons, Inc. 1999.
As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or three-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. For example, the following abbreviations may be used in the examples and throughout the specification: g (grams) ; mg (milligrams) ; L (liters) ; mL (milliliters) ; μL (microliters) ; psi (pounds per square inch) ; M (molar) ; mM (millimolar) ; i. v. (intravenous) ; Hz (Hertz) ; MHz (megahertz) ; mol (moles) ; mmol (millimoles) ; RT (room temperature) ; min (minutes) ; h (hours) ; mp (melting point) ; TLC (thin layer chromatography) ; Rt (retention time) ; RP (reverse phase) ; MeOH (methanol) ; i-PrOH (isopropanol) ; TEA (triethylamine) ; TFA (trifluoroacetic acid) ; TFAA (trifluoroacetic anhydride) ; THF (tetrahydrofuran) ; DMSO (dimethyl sulfoxide) ; EtOAc (ethyl acetate) ; DME (1, 2-dimethoxyethane) ; DCM (dichloromethane) ; DCE (dichloroethane) ; DMF (N, N-dimethylformamide) ; DMPU (N, N'-dimethylpropyleneurea) ; CDI (1, 1-carbonyldiimidazole) ; IBCF (isobutyl chloroformate) ; HOAc (acetic acid) ; HOSu (N-hydroxysuccinimide) ; HOBT (1-hydroxybenzotriazole) ; Et 2O (diethyl ether) ; EDCI (1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride) ; BOC (tert-butyloxycarbonyl) ; FMOC (9-fluorenylmethoxycarbonyl) ; DCC (dicyclohexylcarbodiimide) ; CBZ (benzyloxycarbonyl) ; Ac (acetyl) ; atm (atmosphere) ; TMSE (2- (trimethylsilyl) ethyl) ; TMS (trimethylsilyl) ; TIPS  (triisopropylsilyl) ; TBS (t-butyldimethylsilyl) ; DMAP (4-dimethylaminopyridine) ; Me (methyl) ; OMe (methoxy) ; Et (ethyl) ; tBu (tert-butyl) ; HPLC (high pressure liquid chomatography) ; BOP (bis (2-oxo-3-oxazolidinyl) phosphinic chloride) ; TBAF (tetra-n-butylammonium fluoride) ; m-CPBA (meta-chloroperbenzoic acid) .
References to ether or Et 2O are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in ℃ (degrees Centigrade) . All reactions were conducted under an inert atmosphere at RT unless otherwise noted.
1H NMR spectra were recorded on a Varian Mercury Plus 400. Chemical shifts are expressed in parts per million (ppm) . Coupling constants are in units of hertz (Hz) . Splitting patterns describe apparent multiplicities and are designated as s (singlet) , d (doublet) , t (triplet) , q (quartet) , m (multiplet) and br (broad) .
Low-resolution mass spectra (MS) and compound purity data were acquired on a Shimadzu LC/MS single quadrupole system equipped with electrospray ionization (ESI) source, UV detector (220 and 254 nm) , and evaporative light scattering detector (ELSD) . Thin-layer chromatography was performed on 0.25 mm Superchemgroup silica gel plates (60F-254) , visualized with UV light, 5%ethanolic phosphomolybdic acid, ninhydrin, or p-anisaldehyde solution. Flash column chromatography was performed on silica gel (200-300 mesh, Branch of Qingdao Haiyang Chemical Co., Ltd) .
Synthetic Schemes
Synthetic methods for preparing the compounds of the present invention are illustrated in the following Schemes and Examples. Starting materials are commercially available or may be made according to procedures known in the art or as illustrated herein.
The intermediates shown in the following schemes are either known in the literature or may be prepared by a variety of methods familiar to those skilled in the art.
As an illustration, two of the synthetic approaches of the compounds of formula I of the present disclosure are exemplified in Scheme 1. As shown in the Scheme, the compounds of formula I can be disassembled into the intermediates III and II, the coupling of which can be achieved through alkylation reactions. Alternatively, compounds of formula I can be assembled from intermediates IV and V by cross coupling reactions.
Figure PCTCN2022088989-appb-000063
Scheme 1
As an illustration of the preparation of intermediates of formula II, a preparation of compound IIa is shown in Scheme 2. Starting from aldehyde IIa-A, which is either commercially available or known in the literature, amino ester IIa-C can be prepared via the Wittig-Horner reaction of IIa-A with IIa-B. Intramolecular cyclization of IIa-C leads to lactam IIa-D and reduction of ester group of IIa-D furnishes alcohol IIa-E, which can be converted to IIa with chlorinating agents such as SOCl 2.
Figure PCTCN2022088989-appb-000064
Scheme 2
As a further illustration of the preparation of intermediates of formula II, a preparation of compound IIb is illustrated in Scheme 3. Cross coupling of IIb-A with IIb-B via nucleophilic substitution reaction provides IIb-C. Reduction of the nitro group and intramolecular cyclization leads to lactam IIb-D, which can be converted to IIb-E through oxidative aromatization reactions. Following the reduction/chlorination transformations as described in scheme 2, IIb-E can be readily transformed into intermediates of formula IIb.
Figure PCTCN2022088989-appb-000065
Scheme 3
As an illustration of the preparation of intermediates of formula IV, one preparation of compound IV is shown in Scheme 4. Starting from readily available ketone or aldehyde IV-A, chiral amine IV-D can be prepared through sequential condensation of IV-A with Elman reagent and addition of Grignard reagent followed by hydrolysis with acid. Amine IV-D can be converted into intermediates of formula IV by ring forming transformations known in the arts.
Figure PCTCN2022088989-appb-000066
Scheme 4
In some cases the order of carrying out the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products. The following examples are provided so that the invention might be more fully understood. These examples are illustrative only and should not be construed as limiting the invention in any way.
Example 1
5- (4- ( (6-ethyl-7-oxo-7, 8-dihydro-1, 8-naphthyridin-2-yl) methyl) piperazin-1- yl) -N-methylpicolinamide (1) 
Figure PCTCN2022088989-appb-000067
tert-butyl (6-chloro-3-formylpyridin-2-yl) carbamate (1a)
The title compound tert-butyl (6-chloro-3-formylpyridin-2-yl) carbamate (1a) was prepared according to the method described in Journal of Medicinal Chemistry, 2000, 43, 3134-3147. MS-ESI (m/z) : 257 [M + 1]  +.
2-amino-6-chloronicotinaldehyde (1b)
To a solution of tert-butyl (6-chloro-3-formylpyridin-2-yl) carbamate (1a) (0.53 g, 2.0 mmol ) in DCM (5 mL) was added TFA (5 mL) and stirred at RT for 1 h. The mixture was concentrated in vacuum. The residue was added water (25 mL) and neutralized with solid NaHCO 3 until no gas was evolved. The mixture was extracted with EtOAc (50 mL × 2) , the organic layer was dried over Na 2SO 4 and evaporated to give 2-amino-6-chloronicotinaldehyde (1b) as a yellow solid. MS-ESI (m/z) : 157 [M + 1]  +.
7-chloro-3-ethyl-1, 8-naphthyridin-2 (1H) -one (1c)
To a solution of 2-amino-6-chloronicotinaldehyde (1b) (0.25 g, 1.6 mmol) in Ethyl butyrate (8 mL) was added t-BuOK (0.5 g, 4.5mmol ) and stirred at 120℃ for 1 h. The reaction mixture was cooled to RT, quenched with water (25 mL) and extracted with EtOAc (25 ml × 2) , the organic layer was dried over Na 2SO 4 and concentrated. The residue was purified by flash column chromatography on silica gel eluting with PE/EtOAc = 4: 1 to give 7-chloro-3-ethyl-1, 8-naphthyridin-2 (1H) -one (1c) as a white solid. MS-ESI (m/z) : 209 [M + 1]  +.
3-ethyl-7-vinyl-1, 8-naphthyridin-2 (1H) -one (1d)
To a suspension of 7-chloro-3-ethyl-1, 8-naphthyridin-2 (1H) -one (1c) (0.14 g, 0.66 mmol) and Potassium vinyl-trifluoroborate (0.18 g, 1.34 mmol) in 1, 4-dioxane (5 mL) was added water (0.5 mL) , K 3PO 4 (0.5 g, 1.65 mmol) and PdCl 2 (dppf) (48 mg, 0.06 mmol) under N 2 atmosphere and stirred at 90℃ for 1 h. The reaction mixture was added water (30 mL) and extracted with EtOAc (50 mL × 3) , the organic layer was washed with brine, dried over Na 2SO 4 and concentrated. The residue was purified by flash column chromatography on silica gel eluting with PE/EtOAc = 10: 1 to 4: 1 to give 3-ethyl-7-vinyl-1, 8-naphthyridin-2 (1H) -one (1d) as a white solid. MS-ESI (m/z) : 201 [M + 1]  +.
6-ethyl-7-oxo-7, 8-dihydro-1, 8-naphthyridine-2-carbaldehyde (1f)
To a solution of 3-ethyl-7-vinyl-1, 8-naphthyridin-2 (1H) -one (1d) (20 mg, 0.1 mol) in 1, 4-dioxane (2 mL) and water (0.5 mL) was added NaIO 4 (85 mg, 0.4 mmol) and K 2OsO 4.2H 2O (5 mg, 0.01 mmol) and stirred at RT for 24 h. The reaction mixture was added water (10 mL) and extracted with EtOAc (10 mL × 3) , the organic layer was washed with saturated Na 2SO 3 solution, brine, dried over Na 2SO 4 and concentrated to give 6-ethyl-7-oxo-7, 8-dihydro-1, 8-naphthyridine-2-carbaldehyde (1f) as a white solid. MS-ESI (m/z) : 203 [M +1]  +.
N-methyl-5-piperazin-1 -yl-pyridine-2-carboxamide, 2HCl (1e) 
The title compound N-methyl-5-piperazin-1-yl-pyridine-2-carboxamide, 2HCl (1e) was prepared according to the method described in WO 2021/013735. MS-ESI (m/z) : 221 [M + 1]  +.
5- (4- ( (6-ethyl-7-oxo-7, 8-dihydro-1, 8-naphthyridin-2-yl) methyl) piperazin-1- yl) -N-methylpicolinamide  (1)
To a solution of 6-ethyl-7-oxo-7, 8-dihydro-1, 8-naphthyridine -2-carbaldehyde (1f) (5 mg, 0.025 mmol) and N-methyl-5-piperazin-1-yl-pyridine-2 -carboxamide, 2HCl (1e) (8 mg, 0.027mmol) in DCE (3 mL) was added TEA (5.5 mg, 0.055mmol) and NaBH (OAc)  3 (32 mg, 0.15mmol) and the reaction was stirred at room temperature for overnight. The reaction was quenched with saturated NaHCO 3 and stirred for 0.5 h, extracted with DCM (10 mL × 3) , the organic layer was dried over Na 2SO 4 and concentrated. The residue was purified by preparative TLC eluted with DCM/MeOH = 10: 1 to give 5- (4- ( (6-ethyl-7-oxo-7, 8-dihydro-1, 8-naphthyridin-2-yl) methyl) piperazin-1-yl) -N-methylpicolinamide (1) as a white solid. MS-ESI (m/z) : 407 [M + 1]  +.
Example 2
1'- ( (7-ethyl-6-oxo-5, 6-dihydro-1, 5-naphthyridin-3-yl) methyl) -N-methyl- 1', 2', 3', 6'-tetrahydro- [3, 4'-bipyridine] -6-carboxamide (2)
Figure PCTCN2022088989-appb-000068
7- (chloromethyl) -3-ethyl-1, 5-naphthyridin-2 (1H) -one (2a)
7- (chloromethyl) -3-ethyl-1, 5-naphthyridin-2 (1H) -one (2a) was prepared according to the method described in WO2021/013735.
tert-butyl 6- (methylcarbamoyl) -3', 6'-dihydro- [3, 4'-bipyridine] -1' (2'H) - carboxylate (2b)
A mixture of 5-bromo-N-methylpicolinamide (WO2021/013735) (160 mg, 0.744 mmol) , tert-butyl 4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -3, 6-dihydropyridine-1 (2H) -carboxylate (230 mg, 0.744 mmol) , K 2CO 3 (205 mg, 1.49 mmol) and PdCl 2 (dppf) (55 mg, 0.074 mmol) in DMF (3 mL) was stirred at 95℃ for 1.5 h under N 2 atmosphere. The mixture was cooled to RT and concentrate. The residue was purified by column chromatography on silica gel eluting with DCM /EtOAc (5: 1 ～ 1: 1) to give the title compound tert-butyl 6- (methylcarbamoyl) -3', 6'-dihydro- [3, 4'-bipyridine] -1' (2'H) -carboxylate (2b) . MS-ESI (m/z) : 318 [M + 1]  +.
N-methyl-1', 2', 3', 6'-tetrahydro- [3, 4'-bipyridine] -6-carboxamide (2c)
A mixture of tert-butyl 6- (methylcarbamoyl) -3', 6'-dihydro- [3, 4'-bipyridine] -1' (2'H) -carboxylate (2b) (24 mg, 0.076 mmol) and TFA (1.0 mL, 10 mmol) in DCM (1 mL) was stirred at RT for 20 min. The reaction mixture was evaporated to give the crude product of N-methyl-1', 2', 3', 6'-tetrahydro- [3, 4'-bipyridine] -6-carboxamide (2c) , which was used for next step directly. MS-ESI (m/z) : 218 [M + 1]  +.
1'- ( (7-ethyl-6-oxo-5, 6-dihydro-1, 5-naphthyridin-3-yl) methyl) -N-methyl- 1', 2', 3', 6'-tetrahydro- [3, 4'-bipyridine] -6-carboxamide (2)
A mixture of 7- (chloromethyl) -3-ethyl-1, 5-naphthyridin-2 (1H) -one (2a) (17.0 mg, 0.076 mmol) , N-methyl-1', 2', 3', 6'-tetrahydro- [3, 4'-bipyridine] -6-carboxamide (2c) (16.6 mg, 0.076 mmol) and DIPEA (4 drops) in ACN (1.5 mL) was stirred at 80℃ for 2 h. The reaction mixture was cooled to RT and concentrated. The residue was purified by preparative TLC to give title compound 1'- ( (7-ethyl-6-oxo-5, 6-dihydro-1, 5-naphthyridin-3-yl) methyl) -N-methyl-1', 2', 3', 6'-tetrahydro- [3, 4'-bipyridine] -6-carboxamide (2) . MS-ESI (m/z) : 404 [M + 1]  +.
Example 3
3-ethyl-7- ( (4- (6-methyl-5-oxo-6, 7-dihydro-5H-pyrrolo [3, 4-b] pyridin-2- yl) piperazin-1-yl) methyl) -1, 5-naphthyridin-2 (1H) -one (3)
Figure PCTCN2022088989-appb-000069
methyl 2- (chloromethyl) nicotinate (3a)
A mixture of methyl 2-methylnicotinate (1.9 g, 0.013 mmol) and TCCA (3.7 g, 0.015 mmol) in DCM (50 mL) was stirred at RT for 16 h. The reaction mixture was concentrated. The residue was purified by flash column chromatography on silica gel eluting with PE/EtOAc = 50: 1 to 20: 1 to give methyl 2- (chloromethyl) nicotinate (3a) . MS-ESI (m/z) : 186 [M + 1]  +.
2- (chloromethyl) -3- (methoxycarbonyl) pyridine 1-oxide (3b)
To a solution of methyl 2- (chloromethyl) nicotinate (3a) (1.5 g, 8.1 mmol) in DCM (40 ml) was added m-CPBA (1.7 g, 9.7 mmol) at RT. The mixture was stirred at RT for overnight. The reaction mixture was evaporated to give the crude product of 2- (chloromethyl) -3- (methoxycarbonyl) pyridine 1-oxide (3b) , which was used for next step directly. MS-ESI (m/z) : 202 [M + 1]  +.
methyl 6-chloro-2- (chloromethyl) nicotinate (3c)
A mixture of 2- (chloromethyl) -3- (methoxycarbonyl) pyridine 1-oxide (3b) (500 mg, 2.49 mmol) in POCl 3 (2 mL) was stirred at 110℃ for 15 h. The mixture was poured  into ice water and adjusted with saturated NaHCO 3 aqueous solution to pH = 8 ～ 9. The mixture was extracted by DCM, washed with brine, dried over Na 2SO 4 and concentrated. The residue was purified by flash column chromatography on silica gel eluting with PE/EtOAc = 30: 1 to 20:1 to give methyl 6-chloro-2- (chloromethyl) nicotinate (3c) . MS-ESI (m/z) : 220 [M + 1]  +.
2-chloro-6-methyl-6, 7-dihydro-5H-pyrrolo [3, 4-b] pyridin-5-one (3d)
A mixture of methyl 6-chloro-2- (chloromethyl) nicotinate (3c) (280 mg, 1.278 mmol) in NH 2Me (30%in CH 3OH, 2 mL) was stirred at RT for 20 min. The reaction mixture was evaporated to give the crude product of 2-chloro-6-methyl-6, 7-dihydro-5H-pyrrolo [3, 4-b] pyridin-5-one (3d) , which was used for next step directly. MS-ESI (m/z) : 183 [M + 1]  +.
tert-butyl 4- (6-methyl-5-oxo-6, 7-dihydro-5H-pyrrolo [3, 4-b] pyridin-2- yl) piperazine-1-carboxylate (3e)
A mixture of 2-chloro-6-methyl-6, 7-dihydro-5H-pyrrolo [3, 4-b] pyridin-5-one (3d) (36 mg, 0.2 mmol) , tert-butyl piperazine-1-carboxylate (55 mg, 0.3 mmol) , Pd 2 (dba)  3 (18 mg, 0.02 mmol) , S-phos (16 mg, 0.028 mmol) and K 3PO 4 (85 mg, 0.4 mmol) in DMF (1 mL) was stirred at 130℃ for overnight. The mixture was cooled to RT. The reaction was quenched by water and the mixture was extracted with EtOAc. The extracts were washed with brine, dried over Na 2SO 4 and concentrated. The residue was purified by flash column chromatography on silica gel eluting with PE/EtOAc = 5: 1 to 3: 1 to give tert-butyl 4- (6-methyl-5-oxo-6, 7-dihydro-5H-pyrrolo [3, 4-b] pyridin-2-yl) piperazine-1-carboxylate (3e) . MS-ESI (m/z) : 333 [M + 1]  +.
3-ethyl-7- ( (4- (6-methyl-5-oxo-6, 7-dihydro-5H-pyrrolo [3, 4-b] pyridin-2- yl) piperazin-1-yl) methyl) -1, 5-naphthyridin-2 (1H) -one (3)
The title compound 3-ethyl-7- ( (4- (6-methyl-5-oxo-6, 7-dihydro-5H-pyrrolo [3, 4-b] pyridin-2-yl) piperazin-1-yl) methyl) -1, 5-naphthyridin-2 (1H) -one (3) was prepared according to the synthetic method of 2 by replacing tert-butyl 6- (methylcarbamoyl) -3',6'-dihydro- [3, 4'-bipyridine] -1' (2'H) -carboxylate (2b) with tert-butyl 4- (6-methyl-5-oxo-6, 7-dihydro-5H-pyrrolo [3, 4-b] pyridin-2-yl) piperazine-1-carboxylate (3e) . MS-ESI (m/z) : 419 [M + 1]  +.
Reference compound 1
5- (4- ( (7-ethyl-6-oxo-5, 6-dihydro-1, 5-naphthyridin-3-yl) methyl) piperazin-1- yl) -N-methylpicolinamide (Reference 1)
5- (4- ( (7-ethyl-6-oxo-5, 6-dihydro-1, 5-naphthyridin-3-yl) methyl) piperazin-1-yl) -N-methylpicolinamide (Reference 1) was prepared according to the method described in WO 2021013735. MS-ESI (m/z) : 407 [M + 1]  +.
Following essentially the same procedures described for Examples 1-3, Examples 4-538 listed in Table 1 were prepared from the appropriate starting materials which are commercially available or known in the literature. The structures and names of Examples 4-538 are given in Table 1.
Table 1
Figure PCTCN2022088989-appb-000070
Figure PCTCN2022088989-appb-000071
Figure PCTCN2022088989-appb-000072
Figure PCTCN2022088989-appb-000073
Figure PCTCN2022088989-appb-000074
Figure PCTCN2022088989-appb-000075
Figure PCTCN2022088989-appb-000076
Figure PCTCN2022088989-appb-000077
Figure PCTCN2022088989-appb-000078
Figure PCTCN2022088989-appb-000079
Figure PCTCN2022088989-appb-000080
Figure PCTCN2022088989-appb-000081
Figure PCTCN2022088989-appb-000082
Figure PCTCN2022088989-appb-000083
Figure PCTCN2022088989-appb-000084
Figure PCTCN2022088989-appb-000085
Figure PCTCN2022088989-appb-000086
Figure PCTCN2022088989-appb-000087
Figure PCTCN2022088989-appb-000088
Figure PCTCN2022088989-appb-000089
Figure PCTCN2022088989-appb-000090
Figure PCTCN2022088989-appb-000091
Figure PCTCN2022088989-appb-000092
Figure PCTCN2022088989-appb-000093
Figure PCTCN2022088989-appb-000094
Figure PCTCN2022088989-appb-000095
Figure PCTCN2022088989-appb-000096
Figure PCTCN2022088989-appb-000097
Figure PCTCN2022088989-appb-000098
Figure PCTCN2022088989-appb-000099
Figure PCTCN2022088989-appb-000100
Figure PCTCN2022088989-appb-000101
Figure PCTCN2022088989-appb-000102
Figure PCTCN2022088989-appb-000103
Figure PCTCN2022088989-appb-000104
Figure PCTCN2022088989-appb-000105
Figure PCTCN2022088989-appb-000106
Figure PCTCN2022088989-appb-000107
Figure PCTCN2022088989-appb-000108
Figure PCTCN2022088989-appb-000109
Figure PCTCN2022088989-appb-000110
Figure PCTCN2022088989-appb-000111
Figure PCTCN2022088989-appb-000112
Figure PCTCN2022088989-appb-000113
Figure PCTCN2022088989-appb-000114
Figure PCTCN2022088989-appb-000115
Figure PCTCN2022088989-appb-000116
Figure PCTCN2022088989-appb-000117
Figure PCTCN2022088989-appb-000118
Figure PCTCN2022088989-appb-000119
Figure PCTCN2022088989-appb-000120
Figure PCTCN2022088989-appb-000121
Figure PCTCN2022088989-appb-000122
Cell Proliferation Assays
MTS testing kit was purchased from Promega (Madison, WI, USA) . The RPMI-1640, Penicillin-Streptomycin and Trypsin-EDTA (0.25%) were purchased from BI (Biological Industries, Beit Haemek, Israel) . Fetal bovine serum was purchased from GIBCO (Grand Island, NY, USA) . Dimethyl sulfoxide (DMSO) were purchased from Sigma (St. Louis., MO, USA) . MDA-MB-436 (CAS, Cat. No: TCHu184) cells were cultured in RPMI-1640 supplemented with Penicillin-Streptomycin and 10%FBS.
To investigate whether a compound is able to inhibit the activity of PARP1 in cells, a mechanism-based assay using MDA-MB-436 (BRCA1-deficient) lines was developed. In this assay, the inhibition of PARP1 was reflected by the inhibition of cell proliferation of MDA-MB-436 cells. Cells were plated into 96-well plates at the optimized cell density of 2000 cells/well. Plates were incubated at 37℃, with 5 %CO 2 for 24 h. Compounds were serially diluted and added to the plates with the final concentrations of 10000, 3333.3, 1111.1, 370.4, 123.5, 41.2, 13.7, 4.6 and 1.5 nM. Plates were incubated at 37℃, with 5%CO 2 for 120 h. 20 μL MTS was added into each well and the plates were incubated at 37℃, with 5%CO 2 for 2 h. The absorbance was measured by a microplate reader at 490 nm. IC 50 was calculated using GraphPad Prism 8.0 software.
Select compounds prepared as described above were assayed according to the biological procedures described herein. The results are given in the table 2.
Table 2
Example IC 50 (nM) Example IC 50 (nM)
2 1 192 1
4 5 195 1
13 1 193 1
44 1 194b 3
61 1 220 1
71 1 221 1
118 1 224 1
119 1 226 1
121 1 246 1
126 1 247 1
141 1 249 1
149 1 252 1
150 1 271 1
178 1 285 1
179 1 289 3
213 1 290 1
181b 1 291 2
191 1 / /
MTS testing kit was purchased from Promega (Madison, WI, USA) . The RPMI-1640, IMDM, Penicillin-Streptomycin and Trypsin-EDTA (0.25%) were purchased  from BI (Biological Industries, Beit Haemek, Israel) . Fetal bovine serum was purchased from GIBCO (Grand Island, NY, USA) . Dimethyl sulfoxide (DMSO) were purchased from Sigma (St. Louis., MO, USA) . Capan-1 (ATCC, Cat. No: HTB-79) cells were cultured in IMDM supplemented with 20%FBS and 100 U/mL Penicillin-Streptomycin and MX-1 (Cobioer, Cat. No: CBP60640) cells were cultured in RPMI-1640 supplemented with 10%FBS and 100 U/mL Penicillin-Streptomycin.
To investigate whether a compound is able to inhibit the activity of PARP1 in cells, a mechanism-based assay using Capan-1 (BRCA2-deficient) and MX-1 (BRCA1-deficient) cell lines was developed. In this assay, the inhibition of PARP1 was reflected by the inhibition of cell proliferation of Capan-1 and MX-1 cells. Cells were plated into 96-well plates at the optimized cell density (Capan-1: 10000 cells/well; MX-1: 5000 cells/well) . Plates were incubated at 37℃, with 5 %CO 2 for 24 h. Compounds were serially diluted and added to the plates with the final concentrations of 10000, 3333.3, 1111.1, 370.4, 123.5, 41.2, 13.7, 4.6 and 1.5 nM. Plates were incubated at 37℃, with 5%CO 2 for 7 days. 20 μL MTS was added into each well and the plates were incubated at 37℃, with 5 %CO 2 for 2 h. The absorbance was measured by a microplate reader at 490 nm. IC 50 was calculated using GraphPad Prism 8.0 software.
Select compounds prepared as described above were assayed according to the biological procedures described herein. The results are given in the table 3.
Table 3
Example MX-1 IC 50 (nM) Example MX-1 IC 50 (nM)
2 1 221 2
4 1 246 1
13 3 247 2
194b 3 285 3
213 1 289 1
220 2 291 2
Pharmacokinetics Assays
The purpose of this study was to determine the pharmacokinetics of Compound 2 in male Beagle Dogs (Supplied by Marshall Bioresources, Beijing, China. ) following a single intravenous bolus injection at 1 mg/kg and oral gavage (PO) administration at 3 mg/kg.
Animals in Group 1 were administered with Compound 2 by single intravenous bolus injection at 1 mg/kg, which was formulated in 10%DMSO (Sigma, Batch#LPC0S181) : 60%PEG400 (Sigma, Batch#MKCH6281) : 30%water at 1 mg/mL as a solution. Animals in Group 2 were administered with Compound 2 by single oral gavage (PO) administration at 3 mg/kg, which was formulated in 10%DMSO (Sigma, Batch#BCCG0331) : 60%PEG400 (Sigma, Batch#MKCN6245) : 30%water at 1 mg/mL as a solution. Blood samples were collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose. Concentrations of Compound 2 in plasma were determined by LC/MS/MS (LC: Waters UPLC; MS: Triple Quad 6500 plus) .
Select compounds prepared as described above were assayed according to the biological procedures described herein. The results are given in the table 4.
Table 4
Figure PCTCN2022088989-appb-000123

Claims (23)

  1. A compound of formula (I) :
    Figure PCTCN2022088989-appb-100001
    or a pharmaceutically acceptable salt thereof, wherein:
    X 1 is selected from N and CR 6;
    X 2 is selected from N and CR 7;
    X 3 is selected from N and CR 8;
    X 4 is selected from N and CR 9;
    Ring Q 1 is selected from C 3-10 cycloalkyl, heterocyclyl, and heteroaryl;
    Ring Q 2 is selected from heterocyclyl, aryl, and heteroaryl;
    L is selected from a bond, - (CR C0R D0)  u-, - (CR C0R D0)  uO (CR C0R D0)  t-, - (CR C0R D0)  uNR A0 (CR C0R D0)  t-, and - (CR C0R D0)  uS (CR C0R D0)  t-;
    each R 1 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2- 10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A1R B1, -OR A1, -C (O) R A1, -C (=NR E1) R A1, -C (=N-OR B1) R A1, -C (O) OR A1, -OC (O) R A1, -C (O) NR A1R B1, -C (O) NR A1S (O)  rR A1, -C (O) NR A1S (O)  2OR A1, -C (O) NR A1S (O)  rNR A1R B1, -C (O) NR A1S (O) (=NR E1) R B1, -C (O) NR A1S (O) (=NR E1) NR A1R B1, -NR A1C (O) R B1, -C (=NR E1) NR A1R B1, -NR A1C (=NR E1) R B1, -OC (O) NR A1R B1, -NR A1C (O) OR B1, -NR A1C (O) NR A1R B1, -NR A1C (S) NR A1R B1, -NR A1C (=NR E1) NR A1R B1, -S (O)  rR A1, -S (O) (=NR E1) R B1, -N=S (O) R A1R B1, -S (O)  2OR A1, -OS (O)  2R A1, -NR A1S (O)  rR B1, -NR A1S (O) (=NR E1) R B1, -S (O)  rNR A1R B1, -S (O) (=NR E1) NR A1R B1, -NR A1S (O)  2NR A1R B1, -NR A1S (O) (=NR E1) NR A1R B1, -P (O) R A1R B1 and -P (O) (OR A1) (OR B1) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X1;
    each R 2 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2- 10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A2R B2, -OR A2, -C (O) R A2, -C (=NR E2) R A2, -C (=N-OR B2) R A2, -C (O) OR A2, -OC (O) R A2, -C (O) NR A2R B2, -NR A2C (O) R B2, -C (=NR E2) NR A2R B2, -NR A2C (=NR E2) R B2, -OC (O) NR A2R B2, -NR A2C (O) OR B2, -NR A2C (O) NR A2R B2, -NR A2C (S) NR A2R B2, -NR A2C (=NR E2) NR A2R B2, -S (O)  rR A2, -S (O) (=NR E2) R B2, -N=S (O) R A2R B2, -S (O)  2OR A2, -OS (O)  2R A2, -NR A2S (O)  rR B2, -NR A2S (O) (=NR E2) R B2, -S (O)  rNR A2R B2, -S (O) (=NR E2) NR A2R B2, -NR A2S (O)  2NR A2R B2, -NR A2S (O) (=NR E2) NR A2R B2, -P (O) R A2R B2 and -P (O) (OR A2) (OR B2) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X2;
    R 3 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, CN, NO 2, -NR A3R B3, -OR A3 and -C (O) R A3, wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R X3;
    R 4 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, CN, NO 2, -NR A4R B4, -OR A4, -C (O) R A4, wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R X4;
    or R 3 and R 4 together with the atoms to which they are attached form a C 3-10 cycloalkyl or heterocyclic ring of 4 to 12 members containing 1, 2 or 3 heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups;
    R 5 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A5R B5, -OR A5, -C (O) R A5, -C (=NR E5) R A5, -C (=N-OR B5) R A5, -C (O) OR A5, -OC (O) R A5, -C (O) NR A5R B5, -NR A5C (O) R B5, -C (=NR E5) NR A5R B5, -NR A5C (=NR E5) R B5, -OC (O) NR A5R B5, -NR A5C (O) OR B5, -NR A5C (O) NR A5R B5, -NR A5C (S) NR A5R B5, -NR A5C (=NR E5) NR A5R B5, -S (O)  rR A5, -S (O) (=NR E5) R B5, -N=S (O) R A5R B5, -S (O)  2OR A5, -OS (O)  2R A5, -NR A5S (O)  rR B5, -NR A5S (O) (=NR E5) R B5, -S (O)  rNR A5R B5, -S (O) (=NR E5) NR A5R B5, -NR A5S (O)  2NR A5R B5, -NR A5S (O) (=NR E5) NR A5R B5, -P (O) R A5R B5 and -P (O) (OR A5) (OR B5) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X5;
    R 6 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A6R B6, -OR A6, -C (O) R A6, -C (=NR E6) R A6, -C (=N-OR B6) R A6, -C (O) OR A6, -OC (O) R A6, -C (O) NR A6R B6, -NR A6C (O) R B6, -C (=NR E6) NR A6R B6, -NR A6C (=NR E6) R B6, -OC (O) NR A6R B6, -NR A6C (O) OR B6, -NR A6C (O) NR A6R B6, -NR A6C (S) NR A6R B6, -NR A6C (=NR E6) NR A6R B6, -S (O)  rR A6, -S (O) (=NR E6) R B6, -N=S (O) R A6R B6, -S (O)  2OR A6, -OS (O)  2R A6, -NR A6S (O)  rR B6, -NR A6S (O) (=NR E6) R B6, -S (O)  rNR A6R B6, -S (O) (=NR E6) NR A6R B6, -NR A6S (O)  2NR A6R B6, -NR A6S (O) (=NR E6) NR A6R B6, -P (O) R A6R B6 and -P (O) (OR A6) (OR B6) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X6;
    R 7 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A7R B7, -OR A7, -C (O) R A7, -C (=NR E7) R A7, -C (=N-OR B7) R A7, -C (O) OR A7, -OC (O) R A7, -C (O) NR A7R B7, -NR A7C (O) R B7, -C (=NR E7) NR A7R B7, -NR A7C (=NR E7) R B7, -OC (O) NR A7R B7, -NR A7C (O) OR B7, -NR A7C (O) NR A7R B7, -NR A7C (S) NR A7R B7, -NR A7C (=NR E7) NR A7R B7, -S (O)  rR A7, -S (O) (=NR E7) R B7, -N=S (O) R A7R B7, -S (O)  2OR A7, -OS (O)  2R A7, -NR A7S (O)  rR B7, -NR A7S (O) (=NR E7) R B7, -S (O)  rNR A7R B7, -S (O) (=NR E7) NR A7R B7, -NR A7S (O)  2NR A7R B7, -NR A7S (O) (=NR E7) NR A7R B7, -P (O) R A7R B7 and -P (O) (OR A7) (OR B7) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X7;
    R 8 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4  alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A8R B8, -OR A8, -C (O) R A8, -C (=NR E8) R A8, -C (=N-OR B8) R A8, -C (O) OR A8, -OC (O) R A8, -C (O) NR A8R B8, -NR A8C (O) R B8, -C (=NR E8) NR A8R B8, -NR A8C (=NR E8) R B8, -OC (O) NR A8R B8, -NR A8C (O) OR B8, -NR A8C (O) NR A8R B8, -NR A8C (S) NR A8R B8, -NR A8C (=NR E8) NR A8R B8, -S (O)  rR A8, -S (O) (=NR E8) R B8, -N=S (O) R A8R B8, -S (O)  2OR A8, -OS (O)  2R A8, -NR A8S (O)  rR B8, -NR A8S (O) (=NR E8) R B8, -S (O)  rNR A8R B8, -S (O) (=NR E8) NR A8R B8, -NR A8S (O)  2NR A8R B8, -NR A8S (O) (=NR E8) NR A8R B8, -P (O) R A8R B8 and -P (O) (OR A8) (OR B8) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X8;
    R 9 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A9R B9, -OR A9, -C (O) R A9, -C (=NR E9) R A9, -C (=N-OR B9) R A9, -C (O) OR A9, -OC (O) R A9, -C (O) NR A9R B9, -NR A9C (O) R B9, -C (=NR E9) NR A9R B9, -NR A9C (=NR E9) R B9, -OC (O) NR A9R B9, -NR A9C (O) OR B9, -NR A9C (O) NR A9R B9, -NR A9C (S) NR A9R B9, -NR A9C (=NR E9) NR A9R B9, -S (O)  rR A9, -S (O) (=NR E9) R B9, -N=S (O) R A9R B9, -S (O)  2OR A9, -OS (O)  2R A9, -NR A9S (O)  rR B9, -NR A9S (O) (=NR E9) R B9, -S (O)  rNR A9R B9, -S (O) (=NR E9) NR A9R B9, -NR A9S (O)  2NR A9R B9, -NR A9S (O) (=NR E9) NR A9R B9, -P (O) R A9R B9 and -P (O) (OR A9) (OR B9) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X9;
    wherein
    when X 1 is CH, X 2 is selected from N, CH and CF, X 3 and X 4 are independently selected from N or CH, the moiety
    Figure PCTCN2022088989-appb-100002
    in Formula (I) is
    Figure PCTCN2022088989-appb-100003
    and R B1 is selected from hydrogen and C 1-4 alkyl, the moiety
    Figure PCTCN2022088989-appb-100004
    in Formula (I) is not
    Figure PCTCN2022088989-appb-100005
    wherein L, Q 1, Q 2, R 1, R 2, R 3, R 4, m and n are as defined in formula (I) ;
    each R A0 is independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1- 4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X0;
    each R A1 and R B1 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X1;
    or each “R A1 and R B1” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X1 groups;
    each R A2 and R B2 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein  alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X2;
    or each “R A2 and R B2” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X2 groups;
    each R A3 and R B3 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X3;
    or each “R A3 and R B3” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups;
    each R A4 and R B4 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X4;
    or each “R A4 and R B4” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X4 groups;
    each R A5 and R B5 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X5;
    or each “R A5 and R B5” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X5 groups;
    each R A6 and R B6 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X6;
    or each “R A6 and R B6” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X6 groups;
    each R A7 and R B7 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X7;
    or each “R A7 and R B7” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X7 groups;
    each R A8 and R B8 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X8;
    or each “R A8 and R B8” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X8 groups;
    each R A9 and R B9 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X9;
    or each “R A9 and R B9” together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X9 groups;
    each R C0 and R D0 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X0;
    or R C0 and R D0 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen and optionally substituted with 1, 2 or 3 R X0 groups;
    each R E1, R E2, R E5, R E6, R E7, R E8 and R E9 are independently selected from hydrogen, C 1- 10 alkyl, CN, NO 2, -OR a1, -SR a1, -S (O)  rR a1, -C (O) R a1, -C (O) OR a1, -C (O) NR a1R b1 and -S (O)  rNR a1R b1;
    each R X0, R X1, R X2, R X3, R X4, R X5, R X6, R X7, R X8 and R X9 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, halogen, CN, NO 2, - (CR c1R d1)  tNR a1R b1, - (CR c1R d1)  tOR b1, - (CR c1R d1)  tC (O) R a1, - (CR c1R d1)  tC (=NR e1) R a1, - (CR c1R d1)  tC (=N-OR b1) R a1, - (CR c1R d1)  tC (O) OR b1, - (CR c1R d1)  tOC (O) R b1, - (CR c1R d1)  tC (O) NR a1R b1, - (CR c1R d1)  tNR a1C (O) R b1, - (CR c1R d1)  tC (=NR e1) NR a1R b1, - (CR c1R d1)  tNR a1C (=NR e1) R b1, - (CR c1R d1)  tOC (O) NR a1R b1, - (CR c1R d1)  tNR a1C (O) OR b1, - (CR c1R d1)  tNR a1C (O) NR a1R b1, - (CR c1R d1)  tNR a1C (S) NR a1R b1, - (CR c1R d1)  tNR a1C (=NR e1) NR a1R b1, - (CR c1R d1)  tS (O)  rR b1, - (CR c1R d1)  tS (O) (=NR e1) R b1, - (CR c1R d1)  tN=S (O) R a1R b1, - (CR c1R d1)  tS (O)  2OR b1, - (CR c1R d1)  tOS (O)  2R b1, - (CR c1R d1)  tNR a1S (O)  rR b1, - (CR c1R d1)  tNR a1S (O) (=NR e1) R b1, - (CR c1R d1)  tS (O)  rNR a1R b1, - (CR c1R d1)  tS (O) (=NR e1) NR a1R b1, - (CR c1R d1)  tNR a1S (O)  2NR a1R b1, - (CR c1R d1)  tNR a1S (O) (=NR e1) NR a1R b1, - (CR c1R d1)  tP (O) R a1R b1 and - (CR c1R d1)  tP (O) (OR a1) (OR b1) , wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl  and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y;
    each R a1 and each R b1 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y;
    or R a1 and R b1 together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R Y groups;
    each R c1 and each R d1 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R Y;
    or R c1 and R d1 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1, 2 or 3 R Y groups;
    each R e1 is independently selected from hydrogen, C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, CN, NO 2, -OR a2, -SR a2, -S (O)  rR a2, -C (O) R a2, -C (O) OR a2, -S (O)  rNR a2R b2 and -C (O) NR a2R b2;
    each R Y is independently selected from C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, halogen, CN, -NO 2, -NR a2R b2, -OR a2, -SR a2, -S (O)  rR a2, -S (O)  2OR a2, -OS (O)  2R b2, -S (O)  rNR a2R b2, -P (O) R a2R b2, -P (O) (OR a2) (OR b2) , - (CR c2R d2)  tNR a2R b2, - (CR c2R d2)  tOR b2, - (CR c2R d2)  tSR b2, - (CR c2R d2)  tS (O)  rR b2, - (CR c2R d2)  tP (O) R a2R b2, - (CR c2R d2)  tP (O) (OR a2) (OR b2) , - (CR c2R d2)  tCO 2R b2, - (CR c2R d2)  tC (O) NR a2R b2, - (CR c2R d2)  tNR a2C (O) R b2, - (CR c2R d2)  tNR a2CO 2R b2, - (CR c2R d2)  tOC (O) NR a2R b2, - (CR c2R d2)  tNR a2C (O) NR a2R b2, - (CR c2R d2)  tNR a2SO 2NR a2R b2, - NR a2 (CR c2R d2)  tNR a2R b2, -O (CR c2R d2)  tNR a2R b2, -S (CR c2R d2)  tNR a2R b2, -S (O)  r (CR c2R d2)  tNR a2R b2, -C (O) R a2, -C (O) (CR c2R d2)  tOR b2, -C (O) (CR c2R d2)  tNR a2R b2, -C (O) (CR c2R d2)  tSR b2, -C (O) (CR c2R d2)  tS (O)  rR b2, -CO 2R b2, -CO 2 (CR c2R d2)  tC (O) NR a2R b2, -OC (O) R a2, -CN, -C (O) NR a2R b2, -NR a2C (O) R b2, -OC (O) NR a2R b2, -NR a2C (O) OR b2, -NR a2C (O) NR a2R b2, -NR a2S (O)  rR b2, -CR a2 (=N-OR b2) , -C (=NR e2) R a2, -C (=NR e2) NR a2R b2, -NR a2C (=NR e2) NR a2R b2, -CHF 2, -CF 3, -OCHF 2 and -OCF 3, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from OH, CN, amino, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
    each R a2 and each R b2 are independently selected from hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1- 10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino, di (C 1-10 alkyl) amino, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10  alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
    or R a2 and R b2 together with the atom (s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
    each R c2 and each R d2 are independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, C 1-10 alkylamino, C 3-10 cycloalkylamino, di (C 1-10 alkyl) amino, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
    or R c2 and R d2 together with the carbon atom (s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, OH, C 1-10 alkoxy, C 3-10 cycloalkoxy, C 1-10 alkylthio, C 3-10 cycloalkylthio, amino, C 1-10 alkylamino, C 3-10 cycloalkylamino and di (C 1-10 alkyl) amino;
    each R e2 is independently selected from hydrogen, CN, NO 2, C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, C 1-10 alkoxy, C 3-10 cycloalkoxy, -C (O) C 1-4 alkyl, -C (O) C 3-10 cycloalkyl, -C (O) OC 1-4 alkyl, -C (O) OC 3-10 cycloalkyl, -C (O) N (C 1-4 alkyl)  2, -C (O) N (C 3-10 cycloalkyl)  2, -S (O)  2C 1-4 alkyl, -S (O)  2C 3-10 cycloalkyl, -S (O)  2N (C 1-4 alkyl)  2 and -S (O)  2N (C 3-10 cycloalkyl)  2;
    m is selected from 0, 1, 2, 3 and 4;
    n is selected from 0, 1, 2, 3 and 4;
    each r is independently selected from 0, 1 and 2;
    each t is independently selected from 0, 1, 2, 3 and 4;
    each u is independently selected from 0, 1, 2, 3 and 4.
  2. A compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 6 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A6R B6 and -OR A6, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X6, preferably, R 6 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2, -OH and -NH 2.
  3. A compound of any one of claims 1-2 or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A7R B7 and -OR A7, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X7, preferably, R 7 is  selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2, -OH and -NH 2.
  4. A compound of any one of claims 1-3 or a pharmaceutically acceptable salt thereof, wherein R 8 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A8R B8 and -OR A8, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X8, preferably, R 8 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2, -OH and -NH 2.
  5. A compound of any one of claims 1-4 or a pharmaceutically acceptable salt thereof, wherein R 9 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, NO 2, -NR A9R B9 and -OR A9, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X9, preferably, R 9 is selected from hydrogen, methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, F, Cl, Br, -CN, -NO 2, -OH and -NH 2.
  6. A compound of any one of claims 1-5 or a pharmaceutically acceptable salt thereof, wherein the moiety
    Figure PCTCN2022088989-appb-100006
    in Formula (I) is selected from
    Figure PCTCN2022088989-appb-100007
    Figure PCTCN2022088989-appb-100008
  7. A compound of any one of claims 1-6 or a pharmaceutically acceptable salt thereof, wherein R 5 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, C 3- 10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A5R B5, -OR A5, -C (O) R A5, -C (O) OR A5, -OC (O) R A5, -C (O) NR A5R B5, -NR A5C (O) R B5, -OC (O) NR A5R B5, -NR A5C (O) OR B5, -NR A5C (O) NR A5R B5, -NR A5C (S) NR A5R B5, -S (O)  rR A5, -S (O)  2OR A5, -OS (O)  2R A5, -NR A5S (O)  rR B5 and -S (O)  rNR A5R B5, wherein alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X5, preferably, wherein R 5 is selected from hydrogen, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, methoxy, ethoxy, isopropyl, methoxymethyl, cyclopropyl and phenyl.
  8. A compound of any one of claims 1-7 or a pharmaceutically acceptable salt thereof, wherein Q 1 is heterocyclyl, preferably, Q 1 is selected from
    Figure PCTCN2022088989-appb-100009
    Figure PCTCN2022088989-appb-100010
    Figure PCTCN2022088989-appb-100011
  9. A compound of any one of claims 1-8 or a pharmaceutically acceptable salt thereof, wherein each R 2 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1- 4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, CN, NO 2, -NR A2R B2, -OR A2, -C (O) R A2, -C (O) OR A2, -OC (O) R A2, -C (O) NR A2R B2, -NR A2C (O) R B2, -OC (O) NR A2R B2, -NR A2C (O) OR B2, -NR A2C (O) NR A2R B2, -NR A2C (S) NR A2R B2, -S (O)  rR A2, -S (O) (=NR E2) R B2, -S (O)  2OR A2, -OS (O)  2R A2, -NR A2S (O)  rR B2, -S (O)  rNR A2R B2 and -NR A2S (O)  2NR A2R B2, wherein alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from R X2, preferably, each R 2 is independently selected from hydrogen, F, Cl, Br, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, ethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, methoxy, ethoxy, methoxymethyl, 
    Figure PCTCN2022088989-appb-100012
    -OC (O) CH 3, -CN, -NO 2, -NH 2 and -OH.
  10. A compound of any one of claims 1-9 or a pharmaceutically acceptable salt thereof, wherein the moiety
    Figure PCTCN2022088989-appb-100013
    in Formula (I) is selected from
    Figure PCTCN2022088989-appb-100014
    Figure PCTCN2022088989-appb-100015
    Figure PCTCN2022088989-appb-100016
  11. A compound of any one of claims 1-10 or a pharmaceutically acceptable salt thereof, wherein L is selected from a bond, -CR C0R D0-, - (CR C0R D0)  uO (CR C0R D0)  t-, - (CR C0R D0)  uNR A0 (CR C0R D0)  t-and - (CR C0R D0)  uS (CR C0R D0)  t-, preferably, L is selected from a bond, -CH 2-, -O-, -NH-, and -S-.
  12. A compound of any one of claims 1-11 or a pharmaceutically acceptable salt thereof, wherein Q 2 is selected from 5-12 membered heterocyclyl, aryl, and heteroaryl, preferably, wherein Q 2 is selected from
    Figure PCTCN2022088989-appb-100017
    Figure PCTCN2022088989-appb-100018
  13. A compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof, wherein each R 1 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 3-10 cycloalkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, heteroaryl, CN, NO 2, -NR A1R B1, -OR A1, -C (O) R A1, -C (O) OR A1, -OC (O) R A1, -C (O) NR A1R B1, -C (O) NR A1S (O)  rR A1, -C (O) NR A1S (O)  rNR A1R B1, -C (O) NR A1S (O) (=NR E1) R B1, -NR A1C (O) R B1, -OC (O) NR A1R B1, -NR A1C (O) OR B1, -NR A1C (O) NR A1R B1, -S (O)  rNR A1R B1, -NR A1S (O)  rR B1, -NR A1S (O)  2NR A1R B1 and -NR A1C (S) NR A1R B1, wherein alkyl, cycloalkyl, heterocyclyl and heteroaryl, are each unsubstituted or substituted with at least one substituent, independently selected from R X1, preferably, each R 1 is independently selected from methyl, ethyl, isopropyl, cyclopropyl, F, Cl, 
    Figure PCTCN2022088989-appb-100019
    Figure PCTCN2022088989-appb-100020
    CN, NO 2, -NR A1R B1, -NR A1C (O) R B1, -NR A1C (O) OR B1, -NR A1C (O) NR A1R B1, -NR A1S (O)  rR B1, -OR A1, -C (O) R A1, -C (O) OR A1, -OC (O) R A1, -C (O) NR A1R B1, -C (O) NR A1S (O)  rR A1, -C (O) NR A1S (O)  rNR A1R B1, -C (O) NR A1S (O) (=NR E1) R B1 and -S (O)  rNR A1R B1, wherein methyl, ethyl, isopropyl, cyclopropyl
    Figure PCTCN2022088989-appb-100021
    Figure PCTCN2022088989-appb-100022
    are each unsubstituted or substituted with at least one substituent, independently selected from R X1.
  14. A compound of any one of claims 1-13 or a pharmaceutically acceptable salt thereof, wherein each R X1 is independently selected from C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, halogen, CN, NO 2, - (CR c1R d1)  tNR a1R b1, - (CR c1R d1)  tOR b1, - (CR c1R d1)  tNR a1C (O) R b1, - (CR c1R d1)  tNR a1C (O) OR b1 and - (CR c1R d1)  tNR a1S (O)  rR b1, wherein alkyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R Y, preferably, each R X1 is independently selected from methyl, difluoromethyl, trifluoromethyl, ethyl, difluoroethyl, trifluoroethyl, isopropyl, tert-butyl,  cyclopropyl, methoxy, ethoxy, F, -CN, -NH 2, -NHCH 3, -NHCH 2CH 3, -NHC (O) CH 3, -NHC (O) OCH 3, 
    Figure PCTCN2022088989-appb-100023
  15. A compound of any one of claims 1-14 or a pharmaceutically acceptable salt thereof, wherein the moiety
    Figure PCTCN2022088989-appb-100024
    in Formula (I) is selected from
    Figure PCTCN2022088989-appb-100025
    Figure PCTCN2022088989-appb-100026
    Figure PCTCN2022088989-appb-100027
  16. A compound of any one of claims 1-15 or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, -NH 2 and -OH, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X3, preferably, wherein R 3 is selected from hydrogen and methyl, wherein methyl is unsubstituted or substituted with at least one substituent, independently selected from R X3.
  17. A compound of any one of claims 1-16 or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 3-10 cycloalkyl, CN, -NH 2 and -OH, wherein alkyl, alkenyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from R X4, preferably,  wherein R 4 is selected from hydrogen and methyl, which is unsubstituted or substituted with at least one substituent, independently selected from R X4.
  18. A compound of any one of claims 1-17 or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 together with the atoms to which they are attached form a C 3-10 cycloalkyl or heterocyclic ring of 4 to 8 members containing 1, 2 or 3 heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1, 2 or 3 R X3 groups, preferably, R 3 and R 4 together with the atoms to which they are attached form a cyclopropyl, and optionally substituted with 1, 2 or 3 R X3 groups.
  19. A compound selected from
    Figure PCTCN2022088989-appb-100028
    Figure PCTCN2022088989-appb-100029
    Figure PCTCN2022088989-appb-100030
    Figure PCTCN2022088989-appb-100031
    Figure PCTCN2022088989-appb-100032
    Figure PCTCN2022088989-appb-100033
    Figure PCTCN2022088989-appb-100034
    Figure PCTCN2022088989-appb-100035
    Figure PCTCN2022088989-appb-100036
    Figure PCTCN2022088989-appb-100037
    Figure PCTCN2022088989-appb-100038
    Figure PCTCN2022088989-appb-100039
    Figure PCTCN2022088989-appb-100040
    Figure PCTCN2022088989-appb-100041
    Figure PCTCN2022088989-appb-100042
    and pharmaceutically acceptable salts thereof.
  20. A pharmaceutical composition, comprising a compound of any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.
  21. A method of treating, ameliorating or preventing a condition, which responds to inhibition of PARP1, comprising administering to a subject in need of such treatment an effective amount of a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent.
  22. Use of a compound of any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a cell-proliferative disorder.
  23. Use of a compound of claims 22 or a pharmaceutically acceptable salt thereof, wherein the cell-proliferative disorder is includes but not limited to, breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, testicular cancer, lung cancer (including  NSCLC, SCLC, squamous cell carcinoma or adenocarcinoma) , esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer (including RCC) , liver cancer (including HCC) , pancreatic cancer, stomach (i.e., gastric) cancer, thyroid cancer, chronic lymphocytic leukemia (CLL) , lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia and myeloma.
PCT/CN2022/088989 2021-04-26 2022-04-25 Compounds as parp inhibitors Ceased WO2022228387A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280031108.XA CN117321051A (en) 2021-04-26 2022-04-25 Compounds that are PARP inhibitors

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202163180058P 2021-04-26 2021-04-26
US63/180,058 2021-04-26
US202163218222P 2021-07-02 2021-07-02
US63/218,222 2021-07-02
US202163248264P 2021-09-24 2021-09-24
US63/248,264 2021-09-24
US202163278953P 2021-11-12 2021-11-12
US63/278,953 2021-11-12
US202263320162P 2022-03-15 2022-03-15
US63/320,162 2022-03-15
US202263331810P 2022-04-16 2022-04-16
US63/331,810 2022-04-16

Publications (1)

Publication Number Publication Date
WO2022228387A1 true WO2022228387A1 (en) 2022-11-03

Family

ID=83846702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/088989 Ceased WO2022228387A1 (en) 2021-04-26 2022-04-25 Compounds as parp inhibitors

Country Status (2)

Country Link
TW (1) TW202309027A (en)
WO (1) WO2022228387A1 (en)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220380364A1 (en) * 2021-05-03 2022-12-01 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11591331B2 (en) 2021-04-19 2023-02-28 Xinthera, Inc. PARP1 inhibitors and uses thereof
WO2023046158A1 (en) * 2021-09-26 2023-03-30 张文燕 Azaquinolinone compound and medical use thereof
CN115919859A (en) * 2022-07-14 2023-04-07 四川海思科制药有限公司 Pharmaceutical composition of heteroaryl derivative and application thereof in medicine
US20230159525A1 (en) * 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
WO2023088408A1 (en) * 2021-11-19 2023-05-25 成都百裕制药股份有限公司 Selective parp1 inhibitor and application thereof
WO2023109521A1 (en) * 2021-12-17 2023-06-22 凯复(苏州)生物医药有限公司 Parp inhibitor, pharmaceutical composition comprising same, and use thereof
WO2023141290A1 (en) * 2022-01-21 2023-07-27 Xinthera, Inc. Parp1 inhibitors and uses thereof
WO2023138541A1 (en) * 2022-01-20 2023-07-27 微境生物医药科技(上海)有限公司 Picolinamide parp inhibitor, and preparation method therefor and medical use thereof
WO2023146960A1 (en) * 2022-01-28 2023-08-03 Xinthera, Inc. Parp1 inhibitors and uses thereof
US11795173B1 (en) 2022-04-28 2023-10-24 Xinthera, Inc. Substituted pyridines as PARP1 inhibitors
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
WO2023227052A1 (en) * 2022-05-25 2023-11-30 西藏海思科制药有限公司 Bicyclic derivative parp inhibitor and use thereof
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2023232069A1 (en) * 2022-06-02 2023-12-07 成都苑东生物制药股份有限公司 Azaquinolinone derivative, preparation method therefor and use thereof
WO2024046420A1 (en) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 Fused bicyclic compound, and preparation method therefor and use thereof in medicine
WO2024046366A1 (en) * 2022-09-01 2024-03-07 浙江文达医药科技有限公司 Selective parp1 inhibitor
WO2024067694A1 (en) * 2022-09-30 2024-04-04 中国医药研究开发中心有限公司 Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
WO2024067691A1 (en) * 2022-09-30 2024-04-04 中国医药研究开发中心有限公司 Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2024083218A1 (en) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 Substituted tetrahydropyridine compound and use thereof
WO2024082654A1 (en) * 2022-10-20 2024-04-25 上海海和药物研究开发股份有限公司 Compounds possessing parp1 inhibitory activity, and uses thereof
WO2024083204A1 (en) * 2022-10-21 2024-04-25 上海翰森生物医药科技有限公司 Salt and crystal form of heterocyclic derivative inhibitor, and preparation method therefor and use thereof
WO2024083211A1 (en) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 Heterocyclic deuterated compound and use thereof
WO2024083201A1 (en) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 Fused heterocyclic compound and use thereof
WO2024099364A3 (en) * 2022-11-09 2024-06-13 Laekna Therapeutics Shanghai Co., Ltd. Fused multicyclic compounds and their use as parp1 inhibitors
WO2024131945A1 (en) * 2022-12-23 2024-06-27 深圳扬厉医药技术有限公司 Parp1 inhibitors
US12054479B1 (en) 2022-03-14 2024-08-06 Slap Pharmaceuticals Llc Multicyclic compounds
WO2024179547A1 (en) * 2023-03-01 2024-09-06 Impact Therapeutics (Shanghai) , Inc. Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
WO2024188265A1 (en) * 2023-03-13 2024-09-19 江苏豪森药业集团有限公司 Use of piperidine alkene compound in preparation of drug for treating cancer
WO2024196841A1 (en) * 2023-03-21 2024-09-26 Athos Therapeutics, Inc. Vanin-1 inhibitors
WO2024206172A1 (en) * 2023-03-24 2024-10-03 Xinthera, Inc. Crystalline forms of an azetidine parp1 inhibitor
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024255782A1 (en) * 2023-06-14 2024-12-19 西藏海思科制药有限公司 Bicyclic derivative parp inhibitor and use thereof
US12208141B2 (en) 2019-05-14 2025-01-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025090418A1 (en) * 2023-10-23 2025-05-01 Gilead Sciences, Inc. Parp1 inhibitors and uses thereof
WO2025092973A1 (en) * 2023-11-03 2025-05-08 成都赜灵生物医药科技有限公司 Parp1-targeting compound and use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
US12398121B2 (en) 2018-05-14 2025-08-26 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025261448A1 (en) * 2024-06-19 2025-12-26 浙江扬厉医药技术有限公司 Salt form and crystal form of pyridine amide compound, and preparation methods therefor
WO2025261449A1 (en) * 2024-06-19 2025-12-26 浙江扬厉医药技术有限公司 Pyridine amide compound as parp1 inhibitor, intermediate and preparation method therefor
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
EP4514795A4 (en) * 2022-04-28 2025-12-31 Ningbo Newbay Tech Development Co Ltd COMPOUNDS AS PARP1 INTAMPERS
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007436A2 (en) * 1999-07-28 2001-02-01 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
WO2001042219A2 (en) * 1999-12-07 2001-06-14 Inotek Corporation Novel substituted phenanthridinones and methods of use thereof
WO2001090077A1 (en) * 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
WO2003080581A1 (en) * 2002-03-26 2003-10-02 Fujisawa Pharmaceutical Co., Ltd. Phenanthridinones as parp inhibitors
WO2016066142A1 (en) * 2014-11-01 2016-05-06 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2017219955A1 (en) * 2016-06-22 2017-12-28 Shanghai Fochon Pharmaceutical Co., Ltd. Substituted pyrrolo [2, 3-d] pyridazin-4-ones and pyrazolo [3, 4-d] pyridazin-4-ones as protein kinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007436A2 (en) * 1999-07-28 2001-02-01 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
WO2001042219A2 (en) * 1999-12-07 2001-06-14 Inotek Corporation Novel substituted phenanthridinones and methods of use thereof
WO2001090077A1 (en) * 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
WO2003080581A1 (en) * 2002-03-26 2003-10-02 Fujisawa Pharmaceutical Co., Ltd. Phenanthridinones as parp inhibitors
WO2016066142A1 (en) * 2014-11-01 2016-05-06 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2017219955A1 (en) * 2016-06-22 2017-12-28 Shanghai Fochon Pharmaceutical Co., Ltd. Substituted pyrrolo [2, 3-d] pyridazin-4-ones and pyrazolo [3, 4-d] pyridazin-4-ones as protein kinase inhibitors

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12398121B2 (en) 2018-05-14 2025-08-26 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12208141B2 (en) 2019-05-14 2025-01-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4326720A4 (en) * 2021-04-19 2025-03-19 Xinthera, Inc. PARP1 INHIBITORS AND USES THEREOF
US11591331B2 (en) 2021-04-19 2023-02-28 Xinthera, Inc. PARP1 inhibitors and uses thereof
US12006314B2 (en) * 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US20220380364A1 (en) * 2021-05-03 2022-12-01 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2023046158A1 (en) * 2021-09-26 2023-03-30 张文燕 Azaquinolinone compound and medical use thereof
US20230159525A1 (en) * 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
US11802128B2 (en) 2021-10-01 2023-10-31 Xinthera, Inc. Azetidine and pyrrolidine PARP1 inhibitors and uses thereof
WO2023088408A1 (en) * 2021-11-19 2023-05-25 成都百裕制药股份有限公司 Selective parp1 inhibitor and application thereof
WO2023109521A1 (en) * 2021-12-17 2023-06-22 凯复(苏州)生物医药有限公司 Parp inhibitor, pharmaceutical composition comprising same, and use thereof
WO2023138541A1 (en) * 2022-01-20 2023-07-27 微境生物医药科技(上海)有限公司 Picolinamide parp inhibitor, and preparation method therefor and medical use thereof
CN118434725A (en) * 2022-01-20 2024-08-02 微境生物医药科技(上海)有限公司 Pyridineamide PARP inhibitors, preparation methods and medical uses thereof
CN118434725B (en) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 Pyridine amide PARP inhibitors, their preparation methods and pharmaceutical uses
EP4466269A1 (en) 2022-01-21 2024-11-27 Xinthera, Inc. Parp1 inhibitors and uses thereof
WO2023141290A1 (en) * 2022-01-21 2023-07-27 Xinthera, Inc. Parp1 inhibitors and uses thereof
US11939329B2 (en) 2022-01-21 2024-03-26 Xinthera, Inc. PARP1 inhibitors and uses thereof
US12384780B2 (en) 2022-01-21 2025-08-12 Xinthera, Inc. PARP1 inhibitors and uses thereof
WO2023146960A1 (en) * 2022-01-28 2023-08-03 Xinthera, Inc. Parp1 inhibitors and uses thereof
JP7813374B2 (en) 2022-01-28 2026-02-12 シンセラ， インコーポレイテッド PARP1 inhibitors and their uses
JP2025503116A (en) * 2022-01-28 2025-01-30 シンセラ， インコーポレイテッド PARP1 inhibitors and their uses
US12054479B1 (en) 2022-03-14 2024-08-06 Slap Pharmaceuticals Llc Multicyclic compounds
US12421241B2 (en) 2022-04-28 2025-09-23 Xinthera, Inc. Substituted pyridines as PARP1 inhibitors
US11795173B1 (en) 2022-04-28 2023-10-24 Xinthera, Inc. Substituted pyridines as PARP1 inhibitors
EP4514795A4 (en) * 2022-04-28 2025-12-31 Ningbo Newbay Tech Development Co Ltd COMPOUNDS AS PARP1 INTAMPERS
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
US12006322B2 (en) 2022-04-28 2024-06-11 Xin Thera, Inc. Substituted pyridines as PARP1 inhibitors
WO2023227052A1 (en) * 2022-05-25 2023-11-30 西藏海思科制药有限公司 Bicyclic derivative parp inhibitor and use thereof
WO2023232069A1 (en) * 2022-06-02 2023-12-07 成都苑东生物制药股份有限公司 Azaquinolinone derivative, preparation method therefor and use thereof
CN115919859A (en) * 2022-07-14 2023-04-07 四川海思科制药有限公司 Pharmaceutical composition of heteroaryl derivative and application thereof in medicine
CN115919859B (en) * 2022-07-14 2024-01-05 四川海思科制药有限公司 Pharmaceutical composition of heteroaryl derivative and application of pharmaceutical composition in medicine
WO2024046420A1 (en) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 Fused bicyclic compound, and preparation method therefor and use thereof in medicine
CN119365468A (en) * 2022-08-31 2025-01-24 江苏恒瑞医药股份有限公司 Condensed bicyclic compound, preparation method thereof and application thereof in medicine
WO2024046366A1 (en) * 2022-09-01 2024-03-07 浙江文达医药科技有限公司 Selective parp1 inhibitor
WO2024067694A1 (en) * 2022-09-30 2024-04-04 中国医药研究开发中心有限公司 Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
WO2024067691A1 (en) * 2022-09-30 2024-04-04 中国医药研究开发中心有限公司 Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
WO2024083201A1 (en) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 Fused heterocyclic compound and use thereof
WO2024083218A1 (en) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 Substituted tetrahydropyridine compound and use thereof
WO2024082654A1 (en) * 2022-10-20 2024-04-25 上海海和药物研究开发股份有限公司 Compounds possessing parp1 inhibitory activity, and uses thereof
WO2024083211A1 (en) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 Heterocyclic deuterated compound and use thereof
WO2024083204A1 (en) * 2022-10-21 2024-04-25 上海翰森生物医药科技有限公司 Salt and crystal form of heterocyclic derivative inhibitor, and preparation method therefor and use thereof
WO2024099364A3 (en) * 2022-11-09 2024-06-13 Laekna Therapeutics Shanghai Co., Ltd. Fused multicyclic compounds and their use as parp1 inhibitors
WO2024131945A1 (en) * 2022-12-23 2024-06-27 深圳扬厉医药技术有限公司 Parp1 inhibitors
CN120322435A (en) * 2022-12-23 2025-07-15 浙江扬厉医药技术有限公司 PARP1 inhibitors
WO2024179547A1 (en) * 2023-03-01 2024-09-06 Impact Therapeutics (Shanghai) , Inc. Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
WO2024188265A1 (en) * 2023-03-13 2024-09-19 江苏豪森药业集团有限公司 Use of piperidine alkene compound in preparation of drug for treating cancer
WO2024196841A1 (en) * 2023-03-21 2024-09-26 Athos Therapeutics, Inc. Vanin-1 inhibitors
WO2024206172A1 (en) * 2023-03-24 2024-10-03 Xinthera, Inc. Crystalline forms of an azetidine parp1 inhibitor
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024255782A1 (en) * 2023-06-14 2024-12-19 西藏海思科制药有限公司 Bicyclic derivative parp inhibitor and use thereof
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025090418A1 (en) * 2023-10-23 2025-05-01 Gilead Sciences, Inc. Parp1 inhibitors and uses thereof
WO2025092973A1 (en) * 2023-11-03 2025-05-08 成都赜灵生物医药科技有限公司 Parp1-targeting compound and use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025261449A1 (en) * 2024-06-19 2025-12-26 浙江扬厉医药技术有限公司 Pyridine amide compound as parp1 inhibitor, intermediate and preparation method therefor
WO2025261448A1 (en) * 2024-06-19 2025-12-26 浙江扬厉医药技术有限公司 Salt form and crystal form of pyridine amide compound, and preparation methods therefor
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Also Published As

Publication number Publication date
TW202309027A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
WO2022228387A1 (en) Compounds as parp inhibitors
WO2023078401A1 (en) Compounds as protein kinase inhibitors
WO2021170076A1 (en) Compounds as cdk2/4/6 inhibitors
AU2020283597A1 (en) Substituted pyrrolo (2, 3-b) pyridine and pyrazolo (3, 4-b) pyridine derivatives as protein kinase inhibitors
AU2021268845A1 (en) Compounds as Bcl-2 inhibitors
WO2021180107A1 (en) Compounds useful as kinase inhibitors
WO2017133701A1 (en) Certain protein kinase inhibitors
WO2020063751A1 (en) Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
WO2024099437A1 (en) Compounds as protein kinase inhibitors
EP3452484B1 (en) Certain protein kinase inhibitors
WO2021047584A1 (en) SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS
WO2023231777A1 (en) Compounds as bcl-2 inhibitors
WO2022268065A1 (en) Compounds as erk inhibitors
WO2023078398A1 (en) Compounds as bcl-2 inhibitors
WO2020063659A1 (en) Substituted [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
AU2021383227A9 (en) SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
AU2017280412A1 (en) Substituted pyrrolo (2, 3-D) pyridazin-4-ones and pyrazolo (3, 4-D) pyridazin-4-ones as protein kinase inhibitors
WO2024032755A1 (en) Compounds as bcl-2 inhibitors
RU2824583C2 (en) Substituted pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors
WO2024032776A1 (en) Compounds as bcl-2 inhibitors
CA3023460C (en) Cdk4/6 inhibitors for the treatment of hyper-proliferative diseases
AU2022394660A1 (en) Compounds as bcl-2 inhibitors
WO2020063860A1 (en) Naphthyridinone and pyridopyrimidinone compounds useful as kinases inhibitors
CN118284608A (en) Compounds as BCL-2 inhibitors
WO2021233227A1 (en) Compounds as protein kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22794857

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280031108.X

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22794857

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 22794857

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 18/07/2024)